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 Introduction 
Ardisia, formerly the largest genus in the family Myrsinaceae contains approximately 500 
species and was included in the expanded family of Primulaceae with the implementation of 
APG III system (2009), the third version of a modern, mostly molecular-based system of plant 
taxonomy and its successor APG IV (2016).1,2 At least 70 species have been assigned to 
Crispardisia, the subgenus characterized by leaf nodules (see definition in Chapter 1.1).3 The 
most investigated species from Crispardisia, the coral berry Ardisia crenata SIMS, is a low-
growing evergreen shrub widely dispersed in south-eastern subtropical and tropical regions of 
Asia and invasive in Florida (USA) and La Réunion.4 In the Chinese Pharmacopeia its roots are 
listed as traditional Chinese medicine (TCM) for the treatment of several diseases, especially 
of the respiratory tract.5,6 While the Bacterial Leaf Nodule symbiosis between Crispardisia and 
their respective endophytes has been investigated for a century, the reason for the development 
of this close and obligate relationship remains controversial.7 The cyclic depsipeptide 
FR900359 (FR) from Ardisia crenata was not the key aspect of reported research until recently, 
in spite of FRs enormous potential as pharmacological tool and drug candidate. For this reason, 
the focus of the presented work is put on cyclic peptides, e.g. FR and analogs, from the vascular 
plant A. crenata SIMS and other Crispardisia. Furthermore, the question will be addressed, 
whether symbiont-produced FR is important for the host plant, thus we investigate the 
ecological role of FR for the first time. 
 
Figure 1-1: (A) Cultivation of A. crenata in the green house of the Univ. of Bonn, Germany. (B) Close-up picture 
displaying leaves, flowers, and berries of A. crenata. Diameter of berries ca. 1cm. 
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 Symbiotic plant-bacterial relationships offer a vast potential for 
natural product research 
Endophytes, by definition, are commonly bacteria or fungi, which reside inside the tissues of 
plants beneath the epidermal cell layers and cause no apparent harm to the host.8 Strobel and 
Daisy claim that of the estimated 300,000 plant species existing on earth, at least all 
angiosperms accommodate endophytes.9 This opens a complete new perspective on 
phytochemical research. Although many plants have been extensively studied, the 
corresponding endophytes are barely examined. The investigation of plants’ endophytes can 
lead to a vast range of new microorganisms when considering plants in different settings and 
ecosystems. It is believed that plants benefit of the bioactive metabolites of their endophytes, 
e.g. antimicrobial, antifungal, and insecticidal substances to prevent any damage from plant 
pathogens. Such compounds could be of great pharmaceutical and agricultural value in order to 
fight the problem of ongoing resistance development towards antibiotics and insecticides.10–12 
 Crispardisia-Burkholderia leaf nodule symbiosis  
A system of plant-endophyte symbiosis little investigated is the Bacterial Leaf Symbiosis, e.g. 
found in the subgenus of Ardisia, called Crispardisia, consisting of 70 species. All of these are 
characterized by leaf nodules that are vascularized bumps on the leaf margins open to the 
exterior by way of stomatal pores only in early stages of the nodule development (Figure 1-
1).13,14 To uncover the identity of the bacterial symbionts, Lemaire et al. used a molecular 
phylogenetic approach to investigate nodulated species of Ardisia and concluded that the 
symbionts belong to the genus Burkholderia.15 The vertical transmission was first postulated 
by Miller and is supported by several investigations.16,17 PCR detection showed that the same 
bacteria occur not only in leaf nodules but also in shoot apices and reproductive organs, 
suggesting vertical transmission of these symbionts. Further evidence was provided by the 
sequence similarity of the symbionts harbored by different hosts of the same Crispardisia 
species, irrespective of their geographic origins, as well as by cophylogenetic analysis.3 Within 
Ardisia, the subgenus Crispardisia appears to be monophyletic. The same is true for its 
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symbionts, implying the Ardisia-Burkholderia leaf-nodule symbiosis to have a single origin.3,15
 
Figure 1-2: (A) Leaves from Ardisia crenata with nodules (green circle), (B) Cross-section of a bacterial nodule 
from a Crispardisia. (C) Bacterial symbionts of a Crispardisia. (B and C are taken from Ku & Hu3), (D) Structure 
of endophyte-derived natural product FR900359. 
The genus Burkholderia consists of more than 100 species known for their widespread 
occurrence in diverse ecological niches: It includes (human and plant) pathogens, symbionts, 
nonpathogenic soil bacteria, and plant-growth-promoting bacteria.18,19 There appears to be a 
tremendous variation in genome size ranging from 2.4 Mb to more than 9 Mb19 among these 
phylogenetically closely related organisms, which can explain the broad metabolic diversity of 
Burkholderia. Plasticity of the genomes and horizontal gene transfer between Burkholderia and 
other Proteobacteria also contribute to this.20,21 Ku and Hu showed for other Crispardisia 
species that the nodules are filled with endosymbiotic Burkholderia. Accordingly, the 
corresponding endosymbiotic Burkholderia within the nodules of A. crenata are most probably 
the true FR producer.(Figure 1-2).3 The taxonomy of the genus Burkholderia is currently being 
revised, with some species transferred to the genera Caballeronia and Paraburkholderia. For 
the sake of simplicity, we adhere in this study to the outdated, yet still valid nomenclature. 
To confirm the link between FR and the symbiotic bacteria, we quantified the concentration of 
FR in methanolic extracts of leaf tissue of A. crenata in a former study, serving as basis for 
deeper investigation of the symbiont-host relationship.22 The concentration of FR in crude 
extracts of dissected leaf nodules was 247.0 ± 22.3 μg mg−1, i.e. more than 36 times higher than 
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in leaves where the margins containing the nodules had been cut out (6.7 ± 1.6 μg mg−1).22 This 
gives a clear indication that synthesis of FR is concentrated in the leaf nodules and that the 
endosymbiont is responsible for the synthesis of FR. In that study, we further sequenced the 
genome of the bacterial leaf symbiont from A. crenata and designated it as “Candidatus 
Burkholderia crenata” (Ca. B. crenata).22 Analysis of the only 2.85Mb sized genome sequence 
revealed essential pathways to be malfunctioned, highlighting the advanced evolutionary stage 
of this plant-bacterium symbiosis and ongoing genome reductive evolution. Additionally, the 
putative FR biosynthetic gene cluster frs (Figure 1-4), encoding two nonribosomal peptide 
synthetases (NRPSs), was identified on an extrachromosomal plasmid. This further strengthens 
our assumption that the endophyte Ca. B. crenata is the true FR producer. 
 Nonribosomal peptide biosynthesis using the example of FR 
The biosynthesis of cyclic depsipeptides in microorganisms is well investigated. Many of them 
are synthesized by giant multi-domain nonribosomal peptide synthetases (NRPSs), following 
the so-called thiol template mechanism, which features the domain organization seen in Figure 
1-3.23 The structural diversity of non-ribosomal peptides (NRPs) exceeds by far that of 
ribosomally synthesized peptides. This is achieved by the incorporation of proteinogenic and 
more than 500 presently reported non-proteinogenic amino acids, as well as α-hydroxy and 
other carboxylic acids. Further modifications such as N-, C- and O-methylation, acylation, 
glycosylation, heterocyclic ring formation, dehydration, and conversion of the building blocks 
into their stereoisomers can be conducted by the corresponding enzymes, located on specialized 
domains of those peptide synthetases.24 
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Figure 1-3: Chemical reactions catalyzed by NRPS core domains. A = adenylation-domain, PCP = peptidyl 
carrier protein (thiolation-domain), C = condensation-domain. Domains in action are drawn dark colored with 
white & bold letters. The peptide assembly starts with the selection and activation (by adenylation) of a specific 
amino acid by the A-domain. The activated amino acid is loaded onto the (nucleophilic) thiol moiety of the T-
bound cofactor 4´-phosphopantetheine (ppan). The C-domain catalyzes the C-N bond formation between the 
amino group of the downstream loaded amino acid and the upstream loaded amino acid or peptide (modified 
after25). 
Due to the eroded genome, cultivation of Candidatus Burkholderia crenata (see Chapter 1.1) 
seems unlikely, and indeed numerous cultivation attempts failed, making FR supply dependent 
on cultivating and extracting of A. crenata leaves. By defining all genes necessary for FR 
biosynthesis, we draw a plausible biosynthetic hypothesis for this complex metabolite, 
supported by bioinformatics, in vitro characterizations of biosynthetic enzymes and 
characterization of FR analogs (for detailed information see also Chapter 4.2). Unexpectedly, 
bioinformatics of the frs genes showed the presence of two thioesterase (TE) domains, 
representing two NRPS machineries, which together display a clear colinearity between module 
and domain architecture and FR structure (Figure 1-4). 
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Figure 1-4: Scheme of the putative FR biosynthesis deduced from bioinformatics and in vitro experiments. 
The NRPS genes, the catalytic domains they encode, and the amino acids incorporated by the respective modules 
are displayed. The peptide formation on the FrsA-G NRPS machineries, including release and transesterification 
by FrsA-TE is shown. Domains: A, adenylation; C, condensation; MT, methylation (of phenylalanine); PCP, 
peptidyl carrier protein; E, epimerization and TE, thioesterase (Ile-Thr ring closure). Figure was modified after 
Crüsemann and Reher et al.10 
In order to confirm the completeness of the FR biosynthetic gene cluster, we next aimed to 
transfer the frs genes to a cultivable bacterium for heterologous FR production. In future, 
production of FR by fermentation would alleviate the current laborious extraction and isolation 
process from Ardisia plants. Total synthesis of FR was recently achieved, however with low 
yields and high expenses.26 Heterologous expression would also be a key step to establish an in 
vivo platform to further investigate FR biosynthesis and to generate analogs for 
pharmacological evaluation by mutasynthesis or biosynthetic engineering (see Chapter 4.3). 
 Structural characteristics of the cyclic depsipeptide FR  
Symbiotic life forms are widespread in nature and include complex biochemical interactions to 
the benefit of each partner. Obligatory plant-bacteria associations, as observed in the case of 
the nodulated A. crenata, pose a fascinating ecological system.22 From A. crenata, the cyclic 
depsipeptide FR was already characterized in 198627 and exhibits remarkable structural features 
such as two adjacent ester bonds, and the rare amino acid building blocks N-
methyldehydroalanine and N-,O-dimethylthreonine. The latter is uniquely found in FR, and the 
structurally related natural products YM-254890 (YM) and sameuramide (SA) (Scheme 1-
1).28,29 Structural studies including X-ray crystallography, revealed two cis-peptide bonds in the 
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structure of FR.30 This is exceptional, because generally the trans conformation of amides is 
favored for thermodynamic reasons. 
 
Scheme 1-1: Structures of FR900359 (FR), Sameuramide (SA), and YM-254890 (YM). (Non-proteinogenic) 
amino acid building blocks colored and annotated for FR, including one-letter code. 
Peptides are usually not considered to be promising drug candidates, even though almost all 
pharmacological targets, e.g. receptors, ion channels, enzymes are composed of amino acids. 
However, the problem with linear peptides is that they are digested by proteolytic enzymes 
before they can operate, and cyclic peptides often violate several of Lipinski’s rules i.e. a 
molecular weight less than 500 Da, no more than 5 H-bond donors, and no more than 10 H-
bond acceptors atoms. These rules are an attempt to improve the predictions of druglikeness of 
small molecules, but Lipinski et al. partially revised their applicability for natural products, 
whose biosynthesis is based on evolutionary selection.31–34 Cyclic depsipeptides like FR 
overcome the issue of proteolytic digestion, because they do not possess a terminal amino or 
carboxylic functionality and furthermore the ester bonds are not accessible for the enzymes. In 
addition, N-methylation of peptide bonds prevent enzymatic degradation, e.g. by chymotrypsin, 
resulting in increasing biological half-life.35 Beside enzymatic stability, N-methylated peptides 
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offer numerous additional advantages regarding pharmacodynamics and -kinetics. Multiple N 
-and O-methylations increase the lipophilicity of molecules, resulting in higher intestine 
absorption rates and thus higher bioavailabilities.36,37 Finally, N-methylation decreases the 
number of possible intramolecular and intermolecular hydrogen bonds, offering less 
aggregation potential, and leading along with the cyclic nature of FR to conformational 
restriction. The latter can contribute to increased receptor selectivity and altered potency.38,39 
 Plant-derived natural products as pharmacological tools to study 
GPCR-mediated signaling at different stages 
Structurally complex natural products are often derived from the plant kingdom, and plants 
have been demonstrated to be a fruitful source of bioactive metabolites. It is assumed that plant 
secondary metabolites help the producer organisms to survive in their environment, i.e. by 
interaction with competitors or herbivores.40–42 Therefore, production of such compounds is 
considered to allow occupation of special ecological niches or to provide competitive 
advantages against contenders. Many secondary metabolites from plants but also 
microorganisms are used in medicine, due to their prominent bioactivities and are helpful for a 
vast range of indications (e.g. paclitaxel in cancer, colchicine in gout, morphine for pain). 
Often neglected however, is the application as selective, mostly cell-permeable tools in 
pharmacology. Prominent examples of mainly plant-derived natural products and their 
molecular targets are illustrated in Figure 1-5. As this thesis focusses on the investigation of 
the plant-derived, selective Gαq/11/14 protein inhibitor FR, special emphasis in Figure 1-5 is put 
on plant-derived natural products and their abilities to interact with activated Gαq (Gq) protein 
coupled receptors (GqPCRs) signaling at different stages. Upstream of G proteins, GPCRs are 
situated comprising around 800 members and represent ≈3% of the human genome. They are 
involved in a wide variety of physiological processes by detecting molecules outside the cell 
and activating internal signal transduction pathways and, ultimately, cellular responses.43 Thus 
not surprisingly, currently about 36% of all available medications target GPCRs, which renders 
them as the most important class of drug targets.44  
To exemplify the potential of plant-derived natural products able of interacting with GPCRs 
and their signaling, the human muscarinic acetylcholine receptor M1 was chosen, because it 
couples predominantly to Gq, but to less extent also to Gαs (Gs) and Gαi (Gi).45 
Introduction 
9 
 
 
Figure 1-5: Natural products and their molecular targets with emphasis on GqPCR-mediated signaling in 
mammalian cells. Natural products that are widely applied as pharmacological tools are shown with their 
respective trivial name, structure, and source. Green arrows display activation and red arrows display the inhibition 
of target structure. The signaling cascade upon GqPCR activation is shown with blue arrows. (1) In its inactive 
state the muscarinic M1-receptor, a G protein–coupled receptor (GPCR), is bound to a heterotrimeric G protein. 
M1-receptors are known to predominantly bind Gq/11 proteins, which in turn bind guanosine diphosphate (GDP), 
when inactive. (2) M1-receptor is activated e.g. by the endogenous ligand acetylcholine, leading to a 
conformational change of the receptor and subsequent G protein activation. (3) Active Gq protein heterotrimer 
dissociates into Gα and Gβ,γ subunits (activated state highlighted by light effect), which each contribute to 
downstream signaling. (4) Gαq subunit activates phospholipase Cβ (PLCβ). PLCβ catalyzes the hydrolysis of 
phosphatidylinositol 4,5-bisphosphate (PIP2) to inositol 1,4,5-trisphosphate (IP3, 4b) and diacyl glycerol (DAG). 
(4a) DAG activates membrane-bound protein kinase C (PKC) and facilitates translocation of PKC. (5) Soluble IP3 
diffuses to endoplasmic or sarcoplasmic reticulum (ER or SR respectively) and binds to a ligand-gated Ca2+ 
channel leading to Ca2+ release into the cytoplasm. (6) Elevated Ca2+ levels have multiple effects, e.g. (7) activation 
of calcium-dependent PKC. To a less extent M1-receptors are also reported to bind Gi in certain tissues.46 (8) Gi 
protein-mediated signaling is shown on the left side (brown arrows). (9) Activated Gαi binds and inhibits adenylyl 
cyclase (AC). (10) Thus, AC decreases the production of cAMP from ATP, which, in turn, (11) results in decreased 
activity of cAMP-dependent protein kinase (PKA). For details please refer to the text. 
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 Plant-derived tools interfering with GqPCR activation 
In the first step of the M1 receptor signaling cascade the endogenous ligand acetylcholine binds 
to the receptor and activates it. Binding to the receptor can be prevented by addition of non-
covalent competitive antagonist such as the non-selective natural product atropine from Atropa 
belladonna or the M1-selective scopolamine (Hyoscine) derived e.g. from Datura stramonium 
(Figure 1-5).47 Scopolamine has been used as a research tool to study the involvement of 
acetylcholine in cognition. Results in primates suggest that acetylcholine is involved in the 
encoding of new information into long term memory.48,49 Furthermore, scopolamine has been 
investigated as an antidepressant with a number of small studies finding positive results.50 
 FR900359, a plant-derived tool interfering with Gq protein activation 
Binding of acetylcholine to the M1 receptor activates the latter, resulting in a conformational 
change in the receptor that is transmitted to the bound Gαq subunit of the heterotrimeric Gq 
protein via protein domain dynamics.51 The activated Gαq subunit exchanges GTP with GDP 
which in turn triggers the dissociation of Gαq subunit from the Gβγ dimer and from the receptor 
(see Figures 1-5 and 1-6).51 The latter can be prevented, e.g. by guanine nucleotide dissociation 
inhibitors (GDI). 
Of the few inhibitors for G protein signaling, mechanistic details on the structural level are only 
available for the Gαq/11/14-selective YM, discovered and isolated from Chromobacterium sp. 
QS3666.28,52 Its binding mode, as elucidated by means of mutagenesis and structural data, 
provides a plausible mechanism for inhibition of GDP release.53 Nishimura et al. propose that 
YM forms a cone-like structure with its phenyl group at the head, and is stuck deeply in the 
cleft between both interdomain linkers, thus acting as GDI (see Figure 1-7). The cyclic 
depsipeptide FR from A. crenata supposedly share this mode of action as GDI, which will be 
discussed in detail in this thesis. FR also selectively blocks heterotrimeric G proteins of the Gq 
family (Gαq/11/14) which relay signals from activated GqPCRs to the cell interior, just as the 
bacterial metabolite YM. Docking experiments with FR and Gq suggest this similarity in the 
mode of action between FR and YM (see Figure 1-7).54 FR and YM are unique in that they are 
the only chemicals competent to interdict Gq signaling with high selectivity and potency.54 
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Figure 1-6: Mechanism of the G protein activation cycle. (1) In the inactive state, the heterotrimeric G protein 
rests in the GDP-bound form. (2) Upon activation, e.g. by acetylcholine-mediated M1-receptor activation or 
guanine nucleotide exchange factor (GEF), a conformational change within the G protein induces the release of 
GDP and the binding of GTP to the α-subunit. (3) This triggers the dissociation of α- and βγ-subunit, (4) both of 
which in turn can interact with signaling effectors. (5) GTPase-activating proteins (GAPs) enhance the intrinsic 
GTPase activity of the α-subunit and thus allow the βγ-subunit to re-associate with the GDP-bound α-subunit (6) 
to form an inactive heterotrimeric G protein again. 
FR is thus essential for studies that aim to unravel the contribution of Gq to complex cellular 
signaling processes.55–59 Gq-mediated signaling pathways regulate a large number of essential 
processes in eukaryotic cells.60 By blunting signal transduction of many GqPCRs 
simultaneously, FR may be decisively advantageous as therapeutic to treat conditions where 
multiple GqPCRs contribute to pathology.61–63 Also YM is applied as molecular tool for 
investigations of complex signaling cascades mediated by the Gq pathway. In the field of 
neurosciences, several investigators used YM. In this way Matsuo et al.64 identified a novel Gq 
coupled orphan GPCR, termed GPRg1and Morishita et al.65 applied YM for investigating the 
involvement of Gαq/11 signaling mediated via the endothelin-B receptor in neural progenitor 
proliferation. On the basis of this mode of action, YM demonstrated a series of pharmacological 
effects, e.g. platelet aggregation inhibition, inhibition of neointima formation, decreasing of 
systemic blood pressure and vasorelaxant effects in rats.66,67 
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Figure 1-7: FR inhibits Gq-signaling by acting as guanine nucleotide dissociation inhibitor (GDI). (A) 
Schematic representation of Gq protein activation. Upon activation, a conformational change within the Gq protein 
induces the release of GDP and the binding of GTP to the α-subunit. This triggers the dissociation of α- and βγ-
subunit, both of which in turn can interact with several signaling effectors. Gαq subunits and domains are color 
coded: Gαq Ras domain: yellow, helical domain: red, Gβ: green, Gγ: cyan. (B) Schematic representation of the 
mechanism of action of FR that is acting as guanine nucleotide dissociation inhibitor (GDI) and thus keeping the 
Gq protein in its inactive state. (C) Zoomed-out view of the heterotrimeric Gq protein bound to FR900359 derived 
from docking (taken from Schrage et al.54). 
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 Plant-derived tools interfering with phospholipase Cβ activation 
After dissociation of the heterotrimeric G proteins into Gαq and Gβ,γ subunits each contribute 
to downstream signaling. The Gαq subunit activates phospholipase Cβ (PLCβ). PLCβ catalyzes 
the hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2) to inositol 1,4,5-trisphosphate 
(IP3) and diacyl glycerol (DAG). While the currently most valuable tool for studying PLCβ is 
the small molecule inhibitor U-73122 and analogs thereof68,69, intriguingly also menthol from 
Mentha x piperita previously known to chemically trigger the cold-sensitive Transient receptor 
potential cation channel subfamily M member 8 (TRPM8) and Transient receptor potential 
cation channel, subfamily V, member 3 (TRPV3) in the skin,70 shows an inhibitory effect on 
the PLC pathway.71 
 Plant-derived tools interfering with inositol 1,4,5-trisphosphate (IP3)-mediated 
signaling 
Subsequent to the cleavage of PIP2 to DAG and IP3, the soluble IP3 diffuses to the endoplasmic 
or sarcoplasmic reticulum (ER or SR respectively) and binds to a ligand-gated Ca2+ channel, 
leading to Ca2+ release into the cytoplasm. Thapsigargin is a potent and selective non-
competitive inhibitor of a class of enzymes known by the acronym SERCA, (sarco / 
endoplasmic reticulum Ca2+ ATPase) in the sub-nanomolar range.72 Thus, thapsigargin is useful 
in experimentation, examining the impacts of calcium homeostasis. Structurally, thapsigargin 
is classified as a sesquiterpene lactone of the guaianolide-type, and is isolated from the plant 
Thapsia garganica. Because its mechanism of action provokes apoptosis very effectively, a 
semisynthetic peptide-drug-conjugate (mipsagargin) was tested in a human phase I clinical 
study against androgen-independent metastatic prostate cancer, for which no drug is approved 
at present. It was found to be effective, to have acceptable tolerability and displaying a favorable 
pharmacokinetic profile in patients with solid tumors.73,74 Astonishing in this context, is 
however another study that showed tumor promoting properties of thapsigargin in mammalian 
cells.75 Further effects of thapsigargin are the specific inhibition of the fusion of 
autophagosomes with lysosomes, the last step in the autophagic process.76 
Another natural product used as tool is known to deplete intracellular Ca2+ stores. Ryanodine is 
a diterpenoid from Ryania speciosa. At nanomolar concentrations, ryanodine locks the 
ryanodine receptors (RYR-1, RYR-2, RYR-3) in a half-open state causing Ca2+ release from 
Ca2+ stores of the sarcoplasmic reticulum into the cytoplasm, resulting in massive muscle 
contractions, whereas it fully closes the receptor at micromolar concentration, leading to 
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paralysis.77,78 The vast number of applications for compounds interacting with Ca2+ signaling 
for basic research and in therapy was investigated in detail by Stutzmann and Mattson.79 
 Plant-derived tools, activating or inhibiting protein kinase C 
In terms of GPCR-mediated signaling, elevated Ca2+ as well as DAG levels, have multiple 
effects, e.g. activation of calcium-dependent protein kinase C (PKC), which in turn is involved 
in controlling the function of other proteins via the phosphorylation of serine and threonine 
residues of these proteins.80 There are several natural products reported to inhibit or enhance 
PKC activity such as gossypol, chelerythrine, phorbol esters, and myabenol C.81–84 The latter is 
a stilbenoid resveratrol trimer found in Vitis vinifera with moderate and unselective PKC 
inhibitory activity. Chelerythrine, a benzophenanthridine alkaloid present in the plant 
Chelidonium majus is marketed as a potent, selective, and cell-permeable PKC inhibitor. This 
effect, however, is debunked by many investigators and critically summarized by Wu-Zhang 
and Newton.82 
The latter example demonstrates the potential risks of ever-growing tool boxes without robust 
and high-quality suitability tests. According to the authors82 the continued marketing of 
chelerythrine as a specific PKC inhibitor has resulted in the inappropriate attribution of 
numerous and wide-ranging biological effects to PKC activity. 
Prominent examples of PKC activators are phorbol esters, derived from Euphorbiaceae, i.e. 
Croton tiglium, one of the 50 fundamental herbs used in traditional Chinese medicine. 12-O-
Tetradecanoylphorbol-13-acetate (TPA), also commonly known as phorbol 12-myristate 13-
acetate (PMA) is a diester of phorbol and a potent tumor promoter often employed as a tool in 
biomedical research in models of carcinogenesis.85,86 A structurally related compound, ingenol 
mebutate found in the sap of the plant Euphorbia peplus is applied as drug for the topical 
treatment of actinic keratosis.87 Further it has been found to reactivate latent HIV, thus together 
with anti-retroviral drugs it potentially provides a permanent cure for HIV infection.88 
 Natural products, interfering with GiPCR-mediated signaling 
In a lesser extent, M1-receptors are also reported to bind Gi proteins.46 Gi protein-mediated 
signaling is shown in Figure 1-5 (on the left side, brown arrows). Similar to FR for Gq, pertussis 
toxin (PTX) from Bordetella pertussis locks the Gαi subunit in its GDP-bound, inactive state. 
The mechanism of action differs from that of the Gq inhibitor FR in that PTX catalyzes the 
ADP-ribosylation of the αi subunits of the heterotrimeric Gi protein, preventing the interaction 
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of Gi proteins with their respective GPCRs.89 The value of PTX as a tool to study Gi-related 
processes is undeniable (2928 entries of “pertussis toxin” in titles of scientific publications, 162 
of these have >100 citations each, 04-22-2018, web of science, 
https://apps.webofknowledge.com/WOS_GeneralSearch_input.do?product=WOS&search_m
ode=GeneralSearch&SID=C3sdzHxS5d7xiIivO1J&preferencesSaved=).90–92 
Further downstream, activated and dissociated Gαi binds and inhibits adenylyl cyclase (AC). 
Thus, AC decreases the production of 3',5'-cyclic adenosine monophosphate (cAMP) from 
ATP, which, in turn, results in decreased activity of cAMP-dependent protein kinase (PKA). 
Forskolin, occurring in Plectranthus barbatus, belongs to the group of labdane diterpenes. In 
human and animal organisms, forskolin, acts as direct stimulator of the enzyme AC, responsible 
for cAMP production, and thus has pleiotropic effects. Cyclic adenosine monophosphate acts 
as second messenger, thus as mediator for Gs/Gi coupled signal transduction. Therefore, beside 
its potential for the treatment of glaucoma93,94 forskolin is of particular value as tool in 
biochemistry and pharmacological research on Gi/sPCRs. 
In conclusion it was demonstrated that natural products (especially FR) have tremendous 
potential as lead structures for the development of new drugs95 as well as selective 
pharmacological tools unraveling complex biological processes in physiology and 
pathophysiology.96  
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 Aim of the study 
The cyclic depsipeptide FR900359 (FR) is a selective inhibitor of Gαq/11/14-protein mediated 
signaling of GPCRs and thus extremely useful as a pharmacological tool. This natural product 
is in the center of the DFG-funded research unit 2372. FR is present in the higher plant Ardisia 
crenata, which is known to harbor symbiotic bacteria that we designated as Candidatus 
Burkholderia crenata. 
Within this thesis the ecological function of FR in the plant/symbiont association, which is not 
known to date, shall be investigated. To shed light on the biosynthesis of FR we sequenced the 
genes for a putative nonribosomal peptide synthetase from the endophytic Burkholderia, which 
shall serve as a basis for the heterologous expression and genetic engineering of FR derivatives. 
The sequence of the biosynthetic gene cluster for FR production will also be employed for 
mining publicly available bacterial genomes for bacterial strains, being able to produce FR or 
related compounds. 
To understand the mechanism of action of FR on the molecular level it is necessary to examine 
the structural elements of the depsipeptide FR, responsible for the biological activity. In this 
way the pharmacophore of FR shall be derived. In order to achieve this, structural variants of 
FR shall be obtained by semisynthetic modification of FR, including the development of 
fluorescent FR analogs as molecular tools to study kinetics and the mechanism of cellular 
uptake of FR. Further, FR analogs shall be derived by isolating minor depsipeptide-metabolites 
from A. crenata as well as other Crispardisia known to have related bacterial symbionts. All 
FR derivatives will be assessed in comparison to FR for their bioactivity and will give deep 
insights into structure-activity relationships. 
  
Materials and Methods 
17 
 
 Materials and Methods 
 
 Materials 
 Plant material 
Ardisia crenata was purchased commercially and afterwards cultivated in the 
“Nutzpflanzengarten” of the Institute for Pharmaceutical Biology of the University of Bonn. A. 
lucida leaves were provided by the Botanical Garden Bonn. A herbarium specimen is located 
at the Institute for Pharmaceutical Biology of the University of Bonn. The Ardisia villosa, 
mamillata, hanceana samples were collected in January/2016 at a height of 800 m by excursion 
near Bawang Mountain in Changjiang County, Heinan, China. The specimen were dried at 25 
°C until extraction. 
 
Figure 3-1: Cultivation of Ardisia crenata in the green house of the Univ. of Bonn. 
 
 
Botanical plant name 
 
Drug designation 
 
Origin 
Ardisia crenata SIMS Ardisiae crenatae folium Botanical Garden Bonn 
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Ardisia hanceana Ardisiae hanceanae folium Hao-Fu Dai, Hainan China 
Ardisia lucida Ardisiae lucidae folium Botanical Garden Bonn 
Ardisia mamillata Ardisiae mamillatae folium Hao-Fu Dai, Hainan China 
Ardisia polycephala Ardisiae policephalae folium Botanical Garden Bonn 
Ardisia villosa Ardisiae villosae folium Hao-Fu Dai, Hainan China 
 
 Cultivation, Extraction and growth determination of Chromobacterium vaccinii 
MWU205, DSM 25150 
Chromobacterium vaccinii from a glycerol stock was fermented in Luria-Bertani Medium 
(containing 10 g NaCl, 5 g yeast extract and 10 g tryptone solved in 1 L Milli Q Water and 
adjusted the pH to 7.5 with 5 M NaOH) with carbenicillin (stock concentration: 50 mg/mL; 
final concentration: 0,05 mg/mL) on a rotary shaker at 200 rpm and 25 °C for 24 h. Afterwards 
1% (v/v) of final volume was taken of the pre-culture to inoculate the final cultivation volume 
necessary for the experiment, e.g. 100 mL medium were inoculated with 1 mL medium pre-
culture. Cultivation was also performed by Emilie Goralski and Wiebke Hanke, Institute for 
Pharmaceutical Biology, Univ. of Bonn. 
For growth determination the optical density was measured at 600 nm and 764 nm. 
Measurement was performed once of a sample directly taken out of the culture and once with 
the sample from the culture being centrifuged for 1 minute at 13,300 rpm. The supernatant was 
removed and the pellet was resuspended in 1 mL LB medium. The sample was diluted if 
necessary so that the optical density was around 0.0-0.8.  
Extraction for the production curve of FR and derivatives was done every 12 hours with 40 mL 
butanol for 40 ml culture. After 24 hours the extraction mixture was filled in tubes and 
centrifuged at 4000 rpm for 5 minutes. The organic phase was collected. Afterwards, 40 mL 
butanol was added, mixed, directly centrifuged and again the organic phase was taken. The 
phases were united and evaporated. LCMS measurements of every sample were conducted. 
Experiments were performed by Wiebke Hanke, Institute for Pharmaceutical Biology, Univ. of 
Bonn. 
Chemicals were purchased from Carl Roth and Hedinger. 
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 Chemicals 
 Chemicals: 
  
- 2-Aminoethanethiol hydrochloride Sigma-Aldrich (Steinheim, Germany) 
- Acetic anhydride (99.6%)  VWR International (France) 
- Acetone-d6     Deutero GmbH (Kastellaun, Germany)  
- Acetonitrile HPLC grade)  VWR International (France) 
- Acetonitril-d3   Deutero GmbH (Kastellaun, Germany) 
- Acetyl Chloride    Sigma-Aldrich (Steinheim, Germany) 
- N-Boc-2-aminoethanethiol  Sigma-Aldrich (Steinheim, Germany) 
- BODIPY-630/650-X-SE  ThermoFisher Scientific (Hennef, Germany) 
- n-Butanol    Roth (Karlsruhe, Germany) 
- Chloroform    Roth (Karlsruhe, Germany) 
- Chloroform-d1    Deutero GmbH (Kastellaun, Germany) 
- Deuteriumoxide   Deutero GmbH (Kastellaun, Germany) 
- DCM (pure, anhydrous)  Roth (Karlsruhe, Germany) 
- DMAP    Roth (Karlsruhe, Germany) 
- DMSO-d6    Deutero GmbH (Kastellaun, Germany) 
- Hexanoic anhydride   Sigma-Aldrich (Steinheim, Germany) 
- HPLC- grade water 
- Methanol-d4 (99.8 %)   Deutero GmbH (Kastellaun, Germany) 
- Methanol (hypergrade for LC/MS) Merck (Darmstadt, Germany) 
- Methanol (HPLC gradient grade) Avantor (Deventer, Netherlands) 
- Potassium hydrogen sulfate  Roth (Karlsruhe, Germany) 
- Pyridine (99%)   Roth (Karlsruhe, Germany)  
- Sodium chloride    Roth (Karlsruhe, Germany)  
- Sodium dodecyl sulfate   Sigma-Aldrich (Steinheim, Germany) 
- Sodium hydrogen carbonate Sigma-Aldrich (Steinheim, Germany) 
- Sodium sulfate    Sigma-Aldrich (Steinheim, Germany) 
- TAMRA-Thiol   BioActs (South Corea) 
- TPGS-750-M   Sigma-Aldrich (Steinheim, Germany) 
- Triethylamine   Roth (Karlsruhe, Germany) 
- Trifluoroacetic acid (TFA) 99.9% Roth (Karlsruhe, Germany)  
 
Solvents used for chromatography were distilled before application, especially acetone, ethyl 
acetate, methanol and dichloromethane. Water for HPLC purification was taken from „Milli-Q 
Reagenzwasser“-system (Millipore, Eschborn, Germany). Reagents for chemical derivatization 
of FR were purchased from commercial sources and were used without further purification. 
Oxygen- or water-sensitive reactions were performed under argon atmosphere. Standard 
coupling reagents (HBTU, HOBt, TFFH, PyBOP), resins and amino acid derivatives used for 
Materials and Methods 
20 
 
solid phase synthesis of analogs were purchased from Orpegen Peptide Chemicals GmbH 
(Heidelberg, Germany), Novabiochem and IRIS Biotech (Marktredwitz, Germany), 
respectively. Peptide synthesis reagents (piperidine, DIEA, trifluoroacetic acid, BTSA) and 
solvents (N,N-dimethylformamide, and dichloromethane) were of reagent grade, and solvents 
for chromatography (acetonitrile, water, and methanol) were of analytical grade obtained from 
VWR International (Dresden, Germany). Cell culture reagents were purchased from Invitrogen. 
All other reagents were from Merck (Darmstadt, Germany), Fluka (Buchs, Switzerland), 
Sigma-Aldrich (Steinheim, Germany) and Roth (Karlsruhe, Germany). 
 Other materials 
- Hamilton syringe 100µl   Sigma-Aldrich (Steinheim, Germany) 
- Pasteur pipettes    Roth (Karlsruhe, Germany) 
- Pipette tips 200µl, 1000µl Tip One ®  Starlab GmbH (Hamburg, Germany) 
 
 Extraction of Ardisiae crenatae folium 
After harvesting and drying 150g leaves of Ardisia crenata, the dried leaves were crushed and 
extracted three times with 800ml MeOH each. The methanol crude extract, about 40 g, was 
suspended in 1000ml distilled water and extracted with three times 400ml BuOH in a separation 
funnel to yield about 20 g BuOH-extract. 
 
 Chromatographic methods 
 Thin layer chromatography (TLC) 
Thin layer chromatography was used to get information about the running performance of FR 
and its derivatives in several solution systems and to determine their purity. TLC was carried 
out using either TLC aluminum sheets (20 x 20 cm) silica gel 60 F254 (Merck 1-05554) or TLC 
aluminum sheets (20 x 20 cm) RP-18 F254 (Merck 1-05559) as stationary phase. Standard 
chromatograms of plant extracts and fractions were prepared by applying 20 µL of solution (1 
mg/mL) to a TLC plate and using CHCl3/MeOH/H2O = 26:15:3 as mobile phase under chamber 
saturated conditions. Developed chromatograms were detected under UV light at λ = 254 nm 
(fluorescence quenching) and λ = 366 nm (intrinsic fluorescence). Afterwards they were 
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sprayed with vanillin-sulphuric acid reagent (0.5 g vanillin dissolved in a mixture of 85 ml 
methanol, 10 mL acetic acid and 5 sulphuric acid, TLC plate heated at 110°C after spraying) 
giving colored spots on a white plate and subsequently analyzed. For reaction control of the 
synthesis of compound 12, the plates were sprayed with ninhydrin. 
 Vacuum liquid chromatography (VLC) 
VLC is a method to separate both large and small quantities of mixtures efficiently, rapidly, 
and inexpensively. Basically, it is a column chromatography accelerated by vacuum.97,98  
Fractionation of crude extracts (BuOH) was performed with VLC. Depending on the amount 
of extract, columns with 4 cm diameter (500 mg to 2 g), 6.5 cm diameter (2 to 4 g) or 10 cm (> 
4 g) were used. Vacuum liquid chromatography was carried out using Polygoprep 60-50 RP18 
(Macherey-Nagel, Düren, Germany). Sorbent was poured as a suspension into the column and 
compressed under vacuum for accelerating the separation. Afterwards, the system was 
equilibrated with 200 mL of the first solvent (MeOH/H2O = 30/70). The sample was dissolved 
in low volume of the same solvent mixture and applied on the surface. For RP separation 
water/methanol mixtures with various ratios were used (MeOH/H2O = 30/70  MeOH/H2O = 
100/0). Each fraction contained 200mL solvent when a 10 cm column was used. 
 Size exclusion chromatography (SEC) 
After pre-fractionizing via VLC, based on polarity the following size exclusion 
chromatography (SEC) procedure helped to separate FR from other substances with similar 
polarity but varying size. Therefore, the FR-containing VLC-fraction (Fraction 7) diluted in a 
minimal amount of MeOH was put onto the 100cm in height and 2cm in diameter column, filled 
with Sephadex LH-20 material dispersed in MeOH. After sample loading, the column was 
eluted with MeOH by gravity and eight fractions with 20ml each were collected after the first 
100ml were discarded (dead volume). About ninety percent of FR elute in Fraction 7.3 and 
lower quantities of FR are situated in fraction 7.4 together with high amounts of contaminants. 
 Flash chromatography 
A Reveleris X2 Flash Chromatography System with UV-detector and ELSD was used. 
Software: Navigator. For sample preparation 3 g-, 12 g- or 40 g-solid loader was applied. 
Packing of the solid loaders was achieved through adsorption of the sample onto silica gel 60 
(0.063-0.200 mm, Merck) or Polygoprep 60 C18 (0.05 mm, Machery-Nagel), respectively. The 
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dried material was then filled into the solid loader. Reveleris® flash cartridges, prefilled with 4 
g, 12 g, 40 g, 120g or 220 g of C18-silica, were used (with 40 µm particle size). 
 Solid phase extraction (SPE) 
For solid phase extraction, a Bakerbond C18 column (2000 mg/6mL) was used. Separations 
were performed using water-methanol mixtures with decreasing polarity and accelerated by a 
membrane vacuum pump. Column was equilibrated with the first designated eluent. 
 High performance liquid chromatography (HPLC) 
HPLC is a sort of column chromatography, pressing liquid solvent assisted by pumps through 
a column filled with a solid adsorbent material.99 HPLC is the method of choice for analysis of 
substance mixtures for qualitatively and quantitatively purposes. 
Following systems containing an interface, a pump, an injector, a detector, and a fraction 
collector were used for HPLC purification of extracts and compounds: 
System A:  Waters system, controlled by Millenium software, equipped with a 600 Controller 
pump, a 717 plus autosampler with in-line Degasser AF and a 996 photodiode array detector 
and fractionizer. 
System B: Waters 1525µ binary pump with Waters 2998 diode array detector (DAD). 
Software: Breeze 2 (© 2008 Waters C.) 
System C: Waters HPLC system equipped with a 2695 separation module, a 996 DAD and 
QuickStart Empower 2 software (© 2005 Waters Co.). 
 
Following columns were used: 
Column A: YMC Hydrosphere C18, 3µm, 250x4.6 mm, analytical column (raw peptide 
isolation) 
Column B: Nucleodur RP18 plus column, 5 µm, 250 x 8 mm, semi-preparative column (raw 
peptide isolation) 
Column C: Nucleoshell RP18 plus column 5 μm, 250 x 4.6 mm, analytical column (pure 
FR900359 isolation)  
Column D: Kinetex C18 column 5 μm, 250 x 4.6 mm, analytical column 
 
As solvent for RP columns, usually methanol/water mixtures with ratios between 70/30 and 
100/0 were used. If a degasser was not part of the instruments, the solvent was degassed under 
reduced pressure via water jet pump. For optimization of FR900359 isolation on a RP18 column 
the following modifier were added to the methanol/water solvent: trifluoroacetate (0.05 %). 
Analytical columns were used with a flow of 0.70 to 1 mL/min. 25 μL of an extract, which was 
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adjusted to a concentration of 10-20 mg/mL were injected. Separation was monitored with UV-
detector systems. 
 Isolation protocols 
 Depsipeptide isolation and purification 
Bioassay, LC-MS and 1H NMR guided fractionation of the crude extracts obtained from the 
plant Ardisia crenata, yielded the cyclic depsipeptide FR. The investigated plant material was 
cultivated in the green house of the Botanical Garden Bonn. 
200 g of dried plant leaves were coarsely crashed and extracted with methanol. Further 
purification steps included liquid-liquid extraction, RP-18 vacuum liquid chromatography and 
size exclusion chromatography.  
 
 Isolation of FR and FR analogs (1-4) 
Final purification was done by HPLC with a semi-preparative YMC Hydrosphere RP-18 
column (250 x 4.6 mm, 3µm). The elution system was water (eluent C) and methanol (eluent 
D). The crude peptide was derived with isocratic conditions (80% eluent D for 35 minutes). 
The separation of FR from its analogs was achieved using a Nucleoshell RP18+ column (250 x 
8 mm, 5 μm) with isocratic 75% eluent D for 20 minutes, followed by a linear gradient to 100% 
eluent D in 35 minutes. Pure FR was isolated as a white powder tR: 28.2 min (10 mg from 200 
g dried leaves). The isolation scheme is shown in Scheme 5-1. 
Compound 1 was isolated as described by Crüsemann & Reher et al.10 A shoulder of the FR 
peak eluting prior to FR was collected. This fraction included a peptide mix of FR and another 
similar peptide as judged from LC-MS data. HPLC conditions had to be adjusted to separate 
the new peptide quantitatively from FR. The composition of the mobile phase was changed 
from isocratic 80% methanol to 75% methanol and a Nucleoshell RP18+ column 5 µm, 250 x 
8 mm was applied. The new cyclic depsipeptide, FR-1 (1)) was obtained as white powder (tR: 
23.0 min, 0.7 mg from 200 g dried leaves). The isolation process was repeated until 2.8 mg of 
AC-1 were collected for structure elucidation. 
 
Compound 2 had only slightly different retention times compared to 1 (for the complete 
isolation scheme refer to Scheme 5-1). The composition of the mobile phase was changed from 
isocratic 80% eluent D to 75 % eluent D applying a 75:25 Nucleoshell RP18+ column (250 x 8 
mm, 5 µm) for 20 minutes followed by a linear gradient from 75–100% eluent D within 15 
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minutes. The new cyclic depsipeptide, 2, was obtained as white powder (about 0.2 mg from 200 
g dried leaves, tR = 23.7 min). The isolation process was repeated until 1.6 mg of 2 were 
collected for structure elucidation. 
 
Further, a shoulder of the FR peak eluting after FR was collected. This fraction included a 
peptide mix of FR-3 (3) and FR-4 (4) as judged from LC-MS data. HPLC conditions had to be 
adjusted to separate the new peptides from each other. The composition of the mobile phase 
was changed from isocratic 80% methanol to 75% methanol and a Nucleoshell RP18+ column 
5 µm, 250 x 8 mm was applied. The new cyclic depsipeptides, FR-3/FR-4 = 3:1 were obtained 
as white powder (tR: 30 min, 0.2 mg from 200 g dried leaves). The isolation process was 
repeated until 0.8 mg of FR-3/FR-4 was collected for structure elucidation. Compound 3/4 (FR-
3/FR-4): <0.5mg/kg dried plant material (predominantly leaves). 
 
 Synthetic procedures 
Reagents were purchased from commercial sources and were used without further purification. 
Oxygen- or water-sensitive reactions were performed under argon atmosphere. The synthesized 
compounds were analyzed by uHPLC-MS/MS on a micrOTOF-Q mass spectrometer (Bruker) 
with ESI-source coupled with an HPLC Dionex Ultimate 3000 (Thermo Scientific) using a 
Zorbax Eclipse Plus C18 1.8 µm column, 2.1x50 mm (Agilent). The column temperature was 
45 °C. MS data were acquired over a range from 100–3000 m/z in positive mode. Auto MS/MS 
fragmentation was achieved with increasing collision energy (35–50 keV over a gradient from 
500–2000 m/z) with a frequency of 4 Hz for all ions over a threshold of 100. UPLC begins with 
90% H2O containing 0.1% acetic acid. The gradient starts after 0.5 min to 100% acetonitrile 
(0.1% acetic acid) in 4 min. 2 µL of sample solution was injected to a flow of 0.8 mL/min. 
 Synthesis of FR-Hex (11) 
Compound 11: (2S,3R)-1-((1R)-1-((6S,9S,12S,18R,21S,22R)-21-acetamido-18-benzyl-22-
isopropyl-3-((R)-1-methoxyethyl)-4,9,10,12,16-pentamethyl-15-methylene-2,5,8,11,14,17,20-
heptaoxo-1,19-dioxa-4,7,10,13,16-pentaazacyclodocosan-6-yl)-2-methylpropoxy)-4-methyl-
1-oxo-2-propionamidopentan-3-yl hexanoate 
FR (20 mg, 19.96 µmol) was dissolved in pyridine (1 mL) and stirred at room temperature 
under argon atmosphere. DMAP (12.2 mg, 99.8 µmol) and hexanoic anhydride (21.4 mg, 99.8 
µmol) was added. After 2 h the reaction mixture was heated to 50 °C and stirred. After 16 h at 
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50 °C the reaction was stopped by diluting with 5 mL water and the reaction mixture was 
extracted with CH2Cl2 (3 mL x 3). The combined organic layers were washed with solutions of 
NaHCO3 (pH 9), KHSO4 (pH 2) and saturated NaCl and afterwards dried over Na2SO4 and 
concentrated in vacuo. Crude peptide was purified by HPLC, YMC Hydrosphere C18 column 
(250 x 4.6 mm, 3 µm). The elution system was 0.05% TFA in water (eluent E) and 0.05% TFA 
in acetonitrile (eluent F). A linear gradient was applied from 70% eluent F to 100% eluent F in 
30 minutes. 11 eluted at tR = 13.1 min and after solvent evaporation appeared as white-yellow 
powder (2.6 mg). 
 
 Synthesis of FR-Cys (12) 
Compound 12: (2S,3R)-(1R)-1-((6S,9S,12S,18R,21S,22R)-21-acetamido-15-(((2-
aminoethyl)thio)methyl)-18-benzyl-22-isopropyl-3-((R)-1-methoxyethyl)-4,9,10,12,16-
pentamethyl-2,5,8,11,14,17,20-heptaoxo-1,19-dioxa-4,7,10,13,16-pentaazacyclodocosan-6-
yl)-2-methylpropyl 3-hydroxy-4-methyl-2-propionamidopentanoate 
To a micellar solution of SDS (1 mL), at the critical micelle concentration (CMC) = 8.1 x 10-3 
M), was added FR (20 mg, 19.96 µmol), 2-aminoethanethiol hydrochloride (26.7 mg, 199.6 
µmol) at room temperature. The mixture was stirred vigorously (800 rpm) and monitored by 
TLC until the starting material had been consumed after 12 h. Then the mixture was extracted 
with butanol (3 mL x 3). The combined organic layer was dried over Na2SO4 and concentrated 
in vacuo. The crude peptide mixture was purified by HPLC, Nucleoshell RP18+column (250 x 
4.6 mm, 5 μm). The elution system was water (eluent C) and methanol (eluent D). 12 elutes at 
tR = 27.2 minutes using isocratic conditions (57% eluent D for 35 minutes) and and appears as 
transparent film (6 mg) after solvent evaporation. 
 
 Synthesis of FR-RR-BP (46) 
20 mg of FR were reacted with 10 eq cysteamine hydrochloride, using DL-α-Tocopherol 
methoxypolyethylene glycol succinate (TPGS-750-M, 2 wt %) in aqueous media to obtain 7.5 
mg of compound 12 (25%). The reaction was performed under argon atmosphere to avoid 
cysteamine oxidation to the corresponding disulfide. 
7.5 mg (1 eq) of compund 12 was dissolved in 500 µL DMSO, 10µL of 100 mM triethylamine 
was added to the reaction solution to ensure amine deprotonation. Next, the amine-reactive dye 
BODIPY630/650-X-NHS (5 mg, about 1.1 eq) was added to the reaction solution. The reaction 
mixture was stirred at room temperature for 4 hours, protected from light. Subsequently to 
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freeze-drying, the conjugate was purified via HPLC and the desired conjugated FR-RR-BP (46) 
was obtained in moderate yields (3 mg from 7.5 mg 12, 40%). 
 
 Synthesis of FR-Cys-Boc (47) 
In general we applied the protocol from the synthesis of compound 47 (see Chapter 6.2) with 
small changes. We reacted 35 mg of FR with 20 eq N-Boc-cysteamine under argon atmosphere 
in 1 mL hypergrade methanol containing 10 % milli-Q water; deprotonation of the thiol was 
achieved by addition of 20 eq TEA. The reaction was stirred vigorous for 2.5 h at 40 °C. Then 
we added 10 ml milli-Q water and extracted three times with 15 mL butanol each. Afterwards 
the raw product was purified by flash chromatography (Appendix Figure 10-3) and HPLC to 
yield 27 mg of compound 50 (FR-Cys-Boc) again as mixture of oxidized and unoxidized 
product (Scheme 6-2). 
 
 Synthesis of FR-JK-Boc (48) and FR-JK-BP (49) 
LinkerJK was synthesized and provided by Jim Küppers (Gütschow lab, Institute for 
Pharmaceutical Chemistry I, Univ. of Bonn) and contained two ethylene glycole units with a 
terminal tert-butyloxycarbonyl (=Boc)-protected amine on the one side and a free terminal thiol 
group on the other side (Scheme 6-2). In general the synthesis protocol of compound 12 was 
applied with small changes. 40 mg of FR (about 40 µM) and 120 mg LinkerJK (370 µM) were 
dissolved in 1 mL hypergrade methanol containing 10 % milli-Q water under argon atmosphere; 
pH was adjusted to 9.1 with Na2CO3/NaHCO3 buffer. The reaction was stirred vigorously 
overnight. Next morning, the reaction mixture was heated for 2 h to 45 °C. Afterwards 10 ml 
milli-Q water were added to stop the reaction and extracted three times with 15 mL butanol 
each. The organic phase was dried over Na2SO4 and concentrated in vacuo. Afterwards the 
crude product was purified by flash chromatography (Appendix Figure 10-1) to yield 15 mg of 
the desired FR-Linker conjugate (FR-JK-Boc, 48). The acid-labile Boc group of compound 48 
was then cleaved with a mixture of DCM/TFA = 5/1 and subsequently carefully evaporated 
under reduced pressure. To prevent concentration of TFA we added DCM several times, before 
evaporating to dryness. This procedure was repeated ten times and the outcome controlled by 
thin layer chromatography (TLC) sprayed with ninhydrin to detect the primary amine of 
compound 48. After removal of final TFA residues we carried out the last step of the synthesis, 
adding BODIPY630/650-X-NHS ester in DMSO and trimethylamine as catalyst. The reaction 
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was stirred over night at room temperature and protected from light. After HPLC purification 
of the 10 mg raw product we finally yielded 1.4 mg of the desired product FR-JK-BP (49). 
 Synthesis of FR-TAMRA (50) 
In general, we applied the synthesis protocol of compound 47 (see Chapter 3.5.4) with small 
changes. We reacted 25 mg of FR with 25 mg TAMRA-thiol (2 eq) under argon atmosphere in 
1 mL hypergrade methanol containing 10 % milli-Q water; deprotonation of the thiol was 
achieved by addition of 2 eq TEA. The reaction was stirred vigorous for 2.5 h at 40 °C protected 
from light. Then we added 10 ml milli-Q water and extracted three times with 15 mL butanol 
each. Afterwards the raw product was purified by flash chromatography (Appendix Figure 10-
2) and HPLC to yield 1.1 mg of compound 50 (FR-TAMRA). 
 Synthesis of Fmoc-β-HyLeu-OH 
For the preparation of Fmoc-β-HyLeu-OH, a mixture of H-β-HyLeu-OH (1 equiv.) in DCM 
was stirred while bis(trimethylsilyl)acetamide (6 equiv.) was added dropwise over a duration 
of 15 min at room temperature until complete dissolution and allowed to stir for further 2 h. 
The solution was cooled to 0 °C and DIEA (1.25 equiv.) added at once. Under vigorous stirring 
Fmoc-Cl (1.25 equiv.) was added in portions for a duration of 30 min while stirring at 0 °C. 
This was continued for 1 h on ice and further 4 h at room temperature. The solvent was removed 
and the crude product (oil) was dissolved in ethyl acetate and washed with salt solutions of 5% 
KHSO4, saturated NaCl (brine), saturated NaHCO3, and again with brine. The ethyl acetate was 
dried with sodium sulphate (anhydrous) and then filtered. The solvent was removed and the 
product redissolved in 80% t-BuOH. Subsequent freeze-drying gave Fmoc-β-HyLeu-OH (48%) 
as a white powder. Purity was confirmed by analytical HPLC using a Vydac 218TP54 column 
(C18, 5 µm particle size, 300 Å pore size, 4.6 mm × 25 mm) and a gradient of 20% to 80% 
acetonitrile in water with 0.1% TFA in one hour (tR = 29.86 min). Further Characterization of 
the product was performed by mass spectrometry, NMR spectroscopy and thin layer 
chromatography (TLC). 
MS (ESI): mass calculated for C21H23NO5, 369.2; m/z found, 370.2 [M+H]
+. 1H NMR (600 
MHz, CDCl3) δ ppm 0.92 (d, J = 6.6 Hz, 3H), 1.02 (d, J = 6.6 Hz, 3H), 1.80–1.71 (m, 1H), 3.82 
(dd, J = 9.2, 1.1 Hz, 1H), 4.19 (t, J = 7.2 Hz, 1H), 4.36 (dd, J = 7.2, 4.7 Hz, 2H), 4.58 (dd, J = 
9.4, 1.2 Hz, 1H), 4.84 (br s, 1H), 5.94 (d, J = 9.4 Hz, 1H), 7.27 (dd, J = 7.4, 7.4 Hz, 2H), 7.40–
7.33 (m, 2H), 7.57 (dd, J = 11.7, 7.5 Hz, 2H), 7.73 (dd, J = 7.5, 2.3 Hz, 2H). 13C NMR (151 
MHz, CDCl3, T = 298 K) δ ppm 19.0, 19.3, 30.9, 47.2, 56.3, 67.5, 77.5, 120.1 (2C), 125.3, 
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125.3, 127.2 (2C), 127.8 (2C), 141.4 (2C), 143.7, 144.0, 157.2, 175.7. TLC was performed 
using glass plates impregnated with silica gel 60 F254, 10 x 20 cm. The applied solvent system 
was chloroform/methanol (9:1). Detection was done by UV at a wavelength of 254 nm. The 
observed Rf value was 0.83. 
 
 Peptide synthesis and purification 
Peptides 13-22 were synthesized by Dr. Toni Kühl Britta Nubbemeyer, Justin Patrick 
Odhiambo, Pascal Heimer and Charlotte Anneke Bäuml, Institute for Pharmaceutical 
Chemistry, Univ. of Bonn). The linear precursor peptides of 15, 16, 19, and 20 were synthesized 
on an automated peptide synthesizer EPS 221 (Intavis Bioanalytical Instruments AG, Cologne, 
Germany) according to a standard Fmoc-protocol. Peptides 13, 14, 17, 18, 21, and 22 were 
synthesized manually. The polymer support was 2-chlorotrityl chloride resin with a loading 
capacity of 2.1 mmol/g (Advanced ChemTech 5609 Fern Valley Road, Louisville KY, USA) 
for manual peptide synthesis or alanine-loaded 2-chlorotrityl chloride resin with a loading 
capacity of 0.67 mmol/g (Iris Biotech GmbH, Marktredwitz, Germany) for automated peptide 
synthesis. Amino acid derivatives used were as follows: Fmoc-N-Me-Thr(tBu)-OH; Ac-Thr-
OH; Fmoc-N-Me-Ala-OH; Fmoc-Lys(Ac)-OH and Fmoc-Thr(Ac)-OH, Fmoc-N-Me-D-Phe-
OH, Fmoc-6-Ahx-OH, Boc-Dap(Fmoc)-OH and Fmoc-Leu-OH, Fmoc-β-HyLeu-OH. 
For manual peptide synthesis, coupling reactions were performed as double couplings using 
Fmoc-amino acids (4 equiv.) activated with TFFH (4 equiv.) for 12 min, in the presence of 
DMF and DIPEA (8 equiv.). Fmoc removal was carried out by treating the resin twice with 
20% of piperidine in DMF for 5 and 15 min, respectively. All deprotection and coupling steps 
were followed by intensive washings using DMF and DCM alternately. Peptide cleavage and 
deprotection was accomplished with 5% TIPS in 95% TFA/H2O for peptides 13–22 for 3 h at 
room temperature. The crude peptides were precipitated in cold diethyl ether, centrifuged and 
washed with diethyl ether several times. Linear peptides were of sufficient purity and 
subsequently used without prior purification for the following steps. The peptide cyclization 
was performed using PyBOP (6 equiv.) and DIEA (12 equiv.) in DMF (final concentration of 
peptides: 320 µM) for 6 h at room temperature. 
The crude peptides were evaporated and then purified by semi-preparative reversed-phase 
HPLC using a Shimadzu LC-8A system (Duisburg, Germany) equipped with a C18 column 
(250 × 32 mm, Knauer Eurospher 100, Berlin, Germany). The gradient elution system was 0.1% 
TFA in water (eluent A) and 0.1% TFA in acetonitrile/water (9:1) (eluent B). The peptides were 
eluted with varying gradients of eluent B in eluent A in 120 min as depicted in Table S2 and a 
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flow rate of 10 mL/min. The peaks were detected at 220 nm. Collected fractions were combined, 
freeze-dried and stored at −20 ºC. Purity of the peptides was confirmed by analytical reversed-
phase HPLC on a Shimadzu LC-10AT chromatograph (Duisburg, Germany) equipped with a 
Vydac 218TP54 column (C18, 5 µm particle size, 300 Å pore size, 4.6 mm × 25 mm). The 
peptides were eluted with varying gradients as noted in Table S2. The flow rate was 1 mL/min 
with eluent A: 0.1% TFA in water and eluent B: 0.1% TFA in acetonitrile; detection was at 220 
nm. All peptides used for biological assays were of >95% HPLC purity. 
 
 Chemical characterization of FR-analogs 1-22 
Peptides were characterized by analytical HPLC (see above), amino acid analysis, and mass 
spectrometry. For amino acid analysis, samples (0.5–1 mg) were hydrolyzed in 6 N HCl at 110 
°C for 24 h, dried and used for analysis in sample dilution buffer (Onken Laboratories, 
Hamburg, Germany) on an Eppendorf Biotronik Amino Acid Analyzer LC3000. The molecular 
weight of crude and purified peptides 13–22 was confirmed by mass spectrometry on an ESI 
micrOTOFQ III system (Bruker Daltonics GmbH, Bremen, Germany). 
TLC characterization was performed using glass plates impregnated with silica gel 60 F254, 10 
x 20 cm. Two solvent systems were applied, which were; system A: n-butanol/acetic acid/water 
(48:18:24) and system B: n-propanol/ 25% NH3 (7:3). Detection methods used were UV at a 
wavelength of 254 nm and KI-containing acetic o-tolidin solution. 
The chemical characterization of FR analogs 1-12 is explained in detail in chapters 5.1 and 5.2. 
 
 Structure elucidation  
 Mass spectrometry 
Mass spectrometry was performed on the following systems: 
 LC-ESI-MS using an HPLC coupled to a quadrupole analyzer (system A) 
Samples were adjusted with hypergrade methanol for LC/MS to a concentration of 1 mg/mL. 
500 µL of the extract samples were given to LC/MS analysis or 100 µL of pure compound 
samples. Ms. E. Egereva (Institute for Pharmaceutical Biology, University of Bonn, Germany) 
performed the measurements using an Agilent 1100 system including a diode array detector 
(DAD) and an API 2000 Triple Quadrupole LC/MS/MS with ESI source (Applied 
Biosystems/MDS Sciex, Analyst software). An RP-18 column (Machery-Nagel Nucleodur 100, 
125 x 2 mm, 5 µm) served as stationary phase. Gradient elution was used with following 
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parameters: It started at MeOH/H2O (10/90) and was ramped up to 100% MeOH in 20 min, 
followed by isocratic elution with 100% MeOH, NH4OAc was added as a buffer (c = 2 mM); 
flow rate: 0.25mL/min. Experiments were recorded only in positive ode using a declustering of 
either 30 V (experiment 1) or 70 V (experiment 2).  
 High resolution LC-ESI-MS using a UPLC System coupled to Qq-TOF (system B1) 
Spectra were recorded by Dr. Max Crüsemann (Institute for Pharmaceutical Biology, 
University of Bonn, Germany). A micrOTOF-Q mass spectrometer (Bruker) with ESI-source 
coupled to a HPLC Dionex Ultimate 3000 (Thermo Scientific) and a EC10/2 Nucleoshell C18, 
2.7 µm column (Machery-Nagel) was used. The column temperature was set to 25°C. 
MS data were acquired over a range from 100-3000 m/z in positive mode. Auto MS/MS 
fragmentation was achieved with rising collision energy (35-50 keV over a gradient from 500-
2000 m/z) with a frequency of 4 Hz for all ions over a threshold of 100. 
HPLC started with 90 % H2O containing 0.1 % acetic acid. The gradient starts after 1 min 
ending up with 100 % CAN (0.1 % acetic acid) in 20 min. The flow was set to 0.3 mL/min. 5 
µL per sample solution (0.5 mg/mL) was injected for each run. 
 UPLC/MS of extracts and pure compounds (system B2) 
Fractions from A. crenata were analyzed by UPLC-MS/MS on a micrOTOF-Q mass 
spectrometer (Bruker) with ESI-source coupled with a HPLC Dionex Ultimate 3000 (Thermo 
Scientific) using a Zorbax Eclipse Plus C18 1.8 µm column, 2.1x50 mm (Agilent). The column 
temperature was 45 °C. MS data were acquired over a range from 100-3000 m/z in positive 
mode. Auto MS/MS fragmentation was achieved with rising collision energy (35-50 keV over 
a gradient from 500-2000 m/z) with a frequency of 4 Hz for all ions over a threshold of 100. 
uHPLC begins with 90 % H2O containing 0.1% acetic acid. The gradient starts after 0.5 min to 
100% acetonitrile (0.1% acetic acid) in 4 min. 2 uL of sample solution was injected to a flow 
of 0.8 mL/min. 
 Tandem mass spectrometry (MS-MSn), system C 
Spectra were recorded by Dr. Marc Sylvester (Institute for Biochemistry and Molecular 
Biology, Univ. of Bonn). The dried samples were dissolved in 50 µL ACN/H2O (70/30) per 
vial. 2 µL of this solution was then diluted in an Eppendorf vial using 18 µL of 0.1& formic 
acid. The resulting solution was centrifuged for several minutes at 12,000 g to separate 
precipitates. 
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2 µL (=0.4% of the original sample) were injected onto a C18 trap column (20 mm length, 100 
µm inner diameter) coupled to a C18 analytical column (200 mm length, 75 µm inner diameter), 
made in house with 1.9 µm ReproSIl-Pur 120 C18-AQ particles (Dr. Maisch, Ammerbuch, 
Germany). Solvent A was 0.1% formic acid. Analytes were separated during a linear gradient 
from 1% to 35% solvent B (90% ACN, 0.1% formic acid) within 40 min and 35% to 50% 
within 7 min at a flow rate of 320 nL/min. 
The nanoHPLC was coupled online to an LTQ Orbitrap Velos mass spectrometer using a 
nanoESI ion source (Thermo Fisher Scientific, Bremen, Germany). Precursor ions between 800 
and 1200 m/z were scanned in the Orbitrap detector with a resolution of 30,000 (maximum fill 
time 400 ms, AGC target 106, lock mass 1002.53939 Da (for FR)). The 10 most intense 
precursor ions (threshold intensity 5000) were subjected to collision induced dissociation and 
fragments also analyzed in the linear ion trap. Fragmented ions were excluded from repeat 
analysis for 15 s. 
The term MS/MSn (also known as tandem mass spectroscopy) refers to instruments in which 
two independent stages of m/z analysis are used. This type of analysis helps to establish the 
relationships between ions in a mass spectrum, for example what ions are formed when the M+. 
or other ions in the spectrum undergo fragmentation. This, in turn, helps to elucidate 
fragmentation pathways for the molecule being studied and finally leads to structure 
determination.100 
Peptide fragment ions are labeled according to a nomenclature system developed by Ngoka et 
al.101 based on Biemanns modifications102 of Roepstorffs nomenclature103. Scheme 3-1 serves 
as an example for the initial step of FR fragmentation and illustrates the nomenclature. The 
system makes use of the general formula xnJZ where “x” is the designation for the general type 
of ion series. Thus, after peptides fragment in MS/MSn experiments, they form acylium ions, 
i.e. “b” series, ammonium ions, i.e. “y” series, and if carbon monoxide (CO) is cleaved from 
“b” ions, “a” ions are produced. These types of ions (“a”, “b”, “y”) are usually given, including 
the number (n) of amino acids as a suffix, i.e. “b7” means that an acylium ion is composed of 
seven amino acids. In cyclic peptides breakage of the amide (or ester bond) lead to the formation 
of a linear peptide with a C-terminal oxazolone ring. “J” and “Z” are the one-letter codes for 
the two amino acid residues, which were connected via the former backbone amide or ester 
bond, i.e. “J” is the N-terminal amino acid residue and “Z” the novel C-terminal oxazolone of 
the linearized peptide. If non-proteinogenic amino acids occur in the peptide, nomenclature is 
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modified, for example N-acetyl-hydroxyleucine is designed as L’ instead of L. When a fragment 
ion is sodiated, sodium is omitted from the label for simplicity, and the fragment is designated 
by a superscript asterisk, for example b*nJZ = [bnJZ – H + Na]+. Although peptide backbone 
cleavage is the most useful for sequencing and peptide identification, other fragment ions may 
be observed under high-energy dissociation conditions. These include the side chain loss ions 
d, v, w and immonium ions.104 
 
Scheme 3-1: Initial cleavage of the cyclic backbone of FR, producing the linear acylium ion b*8L’T’. x = type 
of ion = acylium ion (oxazolone) = b, n = number of amino acid residues of which the ion consists of = 8, J = “N-
like” terminus = “N-like”, because in depsipeptides the amino terminus does not exists but a terminal hydroxyl 
group = L’ (N-acetyl-hydroxyleucine), Z = C-terminus = in cyclic peptides often as oxazolone ring, for reasons of 
charge delocalization = T’ (N,O-dimethyl-threonine). 
 
A schematic diagram of MS/MS instrumentation and workflow is illustrated in Scheme 3-2. 
The MS/MS spectra in the current study were recorded on Thermo Dionex UltiMate 3000 with 
splitted nanoflow via UltiMate 3000 RSLCnano connected to Thermo LTQ Orbitrap Velos 
(mass analyzer). Dr. M. Sylvester, scientific officer, Institute of Biochemistry and Molecular 
Biology (IBMB), Bonn, Germany, performed all experiments. 
After sample injection into the Advion TriVersa NanoMate the analyte is ionized by chip-based 
nano-ESI105 and the ions are conveyed to the first analyzer, a linear ion trap (MS1 spectrum). 
There, ions of certain m/z-values are selected and directed to the collision chamber. The 
molecular ions are allowed to collide with neutral molecules, i.e. helium gas. The technique is 
called Collision-induced dissociation (CID), also known as collisionally activated dissociation 
(CAD).106 In the collision cell, some of the kinetic energy is converted into internal energy, 
which results in bond breakage and fragmentation of the molecular ion into smaller fragments. 
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Afterwards the fragment-ions are collected and collisionally cooled in a C-Trap, situated in an 
electromagnetic field. Cooled ions are injected with high energy and precise trajectory into the 
orbitrap mass analyzer. They oscillate axially across the trap at frequency proportional to 
(z/m)1/2. The movement of every ion species (m/z) induces a detectable alternating current, so-
called “image current”. Its frequency is dependent on the m/z-ratio and decreases exponentially 
after shutdown of the excitation current. The FID (free induction decay) is detected by 
electrodes and transformed to the mass spectrum by Fourier Transform (MS2). This is how 
specific ions with certain m/z-values can be isolated.107 The received spectra can be processed 
with the Thermo Scientific software Xcalibur™ resulting in partial or complete structural 
determination of the analyte.  
 
Scheme 3-2: Schematic of tandem mass spectrometry. QIT = quadrupole ion storage trap. For explanation see 
text. 
Beside its higher speed, the major advantage for tandem mass spectrometry is that it enables 
the structural characterization of cyclic peptides produced in such low quantities that normally 
prohibit the use of other structural methods such as NMR.108,109 
 MALDI-TOF 
Spectra were recorded by Dr. Marc Sylvester and Mr. Bernd Gehrig (Institute for Biochemistry 
and Molecular Biology, Univ. of Bonn). The matrix-assisted laser desorption ionization 
(MALDI) combined with a time-of-flight (TOF) mass analyzer is routinely used for the mass 
assignment of peptides and proteins up to a molecular weight of about 105 Da.110 The sample is 
mixed with matrix material in a ratio of 1 to 10000. The matrix has the following functions: 
First of all, it dilutes the sample, preventing interaction of sample molecules with each other, 
secondly it absorbs the laser energy and desorption energy to the sample, and it lastly protects 
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the sample from photolytic disintegration. Also, it supplies the required protons for the 
ionization. For rather hydrophobic peptides like FR, α-cyano-4-hydroxycinnamic acid is the 
matrix of choice. After sample preparation it is irradiated with a laser pulse (nitrogen laser, 
337nm), which lies within the absorption maxima of the matrix. Because of that, it absorbs the 
energy, transfers or takes over protons of the sample and provides the energy needed for 
desorption. Mainly [M+H]+ -and [M + alkaline metal]+  ions are formed. For recording a 
measurement, 100µg of FR or analog was used and several pulses (about 100) were directed 
towards the sample to improve the signal-to-noise ratio. 
 MALDI imaging of A. crenata leaves 
Spectra were recorded under supervision of Dr. Alexander Brachmann (Institute of 
Microbiology, ETH Zurich). A young leaf of A. crenata was immersed in dichloromethane for 
1 min to thin out wax layers of the thick cuticle.111 The leaf was fixed on a conductive carbon 
tape mounted on a stainless steel slide making the leaf underside accessible for MALDI matrix. 
A MALDI matrix spotter (SunChrom SunCollect) was used to coat the leaf uniformly with 7-8 
layers of MALDI matrix (1:1 mixture of α-cyano-4-hydroxycinnamic acid and 2,5-
dihydroxybenzoic acid (Sigma-Aldrich); 30 mg/mL in methanol and 0.1% TFA). MALDI 
imaging was performed on a LTQ Orbitrap XL (Thermo Scientific™) equipped with a nitrogen 
laser (wavelength 337 nm). MALDI FTMS spectra were acquired in positive mode for a mass 
range between 800 and 1200 m/z, a laser energy of 55 μJ, two microscans per step, a resolution 
of R = 60,000 and mass tolerance of 0.01 amu. The leaf was measured at 100 µm pixel size, 
yielding 31,050 pixels in total. Spectra were extracted for the potassium adduct ion of FR 
[M+K]+ = 1040.49 m/z using Image Quest software (Thermo Scientific™). The resulting 2D 
image was displayed in rainbow color scheme and linear scaling type from 7.00E4 to 7.00E6 
showing the abundancies of FR ions in different colors. 
 Nuclear magnetic resonance spectroscopy 
NMR spectra of crude extracts and pure compounds were recorded on a Bruker Avance 300 
DPX operating at 300 MHz (1H) and 75 MHz (13C) at room temperature. Compounds, which 
were isolated in low amounts and two dimensional measurements, were guided on a Bruker 
Ascend 600 spectrometer operating at 600 MHz (1H) and 150 MHz (13C) in the Institute for 
Pharmaceutical Chemistry, University of Bonn, Germany by Dr. S. Kehraus (Institute for 
Pharmaceutical Biology, University of Bonn, Germany). NMR spectra were processed using 
Bruker XWIN-NMR Version 3.5 software and MestReNova 8.0.1. Spectra were referenced to 
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residual solvent signals with resonances at δH/C 7.26/77.0 in the case of CDCl3. The multiplicity 
of the carbons was deduced by DEPT experiments. Structural assignments were based on 
spectra resulting from one or more of the following NMR experiments: 1H, 13C, DEPT-135, 1H-
1H COSY, 1H-13C direct correlation (HSQC), 1H-13C long-range correlation (HMBC), 1H-1H 
ROESY. Chemical shifts of the signals of a compound were compared to calculated values 
using Advanced Chemistry Development (ACD/Labs) Software V11.02 (® 2012 ACD/Labs). 
For structure-activity relationship studies described in Chapter 5.2 NMR spectra of FR, 1, 13, 
and 22 were recorded in 90% H2O/10% D2O, using the freeze-dried solid compound at 298 K 
on a Bruker Avance III or Avance HD spectrometers at proton frequencies of 600 or 500 MHz. 
In all NMR spectra, the 1H peak from water was used as a chemical shift reference by setting 
its frequency at 4.7 ppm. All NMR data were processed and analyzed using TopSpin 3.1 
(Bruker) and CcpNMR Analysis.112 The proton resonance assignment was performed by a 
combination of 2D [1H,1H]-DQF-COSY, [1H,1H]-TOCSY, [1H,1H]-NOESY and/or [1H,1H]-
ROESY and [1H,13C]-HSQC. Distance constraints were extracted from [1H,1H]-NOESY (22 
and FR) or [1H,1H]-EASY ROESY (13) spectra acquired with a mixing time of 120 ms and a 
recycle delay time of 1.5 s. Upper limit distance constraints were calibrated according to their 
intensity in the NOESY spectrum and the intensity of geminal protons was used for peak 
intensity calibration. Torsion angle constraints for FR, 13 and 22 were obtained from 1H and 
13C chemical shift analysis using DANGLE and 3JNHHa-coupling constants.113 Structure 
calculations and refinements were performed with YASARA structure.114–116 The 10 structures 
with the lowest energy were selected to represent the NMR solution structures. Additionally, a 
set of NMR spectra of FR and 1 in CDCl310 and MeOH/H2O/D2O (v:v:v/ 1:1:0.2) was obtained. 
 
 Specific rotation 
Optical rotation measurements were conducted on a Jasco model DIP140 polarimeter (1 dm, 1 
cm3 cell) operating at the wavelength λ=589 nm corresponding to the sodium D line at room 
temperature. The specific optical rotation [α]DT was calculated pursuant to: 
 
T = temperature [ºC] 
[]
D
T
=
100 x 
c x l
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D = sodium D line at λ=589 nm 
c = concentration [g/100 mL] 
l = cell length [dm] 
The compounds were dissolved in an appropriate organic solvent (e.g., MeOH). The rotation 
angles α were determined as an average value based on at least 10 measurements. 
 Bioinformatic procedures 
 Molecular networking 
The MeOH extract from A. crenata leaves and fractions thereof were analyzed with UPLC-
MS/MS. Data files were exported to .mzxml format, and then uploaded to CCMS 
(ccms.ucsd.edu). A molecular network was created using the online workflow at GNPS 
(gnps.ucsd.edu). The data was filtered by removing all MS/MS peaks within +/- 17 Da of the 
precursor m/z. MS/MS spectra were window filtered by choosing only the top 6 peaks in the 
+/- 50 Da window throughout the spectrum. The data was then clustered with MS-Cluster with 
a parent mass tolerance of 0.02 Da and a MS/MS fragment ion tolerance of 0.02 Da to create 
consensus spectra. Further, consensus spectra that contained less than 2 spectra were discarded. 
A network was then created where edges were filtered to have a cosine score above 0.7 and 
more than 6 matched peaks. Further edges between two nodes were kept in the network if and 
only if each of the nodes appeared in each other's respective top 10 most similar nodes. The 
spectra in the network were then searched against GNPS' spectral libraries. The library spectra 
were filtered in the same manner as the input data. All matches kept between network spectra 
and library spectra were required to have a score above 0.7 and at least 6 matched peaks. Results 
were visualized in Cytoscape 3.4.0 (www.cytoscape.org). 
 
 Structures calculations of YM-254890, FR900359 and their analogs 
Molecular structures of the YM and FR derivatives were constructed with the Yasara molecular 
modeling program114,115 employing the crystal structure of Gq-bound YM.53 The resulting 
molecules were geometry optimized with the Yasara YAPAC module using semi-empirical 
quantum chemical methods followed by an energy minimization step in explicit water, using 
the PME method117 and a cut-off distance of 8 Å to describe long-range electrostatics and the 
Yasara2118 force field (0.9% NaCl, 298 K, pH 7.4119). Additionally, selected structures were 
equilibrated through a 100 ns molecular dynamics simulation to probe for their conformational 
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integrity. The final structure was derived from the simulation period suggesting a stable 
conformation as indicated by the Cα RMSD, again followed by an energy minimization. 
Structure calculation experiments were performed by Dr. Daniel Tietze, TU Darmstadt. 
 
 Molecular Docking Studies 
The Gαq target structure was derived from PDB ID 3AH8.53 Docking was performed using 
VINA120 (default parameters). The setup was done with the YASARA molecular modeling 
program,114,115 and the best scoring result of 32 independent docking runs was subjected to 
further analysis. To guide the docking runs the docking cell was placed around the YM binding 
epitope revealed by Nishimura et al.53Ligands and receptor residues were kept flexible during 
the docking runs. Molecular Docking studies were performed by Dr. Daniel Tietze, TU 
Darmstadt. 
 Molecular dynamics simulations  
Energy minimization was carried out for best scoring structures from the docking runs before 
subsequent analysis of Gαq-inhibitor interactions. The energy minimization was achieved by a 
steepest-descent minimization followed by a simulated annealing minimization until 
convergence (<0.05 kJ/mol/200/steps). Charged amino acids were assigned according to the 
predicted pKa of the amino acid side chains by Ewald summation
119 and were neutralized by 
adding counter ions (NaCl). Force field parameters for the ligands were assigned by Yasara’s 
AutoSMILES approach.121,122 
To gain performance, a multiple time step algorithm together with a simulation time step 
interval of 2.5 fs was chosen.115,123 Unless otherwise stated TIP3P water model and the 
Amber14 force field was used for energy minimization and molecular dynamics 
simulations124,125 employing the PME method117 to describe long-range electrostatics at a cut-
off distance of 8 Å at physiological conditions (0.9% NaCl, 298 K, pH 7.4119). 
Molecular graphics were created with YASARA (www.yasara.org) and POVRay 
(www.povray.org). Molecular dynamics simulations were performed by Dr. Daniel Tietze, TU 
Darmstadt. 
 Steered molecular dynamics simulations 
Steered molecular dynamics simulations with constant acceleration were performed taking a 
snapshot from the initial period of the MD run after the structure of the docked protein-inhibitor 
complex was equilibrated and the inhibitor position was stable for some time. Steering was 
achieved by constant acceleration of the center of mass of the α-domain of Gq and the inhibitor. 
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The steering path was set along the direction vector connecting the center of mass of the 
receptor (Gαq) and the center of mass of the FR core structure excluding BODIPY and complete 
ligand unbinding was assumed, when a distance > 30 Å was reached. Accelerations were as 
follow: 750, 1250, 1750, 2250, and 2750 pm/ps2. Integration time steps for intra-molecular and 
inter-molecular forces were 1.25 fs and 2.5 fs. All other simulation parameters were identical 
to the regular MD simulations. Experiments were performed by Dr. Daniel Tietze, TU 
Darmstadt. 
 Life Cell imaging 
Life cell images of compound 46 (FR-RR-BP) on HEK293 cell (wt or Gq/Ko, respectively) 
were taken at a Axiovert 200 M with Reflektor 50 Cy-5 and a Plan-Apochromat 63x/1.40 oil 
Ph 3 objective of a AxioCamMR3 (all Zeiss). Living cells were moistened at 37 °C and 
measured in 300 µL Locke. Experiments were performed by Dr. Thomas Sorkalla, Dr. 
Sebastian Franken, Stefan Aatz, Häberlein lab (Institute for Biochemistry and Molecular 
Biology, Univ. of Bonn). 
 Biological methods: 
 Resazurin-based Cell viability assay with HEK293-cells 
This assay was carried out by Dr. Nicole Merten (Kostenis lab, Institute for Pharmaceutical 
Biology, Univ. of Bonn). Data was generally obtained from three independent experiments, 
performed in triplicates. Cell viability was assessed using a fluorimetric detection of resorufin 
(CellTiter-Blue Cell viability Assay, Promega). HEK293 cells were seeded at a density of 
25,000 cells per well into black 96-well poly-D-lysine-coated plates with clear bottom. 4 h after 
seeding cells were treated with 0.3 % dimethylsulfoxide (DMSO) or 20 µL of compound or the 
respective solvent and incubated for 24 hours at 37 °C and 5% CO2. The next day, 20 µL of 
CellTiter-Blue reagent was added to each well and cells were incubated for 1 h according to the 
manufacturer’s instructions. To detect cell viability, fluorescence (excitation 560 nm, emission 
590 nm) was measured using a FlexStation 3 Benchtop Multimode Plate Reader and data were 
expressed as percentage of cell viability relative to DMSO control ( The cytotoxic anticancer 
drug etoposide was used as a positive control). 
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 Agar Diffusion and Sporulation Assay in Working Group König 
Antimicrobial tests of extracts and isolated pure compounds were performed by Emilie Goralski 
and Ekaterina Egereva (Institute for Pharmaceutical Biology, University of Bonn) following 
the method described by Schulz et al.126 The bacteria Bacillus megaterium de Bary (Gram 
positive) and Escherichia coli (Migula) Castellani & Chambers (gram negative), the fungi 
Microbotryum violaceum (Pers.) Roussel (Ustomycetes), Eurotium rubrum (formerly E. 
repens) König, Spieckermann & Bremer (Ascomycetes) (all from DSMZ; Braunschweig, 
Germany), and Mycotypha microspora Fenner (Zygomycetes kindly provided by B. Schulz, 
Institute of Microbiology, University of Braunschweig, Germany) were used as test organisms. 
Sample solutions contained 1 mg/mL per test sample. 50 µL (equivalent to 50 µg) of each 
solution were pipetted onto a sterile antibiotic filter disk (Schleicher & Schuell 2668®), which 
was then placed onto the appropriate agar medium and sprayed with a suspension of the test 
organism. Growth media, preparation of spraying suspensions, and conditions of incubation 
were carried out according to Schulz et al.126 Growth inhibition was defined as follows: growth 
of the appropriate test organism was significantly inhibited compared to a negative control; 
total inhibition: no growth at all in the appropriate zone. Benzyl penicillin (1 mg/mL MeOH), 
streptomycin (1 mg/mL MeOH) and miconazole (1 mg/2 mL DCM) were used as positive 
controls. 
In a similar manner sporulation experiments were performed with Cryphonectria parasitica 
and Microbotrium violaceum, but agar plates with these fungi were not treated with antibiotics 
or fungicides, but with FR (0.5 mg/mL MeOH). Sporulation were investigated under the 
microscope. 
 Agar Diffusion Assay in Working Group Sahl 
Antimicrobial tests of extracts and isolated pure compounds were performed by Michaele 
Josten (Institute for Medical Microbiology, University of Bonn). Culture plates (5% sheep 
blood Columbia agar, BD) were overlaid with 3 ml Tryptic soy soft agar, inoculated with TSB 
(Tryptic soy broth, Oxoid) growth suspension of the bacteria to be tested. Compounds were 
diluted to a concentration of 1mg/ml (Syringomycin 0,5mg/ml) with DMSO and 3 µl of this 
dilution were placed on the surface of the agar. Compounds diffuse into the agar and the size 
of the inhibition zone was measured after 24 hours incubation at 37 °C. 
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 IP1 accumulation assay  
 Cell lines and culture conditions 
CHO and HEK293 cells stably transfected with the muscarinic M1 receptor127 were obtained 
from the American Type Culture Collection (ATCC). CHO cells were cultivated in Ham´s F12 
Nutrient Mix (Ham´s F12) supplemented with GlutaMax, 10% fetal bovine serum (PAN 
biotech, Germany), 100 U mL-1 Penicillin, 100 mg mL-1 Streptomycin (Invitrogen). For CHO-
M1 cells, 0.2 mg mL-1 G418 was added to the medium. Cells were maintained in humidified 
atmosphere at 37 °C and 5% CO2. HEK293 cells were cultured in Dulbecco´s Modified Eagle´s 
Medium (DMEM, Invitrogen). All cell lines were tested negative by PCR for mycoplasma 
contamination.  
 HTRF-based IP1 and cAMP assays 
All homogenous time-resolved fluorescence (HTRF)-based assays were carried out according 
to manufacturer's instructions (Cisbio GmbH, Berlin). In brief, for the IP1/cAMP assay, 
50,000cells/well were suspended in the respective assay buffers containing 10 mM LiCl (for 
IP1) or 1 mm 3-isobutyl-1-methylxanthine (IBMX, for cAMP), respectively, and incubated in 
a 384-well, white microtiter plate for 15 minutes. To determine inhibitory effects of compounds 
cells were pre-incubated with ligands or solvent for 2 hours prior to stimulation with the stated 
agonists for further 30–35 minutes (100 µM carbachol for IP1, Gq; 1 µM Iperoxo for cAMP, 
Gi; 100 µM Iper-6-phth for cAMP, Gs). Reactions were terminated by addition of lysis buffer 
containing the HTRF® reagents. All incubation steps were carried out at 37 °C and 5% CO2. 
After incubation for at least 1 hour at room temperature HTRF ratios were measured using the 
Mithras LB 940 multimode reader (Berthold technologies) at 665 nm and 620 nm. 
All of the bioassays were performed by Nina Heycke, Suvi Annala, Tobias Benkel or Dr. 
Davide Malfacini (Institute for Pharmaceutical Biology, University of Bonn). The measurement 
of intracellular IP1 was executed as described below. Inhibition of Gq-signaling was 
determined in CHO cells stably expressing the m1-receptor subtype using a competitive 
immuno-assay for IP1 quantification. Data was generally obtained from three independent 
experiments, performed in triplicates. 
 Data evaluation of second messenger HTRF assay 
Results were calculated from the ratio of absorbance at 665 nm/620 nm. Obtained ratio values 
were corrected by a negative control, consisting of buffer and europium cryptate. Calculations 
were performed according to following formula: 
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Delta F = [Ratiosample - Rationeg/ Rationeg] x 100 
Because of the inverse relationship between signal and IP1 concentration, accumulation of IP1 
resulted in a decreased signal. Data were analyzed using GraphPad Prism 5.04 (Graph Pad). 
Levels of IP1 were normalized to the maximum amount of IP1 generated by ligand-induced 
GPCR activation. In some analyses, data were presented as arbitrary units, meaning amount of 
IP1 related to the examined basal levels ((buffer HTRF ratio subtracted by agonist-induced 
HTRF ratio) +buffer HTRF ratio). 
 Wash-out experiments using IP-one HTRF® assay by Cisbio 
To determine the affinity for the Gαq-protein, we investigated wash-out Assays using an IP-one 
HTRF® assay by Cisbio: Cells have been resuspended using an alloy of 1x Stimm-buffer and 
the respective substance ( FR [1µM] and AC1 [30 µM]) and incubated for 2h at 37°C, followed 
by a repetitive (6x) wash-out using PBS, either 1x Stimm-buffer or Carbachol [100µM] 
(Agonist at M1) have been added and incubated for 35min. Subsequently, we added an IP1 
analog coupled to a d2 fluorophore (acceptor) and an anti-IP1 monoclonal antibody labeled 
with Eu Cryptate (donor). Being a competitive immunoassay the read-out, using Mithras LB 
940 by Berthold Technologies, is inversely proportional to the resulting signal. The buffer 
solution contains LiCl to avoid IP1 degradation. Subsequent data analysis has been performed 
using GraphPad Prism 6. All experiments were performed by Nina Heycke and Tobias Benkel 
(Institute for Pharmaceutical Biology, Univ. of Bonn). 
 Dynamic mass redistribution (DMR) assay 
Dynamic mass redistribution assays were conducted as described previously in detail.128 
Briefly, cells were seeded and grown overnight to confluence in 384 well EPIC biosensor plates 
(Corning). On the next day, cells were washed twice with HBSS containing 20 mM HEPES 
adjusted for DMSO and incubated for at least 2 h at 37 °C in the EPIC reader (Corning). FR or 
other potentially Gq-inhibiting compound was added 2 h before the measurement in HBSS 
(+HEPES) at a final concentration of 1 µM. At least 3 min of baseline read were recorded when 
cells were equilibrated (no change in basal DMR) and carbachol was added with a liquid 
handling robotic (Selma, CyBio). DMR changes were monitored for at least 2 h at 37 °C. Raw 
data were processed using the microplate analyzer MS-Excel macro (Corning) and 
subsequently analyzed in GraphPad Prism. Real-time DMR records are depicted as 
representative experiments (mean + s.e.m.) with each trace reflecting the average of three 
technical replicates. Each experiment was repeated at least three times to obtain three 
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independent biological replicates and performed by Tobias Benkel, Nina Heycke, Suvi Annala 
or Dr. Davide Malfacini, Institute for Pharmaceutical Biology, Univ. of Bonn. 
 Competition experiments with [³H]PSB-15900 
Competition experiments with [³H] PSB-15900 at membrane preparations of platelets. 
Membrane preparations were performed by Markus Kuschak (Institute for Pharmaceutical 
Chemistry I, Univ. of Bonn) as previously described.129,130 Competition experiments were 
performed for FR900359 or FR analogs versus [3H]PSB-15900 on platelet cell membrane 
preparations using 9 different concentrations of FR900359 or FR analogs ranging from 0.1 nM 
to 100 µM. Three separate experiments were performed and data were analyzed with GraphPad 
Prism, Version 6.01 (GraphPad Inc., La Jolla, CA). [3H]PSB-15900 was obtained by tritiation 
of FR900359 with tritium gas in analogy to the procedure described by Schrage et al. for the 
preparation of its non-radioactive analog.54 
 Methods for determination of the ecological role of FR900359 
 Quantification of FR in leaves and nodules of A. crenata 
Air-dried plant material (dissected nodules, whole leaves or leaf lamina without nodules) was 
manually ground to a powder and extracted with methanol. The resulting crude extract was 
dried in a rotary evaporator and dissolved in methanol to give a concentration of 1 mg dried 
residue per millilitre. HPLC separation was carried out using a reversed phase C18 column 
(Machery-Nagel Nucleodur 100, 125 mm × 2 mm, 5 μm) with a gradient elution (from 
methanol/H2O 10/90 to methanol 100% in 20 min, followed by isocratic conditions for 10 min 
as washing step. The mobile phase was buffered with ammonium acetate 2 mM at a flow rate 
of 0.25 ml x min−1. The HPLC-MS (ESI) measurements were performed on an Agilent 1100 
Series HPLC including DAD (250 nm) coupled with an API of 2000, Triple Quadrupole, 
LC/MS/MS, Applied Biosystems/MDS Sciex and ESI source. The concentration of FR900359 
in the samples was calculated by linear regression against known concentrations of FR900359 
purified as described by Fujioka and colleagues (1988) (concentrations applied: 100, 300, 1000 
μg x ml−1). Measurements were performed at least in triplicate, and the mean value and the 
standard deviation are given. 
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 Feeding experiments of FR and A. crenata leaves on Acheta domesticus 
In a collaboration with Timo Hartmann from the Museum for Natural History Alexander 
Koenig, Bonn we fed the leaves (dried and fresh) of A. crenata as sole nutrition to house 
crickets (Acheta domesticus) for two days. 
In a further experimental setting, we prepared 0.5cm² pieces of the favorite diet (carrots) of 
house crickets in different geometries: untreated (pentagon), treated with acetone (hexagon), 
or treated with 10µl FR 1µM, 10µM, 100µM, 1mM respectively, dissolved in acetone 
(square). Before the experiment started the crickets hungered for two days. Six crickets only 
obtained untreated carrots, 6 crickets carrots treated with acetone as negative control, 6 
crickets each (30 in total) got 1µM-1mM FR-treated carrots. Furthermore, 6 crickets each (30 
in total) could choose between untreated, acetone-treated and FR-treated (1µM-1mM) carrots 
to examine, if the insects are able to sense FR and thus avoid feeding on it, when alternatives 
were provided. After three days all carrots had been consumed by the crickets. 
 Cloning and transfection of Bombyx mori and Bemisia tabaci Gq proteins 
Bemisia tabaci Gq isoform X1 and Bombyx mori Gq isoform 1 sequences were kindly provided 
by Misty Attwood and Helgi Schiöth (Uppsala University, Sweden). DNA samples were 
generated by GeneCust Europe (Ellange, Luxembourg) and cloned in pcDNA3.1(+). E. coli 
DH5-α was used to amplify the two plasmid DNA. HEK293 cells CRISPR-Cas9 knock out for 
Gq/11 Gα protein subunits were obtained as described previously54 and kindly provided by 
Asuka Inoue (Tohoku University, Japan). HEK293 Gq/11 knock out were transiently 
transfected with 180 ng/cm² DNA of Bemisia tabaci Gq isoform X1 or Bombyx mori Gq 
isoform 1 by using the calcium phosphate co-precipitation method. 
 Competition experiments with [³H]PSB-15900 at membrane preparations of Sf9 
cells and HEK cells expressing Bemisia tabaci and Bombyx mori Gq proteins, 
respectively 
Membrane preparations were performed as previously described.129,130 Competition 
experiments were performed for FR versus its tritiated derivative [3H]PSB-15900 (manuscript 
in preparation) on Spodoptera frugiperda (Sf9) cell membrane preparations using 9 different 
concentrations of FR ranging from 0.1 nM to 3 µM. Three separate experiments were performed 
and data were analyzed with GraphPad Prism, Version 6.01 (GraphPad Inc., La Jolla, CA). 
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[3H]PSB-15900 was obtained by tritiation of FR with tritium gas in analogy to the procedure 
described by Schrage et al. for the preparation of its non-radioactive analog.54 
 Feeding and effect determination of FR on mice 
All animal experiments were carried out according to the guidelines of the German law of 
protection of animal life with approval of the local authorities (LANUV, NRW, Germany). The 
solvent as control or FR were applied orally via gavage in female 10 weeks old CD1 wildtype 
mice. Therefore, 0.2 mg FR was administered in 200 µL (1:10 DMSO in 0.9% NaCl) by a 
stomach tube. After 1 hour blood pressure was determined by a Millar catheter as described 
before.131,132 Briefly, for analgesia ketamine 50 mg/kg and xylazine 5 mg/kg were injected i.p. 
Then, mice were anesthetized by 1.5% isoflurane via a face mask. A small pressure catheter 
was inserted via the right carotid artery into the aorta and systemic pressure was recorded using 
the Millar Aria 1 system (Millar, Houston, TX, USA). For analysis systolic arterial pressure 
(SAP) in mice that had received the solvent or FR was compared exactly 1 hour after drug 
application. After the experiment, the mice were sacrificed by cervical dislocation. Experiments 
were performed by Alexander Seidinger, UKM, Bonn. 
 Feeding and effect determination of FR on insects 
A small cotton particle soaked with 500µl of FR-containing water was served to first instar 
nymphs of a stinkbug (Riptortus pedestris) so that the insects orally take FR. FR was dissolved 
in 100% methanol, diluted with water to 0.2, 0.04, and 0.02 µg/µl concentrations, and tested. 
As a control, distilled water containing methanol (2%) was used. For each experiment, 20 
individuals of the stinkbug were used. Insects were reared in a moisture chamber at 25 ºC under 
a long day regimen (16 h light, 8 h dark), supplied with dried soybean seeds. The FR-containing 
water was exchanged every three days, and survival rate was monitored every day at the same 
time for nine days. Experiments were performed by Dr. T. Ohbayashi, CNRS, Paris.  
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 Results, Section I: Ecological function, Biosynthesis and 
Heterologous expression of FR 
The cyclic depsipeptide FR900359 (FR), isolated from the tropical plant Ardisia crenata, 
displays a strong and selective inhibition of Gq proteins. Therefore, FR is an indispensable 
pharmacological tool to study Gq-related processes, as well as a promising drug candidate. It is 
assumed that FR is the product of the bacterial symbionts of A. crenata that we designated as 
Candidatus Burkholderia crenata.22 Due to structural features of FR it is considered that the 
cyclic depsipeptide is assembled by a NRPS biosynthetic machinery. The detailed knowledge 
of the biosynthetic process will help to develop systems for manipulating the biosynthesis by 
bioengineering, and thus allowed us to create structural derivatives. Our preliminary 
investigations enabled us to identify a NRPS encoded on a plasmid of the Burkholderia 
symbiont, putatively responsible for FR biosynthesis. This would affirm our hypothesis that FR 
is biosynthetically rather derived from the symbiont than the plant. 
The following questions shall be addressed in Section I: 
1. What is the ecological function of FR (Chapter 4.1)? 
2. Is the approx. 34 kb large sequence information frsA-H indeed encoding the biosynthetic 
enzymes for FR production and what is the function of its specific domains (Chapter 4.2)?  
3. How would a heterologous expression system for FR900359 be constructed (Chapter 4.3)? 
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4.1 Research towards the ecological role of FR – More than just a tool 
for pharmacological research designed by nature?  
Plants are one of the major sources for therapeutically applied compounds, e.g. paclitaxel133, 
vinca-alkaloids134,135, camptothecin.136 In most cases the higher plants themselves are the 
producers of these metabolites. However, all of the about 300.000 higher plants are suspected 
to contain endosymbiotic organisms, which were largely neglected by researchers until 
recently.7,9,137 Thus, endophytes open up a new research field in terms of new natural products 
for medical use and also for investigations of the chemical ecology and evolutionary aspects of 
symbioses. In general, it is believed that symbiotic microbes function as biological defense for 
the host plant to combat phytopathogens. The protection mechanism of the endophytes are 
exerted directly by releasing metabolites to attack any antagonists, and indirectly, by either 
inducing host defense mechanisms or promoting growth.11,12,138 Carlier et al. provided evidence 
in this regard for the specialized leaf nodule symbiosis, occurring between the genus 
Burkholderia and plants of Primulaceae, e.g. A. crenata and Rubiaceae, e.g. Psychotria spp. 
This leaf nodule symbiosis (see Chapter 1.1) is considered to be obligate139, because neither 
the host nor the endosymbiont can survive outside the symbiotic interaction.15,140–142  
 
 Investigation of the leaf nodule symbiosis of A. crenata  
In this study we started the investigation of the endosymbiont-host relationship in Crispardisia. 
Nakahashi et al. have previously reported that it had no detrimental effect on the plant when 
they clipped the nodules from mature seedlings of A. crenata.143 They hypothesized that the 
benefit, provided by the bacteria could be limited to another life stage. A similar approach was 
used by Yamada et al. to investigate effects after removal of endosymbiotic bacteria. They 
discovered, that antibiotic treatment of A. crispa and A. punctata seeds with streptomycin led 
inter alia to the development of non-leaf-nodulated plants.144 We applied the same procedure 
for A. crenata and immersed the seeds in streptomycin (1 mg/mL) solution in sterilized dishes 
for seven days, sowed them in flower-pots and cultivated the plants for nine month in a green 
house under controlled conditions. In parallel, we also grew non-treated plants for comparison. 
After nine months, no difference could be observed between treated and non-treated plants. 
Both groups developed well and also all of them contained leaf nodules. In order to investigate 
whether the nodules of the treated plants harbor bacteria or not we harvested the leaves and 
examined them under the microscope. Cross-sections of the nodules revealed that they were 
filled with rod-shaped bacteria (Figure 4-1) and also PCR results were positive for 
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Burkholderia sp. (data not shown). The unsuccessful eradication of Burkholderia symbionts 
despite our antibiotic treatment corroborates the assumption for the vertical transmission of the 
endosymbionts. In order to eradicate the endosymbiotic bacteria in further experiments 
completely, we suggest an extended antibiotic treatment and, e. g. the addition of antibiotics 
also to the applied fertilizer. 
 
Figure 4-1: Bacterial Leaf Nodule of A. crenata was cut off the leaf rim and crushed, Nodules are filled with 
bacteria. Magnification 100x (left), magnification 1000x (right), reveals 1-2µM rod-shaped bacteria.  
Based on genome analysis of the leaf symbiont of the plant Psychotria kirkii (Rubiaceae), 
Candidatus Burkholderia kirkii, it was proven by Sieber et al. that the endophytic bacteria 
produce secondary metabolites of the C7N aminocyclitol family (known for antifungal, 
antibacterial, insecticidal activities).145 These metabolites could bestow a fitness advantage 
upon the host plant, which may provide sufficient selective pressure to maintain the vertically-
transmitted symbionts.146 This emphasizes that genome reduction does not necessarily lead to 
a complete loss of the potential to produce secondary metabolites.147 
In the here investigated case of A. crenata the symbiont, Candidatus Burkholderia crenata (Ca. 
B. crenata) was found to harbor the second smallest Burkholderia genome (2.85Mb) to date.22 
FR is due to its structural features obviously not a typical plant metabolite. For that reason, the 
presence of Ca. B. crenata would explain how and might give an indication where FR is 
produced. We determined the concentration of FR via HPLC-MS in crude extracts of dissected 
leaf nodules to be 247.0 ± 22.3 μg mg−1, i.e. more than 36 times higher (Appendix Figure 10-
4) than in leaves where the margins containing the nodules had been cut out (6.7 ± 1.6 μg 
mg−1).22 To confirm this result we directly tracked FR in a young A. crenata leaf via MALDI 
imaging in the laboratory of Prof. Piel, ETH Zurich under the supervision of Dr. Alexander 
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Brachmann. In that way, we could clearly demonstrate and visualize the co-localization of the 
bacterial leaf nodules, i.e. endosymbiotic Ca. B. crenata and FR (Figures 4-2). 
 
Figure 4-2: (A) MALDI imaging mass spectrometry of an Ardisia crenata leaf. Direct detection of potassium 
adduct of FR (mass tolerance: 0.001 Da) reveal FR to be concentrated at the leaf rim. (B) MALDI MS spectrum 
of a nodulated spot of a young Ardisia crenata leaf. Molecular ion, sodium and potassium adducts of FR are 
labeled and dominate the spectrum. Experiments performed under the supervision of Dr. Alexander Brachmann, 
Piel lab, ETH Zurich. 
 The putative role of FR as a signaling molecule between host plant and 
endosymbiont 
In beneficial bacterial endophyte-plant interactions the production and modulation of 
phytohormones by endophytes play an essential role in plant development and stress tolerance. 
Furthermore, metabolites are reported to act as signals for communication between bacterial 
symbiont and plant, and that host-specific signal exchange may occur.147 
FR is known for the inhibition of Gαq-signaling in mammalian cells, and it is produced by Ca. 
B. crenata (see below, Chapters 4.2, 4.3) living in obligate symbiosis with A. crenata. Hence, 
we asked the question whether A. crenata utilizes this molecule to regulate its own G protein 
signaling. This idea is supported by the structural similarity of mammalian G proteins to the 
plant G protein AtGPA1 from Arabidopsis thaliana. The root mean square deviation (RMSD) 
between the backbones of the superimposed structures of AtGPA1 and Gαi1 and transducin was 
only1.8 Å.148 However, plant G proteins differ from mammalian G proteins in protein 
dynamics. They are self-activating, which means that they do not need GPCRs to promote GDP-
GTP exchange. Therefore, regulation of G protein activation in plants occurs at the deactivation 
step.149,150 Nevertheless, plants may also utilize a GDP dissociation inhibitor (GDI) like FR, 
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which may slow down nucleotide exchange. This question was examined by the Kostenis lab 
(Univ. of Bonn) in collaboration with the Dohlmann lab (Chapel Hill, NC). They found out that 
AtGPA1 was insensitive towards FR (Figure 4-3), contradicting our assumption at least for A. 
thaliana. 
 
Figure 4-3: (A) FR does not interfere with AtGpa1 nucleotide exchange. Measurement of the effect of FR on 
nucleotide exchange of plant AtGpa1 (Arabidopsis thaliana Gpa1) using the fluorescent GDP analog MANT-
GDP. Data are mean ± SEM of three independent experiments and curve fit was based on a one-phase exponential 
decay. w/o, without FR. (B) FR does not impair the stability of plant AtGpa1. Analysis of AtGpa1 protein thermal 
stability in absence or presence of 10 µM FR measured by fast quantitative cysteine reactivity (fQCR). Shown are 
data of a representative experiment. ABD, paminobenzamidine. w/o, without FR. (A) + (B) modified after Schrage 
et al.54 and experiments were performed in the Henrik Dohlmann lab, Chapel Hill, NC, USA. 
 FR shows no antibacterial, antifungal or cytotoxic activity 
Inspired by the antimicrobial secondary metabolites from Candidatus Burkholderia kirkii, we 
intended to study the antibacterial activity of FR, which also serves as unspecific toxicity test 
for FR, because bacteria are not known to have G proteins (Table 4-1). 
Table 4-1: Agar diffusion assay. FR900359 dissolved in DMSO (1 mg/ml). 3µl of this solution were applied to 
agar plates grown with 28 bacterial strains and two yeasts (Candida). DMSO was used as negative control. Values 
in millimeter inhibition zone. Experiments performed by Michaele Josten, Institute for Medical Microbiology, 
Bonn. 
 strain no. DMSO FR900359 
1 MSSA 5185 0 0 
2 MSSA I-11574 0 0 
3 MRSA LT-1334 0 0 
4 MRSA LT-1338 0 0 
5 MRSE LT-1324 0 0 
6 Candida albicans I-11301 0 0 
7 Candida albicans I-11134 0 0 
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8 Citrobacter freundii I-11090 0 0 
9 Klebsiella pneumoniae subsp. ozeanae I-10910 0 0 
10 Enterococcus faecium I-11305b 0 0 
11 Enterococcus faecium I-11054 0 0 
12 Escherichia coli I-11276b 0 0 
13 Escherichia coli O-19592 0 0 
14 Stenotrophomonas maltophilia O-16451 0 0 
15 Stenotrophomonas maltophilia I-10717 0 0 
16 Pseudomonas aeruginosa I-10968 0 0 
17 KNS I-10925 0 0 
18 Staphylococcus simulans  22 0 0 
19 Micrococcus luteus ATCC 4698 0 0 
20 Mycobacterium smegmatis ATCC 70084 0 0 
21 Bacillus subtilis 168 0 0 
22 Arthrobacter crystallopoietes DSM 20117 0 0 
23 Listeria welchimeri DSM 20650 0 0 
24 Staphylococcus aureus 133 0 0 
MSSA = methicillin-sensitive Staphlococcus aureus, MRSA = methicillin-resistant S. aureus, MRSE = 
methicillin-resistant S. epidermis, KNS = coagulase-negative Staphylococci. 
We tested FR against a panel of Gram positive and Gram negative bacteria, as well as fungi. 
None of the tested organisms were harmed by FR. Thus, we concluded that FR displays no 
antimicrobial effects. FR is also not cytotoxic, since 1 µM (FR completely blunts Gq-signaling 
at 1 µM) showed no detectable cytotoxicity towards HEK293 cells (data not shown) and no 
change in cell phenotype (Figure 4-4). 
G proteins in fungi have been only scarcely investigated, yet. So far the Gi protein of mammals 
is 55% identical with GNA1 of fungi, but the Gq sequence is more distinct.151 Gq-like proteins 
in fungi are critical for virulence, morphology, and sporulation.152–160 Consequently, 
sporulation is considered as a fungal process, which would be likely affected by a fungal Gq-
like protein interaction and could be easily monitored by a phenotypic change. Therefore we 
examined the effect of FR (1 mg/mL) towards the fungi Microbotrium violaceum and 
Cryphonectria parasitica (cultivation performed together with Ekaterina Egereva, Univ. of 
Bonn). However no phenotypic difference could be detected between the positive control group 
(treated with 100 µL of a 1 mM solution FR) and the negative control group (untreated, no FR 
supplementation). Both tested fungal species sporulated well despite the treatment with a high 
concentrated dosage with a very potent Gq inhibitor. This indicated that FR does not influence 
signaling of fungal Gq-like proteins.  
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Figure 4-4: Cell viability assay with HEK293 cells (A) w/o any treatment (B) 0.3% DMSO, (C) Etoposide 50 
µM as positive control (D) FR 1 µM dissolved in 0.3 % DMSO. Experiments performed by Dr. Nicole Merten, 
Kostenis lab, Univ. of Bonn. 
 FR is orally bioavailable and effective in mice 
Gq proteins are not exclusively expressed in humans, but are highly conserved in the evolution 
of metazoans.161 A pan-Gq inhibitor, would thus impact any organism with homologous Gq 
proteins, like other mammals than humans or insects, pointing towards the ecological function 
of FR. Oral application of FR to mice (comparable to the situation in the field where mammals 
may prey on A. crenata), which have Gq proteins 100 % homologous to human Gq should thus 
affect the animals, if FR is orally bioavailable. Indeed, oral FR application, resulted in uptake 
of the compound and significant reduction of blood pressure (Figure 4-5, experiment 
performed by Alexander Seidinger, Wenzel lab, University clinic, Bonn). When we compared 
systolic arterial pressure (SAP) after oral application of the solvent (without FR) and with FR 
by a Millar catheter in the aorta, we found a pressure of 79.3±2.0 mmHg, in mice that had 
received the solvent and a strongly reduced pressure of 57.5±3.5 mmHg, in animals after oral 
FR application. 
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Figure 4-5: Statistical analysis of in vivo blood pressure recordings in mice revealed a strong reduction of systolic 
arterial pressure (SAP) in the aorta 1 hour after oral FR application (0.2 mg per mouse, p<0.01). Experiment 
performed by Alexander Seidinger (Wenzel lab, University clinic Bonn, Germany). 
 FR as chemical weapon against insect herbivores 
 Antifeedant effects of A. crenatae folium on Acheta domesticus 
Insects are a major threat for plants. In a collaboration with Timo Hartmann from the Museum 
for Natural History Alexander Koenig, Bonn we fed the leaves (dried and fresh) of A. crenata 
as sole nutrition to house crickets (Acheta domesticus) for 5 days. The insects ignored the leaves 
and rather hungered to death than feeding on them. The antifeedant effect of methanolic A. 
crenata leaf extract was also reported from Sandoval-Mojica et al.162 They had examined the 
extract against nymphs of Schistocerca americana (Orthoptera: Acrididae) and adult Diaprepes 
abbreviatus (Coleoptera: Curculionidae), two serious pests of citrus crops in Florida. 
 Feeding experiments with FR on A. domesticus 
Next, we prepared the favorite diet (carrots) of house crickets and treated the carrots with an 
acetonic solution of FR in different concentrations (n=6 for each concentration, 1µM-1mM, 
and untreated carrots, Chapter 3.8.2). Furthermore, crickets were offered untreated, acetone-
treated and FR-treated (1µM-1mM) carrots at the same time, to examine, if the insects are able 
to sense FR and thus avoid feeding on it, when alternatives were provided (Figure 4-6). In this 
respect, it is worthy to mention that insect G proteins are reported to be involved in tasting, odor 
sensing, but also in metamorphosis.163–168 
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Figure 4-6: Feeding experiments on Acheta domesticus with FR-treated carrots in concentrations from 1µM - 
1mM displayed no detrimental effects for the insects.  
After three days all of the carrots were consumed, and no abnormal behavior of the crickets or 
any toxic effects could be observed. We concluded that FR has no direct toxicity on crickets 
and thus is not the reason for the strong deterrent effect of A. crenata leaves. A. crenata leaves 
possess high concentrations of triterpenoid saponins, which could be responsible for the 
deterrency.169 In this experiment however, the duration was possibly too short to observe long 
term effects. Of course it may also be speculated that Gq proteins of crickets are not sensitive 
to FR. 
 Sequence alignment of Gα subunits of different metazoans around the YM binding site 
In further studies to unravel the interaction of FR with insect Gq, we changed our strategy 
towards a more rational approach. Only recently the crystal structure of YM (a close structural 
analog of FR, see Chapter 1.4) bound to chimeric Gq/i protein was published.53 This study 
included mutations in the Gαq protein and their impact on Gq signaling probed by using YM. 
With this knowledge in mind and the high degree of conservation of Gq proteins of various 
organism an alignment of Gq proteins from several metazoans were done to predict putative 
YM-sensitivity of the respective animals, especially insects. We intended to combine the 
information from Nishimura et al. with the Gαq-subunits from different species sequenced by 
Krishnan et al.161(Figure 4-7). The sequence alignment of G protein α subunits of various 
metazoans around the YM binding site reveals that besides Drosophila melanogaster, many 
insects are suggested to be sensitive to YM as they do not contain mutations in the binding 
motif of YM. Due to the structural similarity of YM and FR we assume identical binding 
properties of both compounds. 
As YM was not commercially available at that point of the study, only the putative influence 
of FR on different organisms will be discussed. 
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Figure 4-7: (A): Mutational analysis of Gαq residues that appear to directly interact with YM-254890, taken 
from53. YM-254890 sensitivity of each Gαq mutant was evaluated by serum response element (SRE) activation. 
The calculated IC50 values of YM-254890 for each Gαq mutant and SRE activity of each Gαq mutant are shown. 
Each value represents the mean ± S.D. from three independent experiments performed in duplicate. Mutant protein 
samples were confirmed to retain proper conformations by the trypsin protection assay. (B) Sequence alignment 
of G protein α subunits of various metazoans around the YM-254890 binding site based on the mutational analysis 
described in (A) using the same color code. The residues that appear to directly interact with YM-254890 are 
shown on a red background. In particular, the residues that form the hydrophobic pocket, which would bind to the 
phenyl group of YM-254890, are marked with a blue background. Organisms belonging to the class of insects are 
labeled in red. HS = Homo sapiens, BM = Bombyx mori, DR = Danio rerio, PM = Petromyzon marinus, CI = 
Ciona intestinalis, BF = Branchiostoma floridae, SP= Strongylocentrotus purpuratus, SK = Saccoglossus 
kowalevskii, CE = Caenorhabditis elegans, SM = Schistosoma mansoni, NV = Nematostella vectensis, TA = 
Trichoplax adhaerens, AQ = Amphimedon queenslandica, GG = Gallus gallus, LG = Lottia gigantean, AG = 
Anopheles gambiae, AP = Acyrthosiphon pisum, AM = Apis mellifera, PH = Pediculus humanus. Sequences were 
provided by Misty M. Attwood, Schiöth lab, University of Upsalla. 
 Affinity of FR to pest insect G proteins 
Using a competitive radioligand binding assay, applying the tritiated FR radioligand [³H]PSB-
15900, affinity of FR to G proteins of distinct pest insects (Bombyx mori , Spodoptera 
frugiperda, Bemisia tabaci) was assessed (Assays performed by Markus Kuschak, Müller lab, 
Univ. of Bonn). 
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B. mori and B. tabaci (silverleaf whitefly) are native insects to subtropical and tropical Asia, 
the geographical origin of A. crenata. Membrane preparations of both species were provided 
by Dr. Davide Malfacini, Kostenis lab, Univ. of Bonn). Further on we investigated Gq proteins, 
endogenously expressed in the Sf9 cell line developed from ovaries of S. frugiperda, which is 
found in the Americas. It is the larval stage (caterpillar) of the fall armyworm moth. These 
insects can damage crops, mainly maize, eating up the entire crop before moving to another 
plantation.  
Membrane preparations, which contained G proteins of Sf9, B. mori, or B. tabaci were used; 
the radioligand concentration was 5 nM. Non-specific binding of the radioligand [³H]PSB-
15900 was determined in the presence of 5 μM FR. FR showed a pIC50 value of 8.13 ± 0.06 at 
SF9 membrane preparations, 8.98 ± 0.05 at B. mori membrane preparations and 9.27 ± 0.10 at 
B. tabaci membrane preparations (see Figure 4-8). This indicates that FR displays very high 
affinity for Gq proteins expressed in insect cells, even surpassing affinity for mammalian Gq 
proteins.  
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Figure 4-8: Competition binding study of FR versus [3H]PSB-15900 (5 nm), the tritiated derivative of FR, at Sf9 
insect cell membranes, and at Gq proteins of Bombyx mori and Bemisia tabaci expressed in Gq-knockout HEK 
cell membrane preparations. Values represent means: SEM of three independent experiments. pIC50 values of 
8.13–9.27 were determined. Experiments were performed by Markus Kuschak, Müller lab, University of Bonn, 
Germany. 
 Feeding experiments with FR on bean bug larvae 
The bean bug Riptortus pedestris is a sucking pest of soybean, common beans and various other 
crops that is found in eastern Asia. Both adults and nymphs feed on the soybean pods.170 
Toxicity of FR towards these insects was assessed, showing killing and preventing of molting 
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of bean bug nymphs by Dr. Tsubasa Ohbayashi, CNRS, Université Paris, France (Figure 4-9). 
After seven days, all of the R. pedestris nymphs were dead when exposed to FR at concentration 
of 0.2 and 0.04 µg/µl (see Figure 1D). Additionally, 18 of 20 insects could not molt to 2nd instar 
with 0.04 µg/µl FR and no insects could molt to 2nd instar when exposed to 0.2 µg/µl FR. Thus, 
FR was demonstrated to have insecticidal and molting-inhibiting activity, but did not display 
acute toxic effects towards R. pedestris in a concentration-dependent manner. 
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Figure 4-9: Exposure of nymphs of a bean bug (Riptortus pedestris) to different concentrations of FR; the survival 
rate was measured. Experiments were performed by Dr. Tsubasa Ohbayashi, CNRS, Université Paris, France. 
An ecological role of FR as defense chemical for the host plant has been discussed before.22 
The results of Chapter 4.1.5 add further evidence to this assumption. First of all, bioinformatics 
predicted for several insect Gq proteins to be FR-sensitive, which could be affirmed using 
binding assays of Gq proteins from distinct pest insects. Finally, feeding experiments on R. 
pedestris confirmed potent effects of FR towards a specific insect species. Altogether this 
suggests a protective role of FR for the host plant against herbivores.  
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 Bioinformatics and in vitro enzymatic studies on FR biosynthesis 
As described in Chapter 1.1, we sequenced the genome of the bacterial leaf symbiont Ca. B. 
crenata from A. crenata.22 Analysis of the genome sequence revealed essential pathways to be 
malfunctional, highlighting the advanced evolutionary stage of this plant-bacterium symbiosis 
and ongoing genome reductive evolution. In that study, the putative FR biosynthetic gene 
cluster frs (Figure 4-10), encoding a nonribosomal peptide synthetase (NRPS), was identified 
on an extrachromosomal plasmid. Due to the eroded genome, cultivation of Ca. B. crenata 
seemed unlikely, and indeed numerous cultivation attempts failed, making FR supply 
dependent on cultivating and extracting A. crenata leaves. By defining all genes necessary for 
FR biosynthesis, we draw a plausible biosynthetic hypothesis for this complex metabolite, 
supported by bioinformatics, in vitro characterizations of biosynthetic enzymes and 
characterization of FR analogs. This now paves the way for a biotechnological production of 
FR. The following experiments were conducted by Dr. Max Crüsemann (Institute for 
Pharmaceutical Biology, Univ. of Bonn) and coworkers. 
Unexpectedly, bioinformatics of the frs genes showed the presence of two thioesterase (TE) 
domains, representing two NRPS machineries, which together display a clear colinearity 
between module and domain architecture and FR structure (Figure 4-10).10,22 
 
Figure 4-10: Scheme of the putative FR biosynthesis deduced from bioinformatics and in vitro experiments. 
The NRPS genes, the catalytic domains they encode, and the amino acids incorporated by the respective modules 
are displayed. The peptide formation on the FrsA-G NRPS machineries, including release and transesterification 
by FrsA-TE is shown. Domains: A, adenylation; C, condensation; MT, methylation; PCP, peptidyl carrier protein; 
E, epimerization and TE, thioesterase (Ile-Thr ring closure). Figure was modified after10. 
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To further analyze the FR-NRPS, we first investigated the Frs condensation (C) domains 
bioinformatically. This is done to classify C domains by function such as epimerization, and 
acceptance of acyl groups, L or D amino acids.171 We aligned the C domain sequences with 
available sequences based on the NaPDoS database172 to construct a phylogenetic tree (Figure 
4-11), which confirmed most of the proposed features such as transfer of acyl units for FrsA 
and FrsD C domains. 
In FR the acyl residues transferred by FrsA and FrsD C domains are propionic and acetic acid. 
These C domains however, have somewhat flexible substrate specificity. This is illustrated by 
an unusual FR derivative, i.e. FR-1 (1), that we isolated from dried A. crenata leaves. In 1 the 
acetate unit of FR is replaced by a 3-hydroxypropionate moiety, the latter being a most 
uncommon acyl residue for bacterial natural products. The structure of 1 was unambiguously 
established from NMR data (Chapter 5.1.1, Table 5-1, Appendix Figures 10-14 – 10-20, 
Scheme 10-1), especially in comparison to those of FR (Appendix Figures 10-5 – 10-13, 
Scheme 10-1, Table 10-1). 
 
 
Figure 4-11: Phylogenetic tree of condensation domains in the frs gene cluster taken from10. The C domain 
phylogenetic tree CDH confirms most of the proposed features such as transfer of acyl units for FrsA and FrsD C 
domains (starter C domains C1 and C2). Furthermore, that the three determined LCL C domains, catalyzing bonds 
between two L-amino acids in modules 3, 6, and 8 (C3,C7 and C9), clade as expected, as well as the epimerase 
domain and D-phenyllactate-accepting domain in module 4 (C4 and C5). Curiously, the C domains in modules 5 
and 7 (C6 and C8), connecting the L-configured N-methyldehydroalanine and –alanine with L-alanine and L-OH-
leucine, cluster with the DCL domains, usually linking D- with L-amino acids. 
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Our classification of C domains showed furthermore, that the three determined LCL C domains, 
catalyzing bonds between two L-amino acids in modules 3, 6, and 8, clade as expected, as well 
as the D-phenyllactate-accepting domain in module 4. Curiously, the C domains in modules 5 
and 7, connecting the L-configured N-methyldehydroalanine and N-methylalanine with L-
alanine and L-OH-leucine, cluster with the DCL domains (Scheme 4-1), usually linking D- 
with L-amino acids.  
 
Scheme 4-1: Proposed biosynthesis of non-proteinogenic building blocks. 
The monomodular NRPS FrsA, responsible for the synthesis of N-propionylhydroxyleucine, 
contains a TE that likely transfers this building block onto the cyclic peptidic substrate. We thus 
hypothesize that FR biosynthesis proceeds first by the generation of a TE bound heptapeptide 
by FrsD-G (Figure 4-10). The FrsG TE then catalyzes offloading and intramolecular 
cyclization of the intermediate. Finally, the FrsA TE is predicted to perform an intermolecular 
transesterification by transferring N-propionylhydroxyleucine onto the free β-hydroxyl moiety 
of the cycloheptapeptide. A similar mechanism has, to our knowledge, so far only been 
observed in the biosynthesis of the salinamides, nonribosomal peptides from a marine 
streptomycete.173 MS/MS molecular networking174 was applied to detect minor biosynthetic 
intermediates confirming our hypothesis (for detailed workflow see Chapter 5.1.2). Indeed, a 
molecular ion with m/z 817 strongly suggested the presence of only the FR macrocycle without 
the N-propionylhydroxyleucine side chain (see Chapter 5.1.2, Scheme 5-5). Interestingly, a 
similar congener of the structurally related YM was characterized, pointing to an analogous 
biosynthetic route.52 
Although 7 of 8 building blocks of FR are non-proteinogenic, remarkably the frs gene cluster 
contains only two putative tailoring genes, i.e. frsC and frsH. Bioinformatic analysis of FrsC 
revealed high sequence similarity to malate dehydrogenases (MDH)175,176 and L-lactate 
dehydrogenases (L-LDH) with all conserved residues necessary for the reduction of a keto 
function in the substrate (see Crüsemann & Reher et al.10). Thus, we propose, that FrsC 
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catalyzes the reductive formation of L-phenyllactate from phenylpyruvate, an intermediate 
from phenylalanine metabolism. The epimerization domain encoded in FrsE, which is 
functional based on bioinformatics (see Crüsemann & Reher et al.10), then catalyzes the 
formation of D-phenyllactate. 
The other encoded modifying enzyme in the frs genes, FrsH, did not exhibit high sequence 
homology to any other characterized protein. However, a more detailed bioinformatics search 
revealed homologies in the active center to CmlA, a non-heme iron-dependent β-hydroxylase 
from chloramphenicol biosynthesis (see Crüsemann & Reher et al.10). CmlA catalyzes the 
hydroxylation of para-aminophenylalanine, when bound to the peptidyl carrier protein 
(PCP).177,178 A structural model of FrsH generated by Dr. Max Crüsemann (Institute for 
Pharmaceutical Biology, Univ. of Bonn) supports the anticipated similarity of FrsH and CmlA 
(Figure 4-12). 
 
Figure 4-12: Structural model of FrsH, generated by I-TASSER based on CmlA taken from10. (A) Structure 
of CmlA, taken from PSB (Accession number: 4JO0). (B) Structural model of FrsH, generated by I-TASSER179, 
based on CmlA (Estimated RMSD: 3.2±2.2 Å). (C) Overlay of both structures. 
Analogous to chloramphenicol biosynthesis, we reasoned that hydroxylation of leucines in FR 
could take place on the leucinyl-PCP of modules 1, 2, and 7. To investigate this hypothesis, 
frsA and frsD adenylation (A) domain-encoding regions (modules 1 and 2) were cloned into 
pET28 and expressed in E. coli with or without the MbtH-like protein (MLP) FrsB (see 
Crüsemann & Reher et al.10). MLPs are small, highly conserved proteins that are frequently 
associated with bacterial NRPSs and are in many but not all cases crucial for A domain 
activity.180 However, SDS gels of single expression and coexpression experiments showed that 
the A domains of FrsA and FrsD do not bind to FrsB during purification. An 18O4-ATP 
exchange assay181 could detect adenylating activity for both A domains without the presence of 
FrsB. Interestingly, leucine was preferentially activated by both domains, while 3-OH-leucine 
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was accepted to a much lower extent (see Crüsemann & Reher et al.10). This result strongly 
supports loading of leucine, followed by a hydroxylation of leucinyl-PCP by FrsH in three 
different modules. 
Since there is no obvious candidate for dehydroalanine formation in the frs genes, we 
hypothesize that the dehydrating activity is embedded in a C domain as it was speculated for 
microcystin biosynthesis.182 In a phylogenetic analysis, the McyA C domain forms a separate 
clade with other domains that are hypothesized to perform dehydrations.172 However, our 
phylogenetic analysis points to a different dehydration mechanism in FR biosynthesis, since the 
C domain in module 5 is not clustering with the above mentioned domains (Figure 4-11).  
 Heterologous expression of FR in E. coli 
In order to confirm the completeness of the FR biosynthetic gene cluster, we next aimed to 
transfer the frs genes to a cultivable bacterium for heterologous FR production. In future, 
production of FR by fermentation would alleviate the current laborious extraction and isolation 
process from Ardisia plants. Total synthesis of FR was recently achieved, however with low 
yields and high expenses.26 Heterologous expression would also be a key step to establish an in 
vivo platform to further investigate FR biosynthesis and to generate analogs for 
pharmacological evaluation by mutasynthesis or biosynthetic engineering. The following 
experiments were conducted by Dr. Max Crüsemann (Institute for Pharmaceutical Biology, 
Univ. of Bonn) and coworkers. 
Clone I9E from our BAC library22 kindly provided by Dr. Aurelièn Carlier (Univ. Of 
Zurich/Ghent) contained all frs genes. However, cultivation of E. coli strains with I9E did not 
lead to FR production. To switch on FR production, the constitutive promoter pS7183 was cloned 
upstream of frsA via PCR-based recombineering, yielding pMC1 (Figure 4-13A). First 
attempts to cultivate E. coli strains carrying pMC1 under various different conditions still 
yielded no FR. One reason for the lack of FR production could be due to protein insolubility. 
Thus, we sought to co-express the FR biosynthesis genes with chaperones. Constitutively high 
concentrations of molecular chaperones are regarded as essential for protein stability in obligate 
symbionts with reduced genomes,184 a phenomenon that was also observed in other leaf nodule 
symbioses.185 To ensure co-expression from both plasmids, we exchanged the resistance 
cassette for chloramphenicol against one for kanamycin in pMC1 to maintain the 
chloramphenicol-resistant chaperone plasmids in the expression strains. This was again 
achieved using PCR-based recombineering, yielding pMC2, that was subsequently co-
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transformed with either of the five available chaperone plasmids in both E. coli BAP1 and 
BL21. All 10 resulting expression strains were then cultivated in LB and M9 minimal media at 
temperatures of 16, 30 and 37 ˚C. Of the 60 conditions tested, we could only detect FR (1 µg/L) 
in n-butanol extracts of cultures of E. coli BL21 or BAP1 co-expressing pMC2 and pG-KJE8 
(encoding the E. coli chaperones DnaK, DnaJ, GrpE, GroES and GroEL) grown in M9 medium 
at 16 °C (Figure 4-13B). The exact mass of all FR adducts as well as retention time and MS2 
spectrum correspond to an authentic FR standard (Figure 4-13C1-C2), confirming FR 
production in the heterologous host. 
 
Figure 4-13: Heterologous expression of FR900359 modified after Crüsemann and Reher et al.10 (A) BAC 
library clone I9E (55 kbp), pSMART (from Dr. A. Carlier, Univ. Zurich). (B) Co-transformation with 5 chaperone-
containing plasmids into E.coli BL21(DE3) E.coli BAP1, cultivation for three days at 16 °C and subsequent n-
butanol extraction. C: UPLC-MS/MS analysis. (C1) Extracted ion chromatogram of m/z 1002.539. Comparison 
of FR standard with extract gained from E.coli BL21(DE3). (C2): MS spectrum of FR standard and extract gained 
from E.coli BL21(DE3). Experiments performed by Dr. Max Crüsemann, Univ. Bonn. 
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Conclusion Section I 
Gq inhibition is a novel mode of action for defense chemicals, and targeting Gq seems crucial 
for the ecological function of FR, as shown by in vivo experiments on mice, affinity to insect 
Gq proteins and insect toxicity studies. Interestingly, FR is produced by the bacterial symbiont 
of A. crenata. This uncultured endosymbiont, i.e. Candidatus Burkholderia crenata was 
sequenced and revealed the FR nonribosomal peptide synthetase (frs) gene cluster. FR 
biosynthesis was finally proven by expression of the frs genes in E. coli, which led to 
heterologous FR production in a cultivable, bacterial host for the first time. Heterologous 
expression of a natural product from an uncultivated endosymbiotic to our knowledge, has 
rarely been achieved.186,187 Our results lay the foundation for future production of FR, 
independent from time- and work-intensive plant cultivation, harvesting and extraction. 
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 Results, Section II: Detection, Isolation and Structure 
Activity Relationship studies of new FR analogs 
Chapter 5.1: 
GPCR signaling is considered as a highly important research field as 36% of all available 
medicinal drugs target GPCRs.44 The natural product FR has proven to be a most valuable tool 
to study GqPCRs (see Chapter 1.4). Compared to the structural analog YM, FR contains an 
acetylated β-hydroxyleucine residue instead of an acetylated threonine in the cyclic part of the 
molecule, and a propionate unit replaces an acetate acyl residue located at the side chain 
(Scheme 1-1). Such depsipeptides are typically produced by non-ribosomal peptide 
synthetases, biosynthetic machineries, which are known to produce - apart from their major 
product (here FR, YM) - also minor compounds, due to some promiscuity of the biosynthetic 
enzymes (see Chapter 1-2, Chapter 4-2).10,188 Indeed, Taniguchi et al. were able to isolate 
further YM derivatives from the culture broth of Chromobacterium sp. QS3666.52 These small 
structural changes, e.g. propionyl instead of acetyl residues, isoleucine instead of leucine, 
originate from biosynthetic enzymes, accepting to a certain extent structurally related building 
blocks. 
It could thus be considered very likely that extracts of A. crenata also contain further FR 
analogs. Furthermore, it is known that Ardisia species, other than A. crenata from the subgenus 
Crispardisia, also harbor symbiotic bacteria, of the genus Burkholderia, and are thus of special 
interest for our research.15 Indeed, these plants were expected to be a further source of FR 
analogs. Finally, in our attempt to detect and isolate further FR derivatives, genome mining of 
publicly available bacterial genomes was thought to lead to the detection of biosynthetic genes 
related to those for FR and thus reveal further bacterial sources that could be exploited.  
The following questions are addressed in Chapter 5.1: 
1. Can we obtain further FR derivatives from A. crenata and what is their structure? 
 Chapter 5.1.1 and 5.1.2 
2. Do other Ardisia species also contain similar cyclic depsipeptides? 
 Chapter 5.1.3 and 5.1.4 
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3. Can we obtain culturable bacteria from culture collections, which harbor biosynthetic genes 
for depsipeptides identical or similar to those for FR and do they produce compounds under 
laboratory conditions? 
 Chapter 5.1.5 
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 Discovery of new FR analogs and further natural sources of FR  
Natural products mostly occur as a mixture of closely related metabolites. Often a major 
metabolite is accompanied by much smaller quantities of derivatives as described by Taniguchi 
et al. for YM.52 Taniguchi et al. were able to work with a cultivable bacterium in a 
pharmaceutical industry framework (Yamanouchi Pharmaceutical Co) using an industrial scale 
fermenter. From the fermentation broth (80 L) they were able to isolate 1.2 g YM. Hence, the 
minor metabolites could still be isolated in yields > 30 mg, i.e. 35 mg for YM-280193, which 
facilitated their structure elucidation via NMR.52 
In contrast, we were dependent on the material from a slow growing plant source in form of the 
perennial shrub of A. crenata, with rather demanding growing conditions (green house planting, 
humidity adapted, limited temperature range), which provided lower yields. One extraction 
cycle, which consisted of 200 g of dry leaf material provided about 10 mg of the major 
metabolite FR. Assuming quantities for FR analogs of about 3% of the FR amounts or lower, 
we expected less than 0.5 mg of putative FR analogs per extraction cycle, making structure 
elucidation via NMR experiments very difficult or in some cases even not feasible. Therefore, 
in some cases we applied different approaches allowing us to deduce merely putative structures. 
Derivatives present in higher amounts were obtained using activity-guided fractionation of 
Ardisia extracts, whereas mass spectrometry-based Global Natural Products Molecular 
Networking (GNPS) was used to detect new and very minor FR analogs. LCMS² based 
structural assignment was used to determine the putative structures of the latter.174 
 New FR analogs derived from A. crenata assisted by bioactivity-guided 
fractionation  
NRPS machineries are often known for producing one major metabolite, and to a smaller extent 
also derivatives due to the “erroneous” loading of substrates. To obtain these minor metabolites 
we started an activity-guided isolation approach towards dried A. crenata leaves. 
Dried plant leaves were coarsely grinded and extracted with methanol. Further purification 
steps included liquid-liquid extraction, RP-18 vacuum liquid chromatography and size 
exclusion chromatography. Final purification was done by HPLC with a semi-preparative RP-
18 column. The elution system was water (eluent A) and methanol (eluent B). The crude peptide 
mixture (including FR and its analogs FR-1, FR-2, FR-3/FR-4) was derived with isocratic 
conditions (80% eluent B for 35 minutes). The separation of FR from its putative analogs was 
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achieved applying different further HPLC purification steps for each of the analogs. The 
isolation scheme is shown in Scheme 5-1. 
FR-1 (1, formerly called AC-1) was isolated as described by Crüsemann & Reher et al (for 1D 
and 2D NMR data refer to Appendix Figures 10-14 to 10-20, Scheme 10-2).10 In short, from 
200 g of dried A. crenata leaves we obtained 0.7 mg of compound 1. 
HPLC conditions had to be adjusted to separate FR-2 (2, formerly called AC-0, manuscript 
including structure elucidation submitted) from 1 (for the complete isolation scheme refer to 
Scheme 5-1, Chapter 3.4, and Appendix Figures 10-21 to 10-26, Scheme 10-3). The 
composition of the mobile phase was changed from isocratic 80% eluent B to 75 % eluent B 
applying a 75:25 Nucleoshell RP18+ column (250 x 8 mm, 5 µm) for 20 minutes followed by a 
linear gradient from 75–100% eluent B within 15 minutes. The new cyclic depsipeptide, 2, was 
obtained as white powder (about 0.2 mg from 200 g dried leaves, tR = 23.7 min). The isolation 
process was repeated until 1.6 mg of 2 were collected for structure elucidation. 
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Scheme 5-1: Workflow chart for the extraction of FR- and analogs from dried leaves of the plant A. crenata. 
 Structure Elucidation of 1 (FR-1) 
The molecular formula of 1 (FR-1) was determined to be C50H77N7O16, based on HR-FTICR 
mass spectral measurements (calcd. 1032.5500; obsd. 1032.5533) for [M+H]+. Sequential 
fragmentation of the depsipeptide via collision induced dissociation demonstrated the structural 
similarities between FR and 1, and further indicated that 1 differs from FR regarding the acyl 
residue of the respective N-acetylhydroxyleucine-1 (L’) of FR (Figure 5-2). From extensive 
NMR spectral data analysis (1H, 13C, 1H-1H-COSY, 1H-13C-HSQC, 1H-13C-HMBC, 1H-1H-
ROESY) we concluded for 1 that 3-hydroxypropionic acid is placed at this L’ residue instead 
of acetic acid (as in FR, Scheme 1-1, Scheme 5-2) that we label as L* in the following. 
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Evidence was provided from (i) the lacking NMR signals for an acetate moiety at δH 2.23 / δC 
22.6 as observed for FR, (ii) the additional NMR signals for the methylene groups CH2-24 and 
CH2-25 of which C-25 had to be substituted with oxygen, resulting in resonances at δH 2.80 / 
δC 37.3 and δH 3.93 / δC 59.5, respectively (1D-NMR and HSQC spectral data), as well as (iii) 
the COSY correlations of resonances for H2-24 and H2-25 to each other and HMBC correlations 
of both methylene group resonances to the neighboring amide carbonyl group (C-23, δC 174.1 
ppm). For the complete assignment, please refer to Table 5-1 and Appendix Figures 10-14 to 
10-21. The position of the hydroxypropionyl moiety at NH-18 was also verified from the results 
of LCMS2 experiments (Figure 5-2). 
 
Scheme 5-2: Structure and numbering of C-atoms of 1 (FR-1). 
 
Compound 1 (FR-1): 5 mg/kg dried plant material (predominantly leaves), C50H77N7O16, HR-
FTICR (calcd. 1032.5500; obsd. 1032.5533) for [M+H]+, [α]D20=-35.4°·ml·dm−1·g−1 
(c=0.72g/ml in methanol), NMR data see Table 5-1. 
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Table 5-1: 1H and 13C NMR spectroscopic data of 1 (FR-1) in CDCl3 (1H: 600 MHz; 13C: 150 MHz). 
Residue[c] No C/H[b] δC[a], mult δH[a] (mult, J in Hz) 
Ala 1 172.5, C – 
 2 45.7, CH 4.91 (dq, 9.1, 6.6) 
 2-NH – 8.50 (d, 9.1) 
 3 18.0, CH3 1.39 (d, 6.6) 
N-Me-Dha 4 163.8, C – 
 5 145.3, C – 
 6 107.2, CH2 a: 5.34 (d, 2.2) 
   b: 5.09 (d, 2.2) 
 7 36.4, CH3 3.18 (s) 
Pla 8 167.9, C – 
 9 72.8, CH 5.22 (dd, 3.9, 8.9) 
 10 36.7, CH2 a: 3.12 (dd, 3.9, 14.9) 
   b: 2.97 (dd, 8.9, 14.9) 
 11 136.0, C – 
 12/16 129.5, CH 7.24 (d, 7.7) 
 13/15 128.6, CH 7.30 (t, 7.7) 
 14 127.0, CH 7.24 (t, 7.7) 
N-(3-hydroxypropionyl)-
β-HyLeu-1 
17 169.0, C 
– 
 18 50.3, CH 5.25 (dd, 1.8, 10.0) 
 18-NH – 7.62 (d, 10.0) 
 19 77.5, CH 5.14 (dd, 1.8, 10.0)  
 20 29.0, CH 1.89 (m) 
 21 18.86, CH3 1.01 (d, 6.6) 
 22 18.5, CH3 0.86 (d, 6.6) 
 23 174.1, C – 
 24 37.3, CH2 2.80 (brt, 5.5) 
 25 59.5, CH2 3.93 (t, 5.5) 
 25-OH – n.d. [d] 
N,O-Me2-Thr 26 166.4, C – 
 27 64.5, CH 4.06 (d, 9.9) 
 28 72.4, CH 3.76 (m) 
 29 16.3, CH3 1.18 (d, 5.8) 
 30 28.8, CH3 2.70 (s) 
 31 57.2, CH3 3.41 (s) 
β-HyLeu 32 171.1, C – 
 33 46.7, CH 5.34 (m) 
 33-NH – 6.78 (d, 10.0) 
 34 77.0, CH 5.32 (m) 
 35 30.5, CH 1.71 (m) 
 36 19.4, CH3 1.09 (d, 6.6) 
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 37 18.2, CH3 0.83 (d, 6.6) 
N-Me-Ala 38 170.1, C – 
 39 56.4, CH 4.69 (q, 6.6) 
 40 14.3, CH3 1.40 (d, 6.6) 
 41 31.4, CH3 2.88 (s) 
N-Pr-β-HyLeu-2 42 170.2, C – 
 43 56.9, CH 4.56 (dd, 2.0, 7.8) 
 43-NH – 7.17 (d, 7.8) 
 44 78.3, CH 3.73 (m) 
 44-OH – 6.84 (d, 4.4) 
 45 30.0, CH 1.98 (m) 
 46 20.5, CH3 1.17 (d, 6.6) 
 47 18.92, CH3 0.88 (d, 6.6) 
 48 174.8, C – 
 49 28.7, CH2 a: 2.58 (dq, 14.8, 7.7) 
   b: 2.49 (dq, 14.8, 7.7) 
 50 10.0, CH3 1.19 (t, 7.7) 
[a] Assignments are based on extensive 1D and 2D NMR measurements (HMBC, HSQC, COSY). See also SI. [b] Numbers 
according to Scheme S2. [c] Residues: Ala = alanine, N-Me-Dha = N-methyldehydroalanine, Pla = 3-phenyllactic acid, N-(3-
hydroxypropionyl)-Hle-1 = N-3-hydroxypropionylhydroxyleucine-1, N,O-Me2-Thr = N,O-dimethylthreonine, β-HyLeu = 
hydroxyleucine, N-Me-Ala = N-methylalanine, N-Pr-β-HyLeu 2= N-propionylhydroxyleucine-2. [d] n.d. = not determined.  
 Structure elucidation of 2 (FR-2) 
The molecular formula of 2 was determined to be C48H73N7O15, based on HR-FTICR mass 
measurements (calcd. 988.5237; obsd. 988.5236) for [M+H]+. Compared with FR, compound 
2 thus had a molecular mass 14.01 Da lower, which indicated that compound 2 contains one 
methylene group less in its structure. Sequential fragmentation of the depsipeptide 2 via 
collision induced dissociation demonstrated close structural similarities between FR and 2, and 
further indicated that 2 differs from FR regarding the acyl residue of N-
propionylhydroxyleucine-2 (L’’’) of FR (Figure 5-2). In general, FR, 1, and 2 have similar MS 
fragmentation patterns. The compounds can be distinguished by characteristic Δm/z values 
resulting from the different composition and incorporation of amino acids into the cyclic 
peptide backbone. In the first fragmentation step compound 2 loses the side chain, which can 
be seen in the MS spectra as a 171.10 Da fragment (N-acetylhydroxyleucine-2 = L^). Instead, 
for FR a m/z 185.11 Da fragment, i.e. N-propionylhydroxyleucine-2 is cleaved off. Comparison 
of further fragments also proved that in compound 2 the N-acyl residue at C-42 is different (see 
also Scheme 5-3). These MS data together with extensive NMR spectral data analysis (1H, 13C, 
1H-1H-COSY, 1H-13C-HSQC, 1H-13C-HMBC) lead us conclude that in 2 an acetic acid moiety 
is placed at the side chain hydroxyleucine residue instead of the propionic acid, which is present 
at the analogous position of FR. 
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Scheme 5-3: Fragmentation pathways of first-generation (MS²) product ions obtained from FR and 
compound 2 (FR-2). m/z 1002.54 (FR) or rather m/z 988.52 (2) lose their distinctive side-chain amino acid N-
propionylhydroxyleucine-2 (FR) or N-acetylhydroxyleucine-2 = L^ (2), resulting in the formation of the same 
fragment, i.e. m/z 817.43 for both compounds. 
Evidence was provided from (i) the lacking NMR signals for a propionate methylene CH2-48, 
at δH 2.57 and δH 2.50 / δC 28.2 and a methyl moiety CH3-49 at δH 1.19 / δC 10.1, respectively 
(as compared to FR (Appendix Figures 10-21 to 10-26), (ii) the additional NMR signals for 
the acetate methyl group CH3-48 at δH 2.24 / δC 22.7, (1D-NMR and HSQC spectral data of 2), 
as well as (iii) the HMBC correlation of methyl group resonance CH3-48 to that of the 
neighboring amide carbonyl group (C-47, δC 171.4, Table 5-2, Appendix, Figures 10-21 to 10-
26). The position of the acetate moiety at NH-42 was evident from HMBC correlations between 
the resonance for NH-42 (δH 7.27) and that of C-47 (δC 171.4). Further evidence for the site of 
modification of 2 as compared to FR came from LCMS2 experiments (Figure 5-2). 
Compound 2 (FR-2): 1mg/kg dried plant material (predominantly leaves), C48H73N7O15, HR-
FTICR (calcd. 988.5237; obsd. 988.5236) for [M+H]+, [α]D20=-70.2°·ml·dm−1·g−1 (c=0.58g/ml 
in methanol), NMR data see Table 5-2. 
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Table 5-2: 1H and 13C NMR spectroscopic data of 2 (FR-2) in CDCl3 (1H: 300 MHz; 13C: 75 MHz). 
Residue[c] No C/H[b] δC[a], mult δH[a] (mult, J in Hz) 
Ala 1 172.8, C – 
 2 45.9, CH 4.90 (m) 
 2-NH – 8.53 (d, 9.2) 
 3 18.1, CH3 1.39 (d, 6.8) 
N-Me-Dha 4 164.0, C – 
 5 145.4, C – 
 6a 106.9, CH2 a 5.32 (d, 2.0) 
 6b – b 5.07 (d, 2.0) 
 7 36.3, CH3 3.15 (s) 
Pla 8 167.9, C – 
 9 72.8, CH 5.21 (dd, 4.1, 8.2) 
 10a 36.8, CH2 a 3.11 (dd, 4.1, 14.8)  
 10b – b 2.98 (dd, 8.2, 14.8) 
 11 136.1, C – 
 12/16 129.7, CH 7.26[d] 
 13/15 128.7, CH 7.29[d] 
 14 127.1, CH 7.23[d] 
N-Ac-β-HyLeu-1 17 169.4, C – 
 18 50.5, CH 5.26 (brd, 10.0) 
 18-NH – 7.54, (d, 10,0) 
 19 77.8, CH 5.11 (brd, 10.0) 
 20 29.0, CH 1.91 (m) 
 21 19.1, CH3 1.01 (d, 6.5) 
 22 19.0, CH3 0.85 (d, 6.6) 
 23 171.6, C – 
 24 22.6, CH3 2.23 (s) 
N,O-Me2-Thr 25 166.6, C – 
 26 64.6, CH 4.07 (d, 9.8) 
 27 72.5, CH 3.74 (m) 
 28 16.4, CH3 1.17 (d, 5.8) 
 29 28.9, CH3 2.69 (s) 
 30 57.3, CH3 3.40 (s) 
β-HyLeu 31 171.2, C – 
 32 46.8, CH 5.35 (d, 10.0) 
 32-NH  6.73, (d, 10.0) 
 33 77.4, CH 5.31 (m) 
 34 30.7, CH 1.71 (m) 
 35 19.5, CH3 1.09 (d, 6.6) 
 36 18.4, CH3 0.83 (d, 6.6) 
N-Me-Ala 37 170.1, C – 
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 38 56.6, CH  4.71 (q, 7.0) 
 39 14.4, CH3 1.39 (d, 7.0) 
 40 31.5, CH3 2.88 (s) 
N-Ac-β-HyLeu-2 41 170.3, C – 
 42 57.1, CH 4.53 (dd, 1.3, 7.6) 
 42-NH – 7.27 (m) 
 43 78.3, CH 3.73 (m) 
 43-OH – 6.88 (d, 4.5) 
 44 30.2, CH 1.98 (m) 
 45 20.6, CH3 1.17 (d, 6.6) 
 46 18.7, CH3 0.88 (d, 6.8) 
 47 171.4, C – 
 48 22.7, CH3 2.24 (s) 
[a] Assignments are based on extensive 1D and 2D NMR measurements (HMBC, HSQC, COSY).. [b] Numbers according to 
Scheme S3. [c] Residues: Ala = alanine, N-Me-Dha = N-methyldehydroalanine, Pla = 3-phenyllactic acid, N-Ac-β-HyLeu1 = 
N-acetylhydroxyleucine-1, N,O-Me2-Thr = N,O-dimethylthreonine, β-HyLeu = hydroxyleucine, N-Me-Ala = N-methylalanine. 
, N-Ac-β-HyLeu2 = N-acetylhydroxyleucine-2. [d] overlaying resonances. 
Structure activity relationship studies of 1 and 2 are described in Chapter 5.2. 
 New FR analogs derived from A. crenata detected via MS-based molecular 
networking 
Wang et al. and Yang et al. demonstrated that global natural product social molecular 
networking (GNPS), an approach that organizes MS/MS data based on chemical similarity, is 
powerful to identify known and new natural products in a complex matrix.174,189 This MS²-
based approach allows comparisons of fragmentation patterns of molecular ions leading to 
clustering of structurally similar compounds and their visualization in a molecular network. 
Here, molecular ions represent nodes, which are connected by edges, highlighting the structural 
relationships and similarities of the molecules. Molecular networking has been successfully 
applied to dereplicate natural products from complex extracts,183 to compare the metabolomes 
of various natural product producers190 and to improve and accelerate natural product isolation 
and structure elucidation workflows.191–194 Further, molecular networking should not only 
dereplicate known molecules from complex mixtures, but also capture related analogs, making 
it most valuable this study. 
We integrated molecular networking in our study applying the following workflow. First, A. 
crenata leaves were extracted with methanol and after liquid-liquid distribution, a butanolic 
extract was obtained. Subsequently, the butanol phase was further fractionated using vacuum 
liquid chromatography and size exclusion chromatography on Sephadex LH-20 and monitored 
by bioactivity (IP1 accumulation assay, Chapter 3.7.4). This depsipeptide containing fraction 
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was investigated applying MS²-based GNPS molecular networking to visualize the FR 
molecular family (Figure 5-1). 
 
Figure 5-1: Molecular network of the FR molecular family from Ardisia leaves (Sephadex fraction 7-3). 
Nodes display distinct m/z features, corresponding to their parent mass. Width of edges is proportional to cosine. 
Sizes of the nodes correspond to extraction number of species (small nodes all originate from A. crenata extract, 
m/z 1002.54 and 1019.56 were also detected in A. hanceana, A. villosa, and A. lucida). Highlighted in red are FR 
and the structural-related derivatives FR-1 to FR-5 (1-5). Orange-labeled nodes display putative FR analogs 6-10, 
lacking the side chain N-propionylhydroxyleucine2. For (putative) structures of 1-10, see Schemes 5-5 and 5-6. 
The molecular network of the FR family (Figure 5-1) shows 22 nodes. The protonated FR (m/z 
1002.54) molecular ion clusters with those of 1 (m/z 1032.55)10 and 2 (m/z 988.53), described 
in Chapter 5-1 , and additionally with those of analogous peptides, e.g. m/z 974.51, 1016.55, 
and 817.44. 
In order to deduce putative structures of to date unknown FR derivatives, one characteristic MS 
fragmentation pathway, observed for proton adducts of FR and presumably all putative FR 
analogs, was thoroughly analyzed and is shown in Scheme 5-4. In a first step, the core structure 
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is cleaved between alanine and N-methylalanine and linearized. In cyclic peptides breakage of 
the amide (or ester bond for depsipeptides, respectively) is reported to lead to the formation of 
a linear peptide with a C-terminal oxazolone ring195, which sequentially loses amino acids. This 
is clearly evident when LCMS² spectra of FR are compared with those of the known and 
structurally proven analogs 110 and 2. The different acylations in 1 and 2 lead to a characteristic 
change in the mass of the respective fragments (Scheme 5-4). 
 
Scheme 5-4: (A) Fragmentation pathway of FR900359 (FR). FR ring structure is first cleaved, followed by 
sequential loss of amino acids see also Scheme 1-1 (m/z 1002.54  (-L’’’) m/z 817.44  (-L’’) m/z 688.35 (-
A’) m/z 603.30  (-T’) m/z 474.22  (-L’) m/z 303.14 (-A) m/z 232.10). Peptide fragment ions are labeled in 
one-letter amino acid code, according to a nomenclature system described in Chapter 3.4.1.3. L’’’ = N-
propionylhydroxyleucine-2, L’’ = hydroxyleucine, A’ = N-methylalanine, T’ = N,O-dimethylthreonine, L’ = N-
acetylhydroxyleucine-1, A = alanine, F’ = phenyllactic acid, A’’ = N-methyldehydroalanine. (B) Fragmentation 
pathway of 1 (FR-1). L* = N-3-hydroxypropionylhydroxyleucine-1. (C) Fragmentation pathway of 2 (FR-2). L^ 
= N-acetylhydroxyleucine-2. 
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Knowledge on the typical MS fragmentation pattern of FR and related compounds, now allowed 
to search MS data for the presences of further derivatives. In-depth analysis of the LCMS² data 
revealed next to the compound peak of compound 2 a peak of compound 5. Both compounds 
share the same m/z feature of 988.53 for the molecular ion at, but display different fragmentation 
patterns and retention times. Whereas compound 2 elutes at tR 4.0 minutes (HPLC conditions 
see Chapter 3.6.1.3), the isomer (5) elutes slightly earlier (tR = 3.7 minutes). We compared the 
MS² spectra of 5, 2 and of FR. According to Scheme 5-4, the first fragmentation step is the 
cleavage of the side-chain (for FR N-propionylhydroxyleucine-2 = L’’’). As 2 differs from FR 
in the side chain, the loss of the latter leads to the same m/z 817.44 for FR and 2 (Figure 5-2). 
In contrast, 5 must have the same side chain as FR, as after cleaving of L’’’, 5 displays m/z 
803.42, which is equivalent to the fragment of FR (m/z 817.44), except that it has a 14.01 Da 
lower mass. The subsequent three fragmentation steps also result in equivalent fragment ions 
for 5 and FR, again with a 14.01 Da lower mass for the ions of 5. The fourth fragmentation step 
finally allowed to distinguish between FR and 5. While a Δm/z 129.08 (N,O-dimethylthreonine 
= T’) loss from the m/z 603.30 ion of FR resulted in the m/z 474.22 ion, for 5 a Δm/z 115.07 
loss of the corresponding m/z 589.29 ion lead to the same m/z 474.22 ion. Thus, we concluded 
that 5 differs from FR in the T’ building block (T° for 5), which was further supported by other 
fragmentation pathways. Based on the NRPS origin of FR and its analogs, for T° three possible 
and reasonable structures remain, i.e. N-methylthreonine, O-methylthreonine and N,O-
dimethylserine (Appendix Scheme 10-4). So, LCMS² analysis enabled us to reduce the number 
of possible structures for 5 from several hundred to three. Compound 5 is only present in minute 
amounts in the extract and could not be isolated yet. 
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Figure 5-2: (A) Schematic structure of FR900359 (FR), FR-1 (1), FR-2 (2), and putative FR-5 (5). Peptide 
fragment ions are labeled in one-letter amino acid code, according to a nomenclature system described in Chapter 
3.4.1.3. b° = b-ion with loss of water. L’ = N-acetylhydroxyleucine-1, L* = N-3-hydroxypropionyl-hydroxyleucine-
1, F’ = phenyllactic acid, A’’ = N-methyldehydroalanine, A = alanine, A’ = N-methylalanine, L’’ = 
hydroxyleucine, T’ = = N,O-dimethylthreonine, L’’’ = N-propionylhydroxyleucine-2, L^ = N-
acetylhydroxyleucine-2, T° = three possibilities, i.e. N-methylthreonine, O-methylthreonine and N,O-
dimethylserine (please also refer to Scheme S2. (B) Comparison of first-generation, product-ion spectra of FR, 1, 
2, and 5; [M+H]+. 1 has a different acylation residue at L’; instead of an acetate residue (L’ in FR), 1 contains of 
a 3-hydroxypropionate residue (L*). 2 has a different acylation residue at L’’’; instead of an propionate residue 
(L’’’ in FR), 2 contains of an acetate residue (L^). 5 differs from FR in the amino acid N,O-dimethylthreonine 
(T’). 5 cannot be assigned unambiguously based on LCMS² analysis only. 
 
In a former study we assigned m/z 817.44 as putative biosynthetic FR-precursor FR-SC (6), 
standing for FR without the N-propionylhydroxyleucine-2 side-chain.10 Interestingly, a similar 
congener of the structurally related YM (YM lacking the side chain = YM-280193) was 
characterized, pointing to an analogous biosynthetic route.196 Apart from compound 6 (m/z 
817.44) further compounds having only the cyclic part of FR, but with subtle differences were 
observed. Analysis of fragments at m/z 831.46 (7, FR-SC1), m/z 803.43 (8, FR-SC2), m/z 
847.45 (9, FR-SC3), and m/z 888.47 (10, FR-SC4), clustering with m/z 817.44 evidenced this 
assumption and suggested that there are a multitude of further FR derivatives differing from the 
major metabolite by lacking the side chain and some features of the cyclic part of FR (Figure 
5-3). 
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Figure 5-3: Schematic structure of FR-SC (6), and derivatives thereof 7, 8, 9, and 10 on the right side. FR 
derivatives 6-10 are all lacking the side chain L’’’ = N-propionylhydroxyleucine-2. Peptide fragment ions are 
labeled in one-letter amino acid code, according to a nomenclature system described in Chapter 3.4.1.3. b° = b-
ion with loss of water. L’ = N-acetylhydroxyleucine-1, F’ = phenyllactic acid, A’’ = N-methyldehydroalanine, A 
= alanine, A’ = N-methylalanine, L’’ = hydroxyleucine, T’ = N,O-dimethylthreonine, L^ = N-
propionylhydroxyleucine-1, L° = N-3HPr-Hle = N-3hydroxypropionylhydroxyleucine-1. (B) Comparison of first-
generation product-ion spectra of 6-9; [M+H]+. 6, 7, and 9 have different acylation residues at L’; instead of an 
acetate residue (L’ in 6), 7 contains of a propionate residue (L^) and 9 contains of a 3-hydroxypropionate residue 
(L°). 8 differs from 6 in the amino acid N-methylalanine (A’). A’ is substituted in 8 by alanine (A). 
 
In that way we assigned 7 to be the cyclic part of 3 (for structure elucidation refer to following 
pages) with an N-propionylhydroxyleucine-1 instead of N-acetylhydroxyleucine-1, 8 to be the 
cyclic part of 5 with a modified N,O-dimethyl-threonine residue lacking one methylene group, 
9 to be the precursor of 1 thus harboring N-3-hydroxypropionylhydroxyleucine-1 instead of N-
acetylhydroxyleucine-1, and most interestingly 10 to be an analog of 6 with an additional 
alanine moiety in its cyclic backbone (Scheme 5-5). These putative derivatives suggest that the 
trans-esterification step, which attaches the side chain to the cyclic core peptide is the last step 
in the biosynthesis. Compound 10 also demonstrates unexpected flexibility of the FR-NRPS, 
as apparently module 5 has to be used twice to incorporate an additional alanine unit. 
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Scheme 5-5: Putative structures of 6, 7, 8, 9, and 10. All FR derivatives shown lack the N-
propionylhydroxyleucine2 side chain (yellow box, Scheme S1). Putative structural differences from 6 are 
highlighted (blue box). 
 
These results encouraged us to analyze further FR analogs clustering with FR in the MS²-based 
network, i.e., compounds 3 and 4. From the molecular network an ion with m/z 1016.55 (Figure 
5-1) attracted our attention, because it directly clustered with the FR ion (m/z 1002.54). 
Investigation of the extracted ion chromatogram of the LCMS measurement for m/z 1016.55 of 
the isolated sample indicated, that it was not a single compound, but consisted of two isomeric 
compounds as evident from slightly different retention times (ΔtR 0.2 min). We named these 
compounds FR-3 (3) and FR-4 (4). 1H-NMR spectroscopy revealed that the compounds were 
present in in a 1:1 mixture (Appendix Figures 10-27 to 10-31) making an assignment of 
resonances impossible at this stage. The molecular formulae of 3 and 4 were determined to be 
C50H77N7O15 (calcd. 1016.5550; obsd. 1016.5544 (3) and 1016.5553 (4), respectively) for 
[M+H]+. These results showed a mass difference of 14.01 Da between FR and compounds 3 
and 4, and suggested an additional methylene group in the structures of 3 and 4. In-depth MS² 
analysis allowed us to analyze 3 and 4 separately. It revealed that FR, 3 and 4 can be 
distinguished by different Δm/z values resulting from differently modified amino acids that 
were sequentially lost, similar as above described for 2 and 5 (Figure 5-4). In the fifth 
fragmentation step, the m/z 474.22 of FR loses N-acetyl-hydroxyleucine1 (L’, Δm/z 171.08 Da) 
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to yield the m/z 303.14 ion. The corresponding m/z 488.24 ion of 3 loses Δm/z 185.10 Da 
fragment to give the same m/z 303.14 ion. Thus, together with further evidence from other 
fragmentation pathways, we conclude that 3 has a modified L’ residue, designated as L° in the 
following. Taking biosynthetic considerations into account reduced the possible structures of 
L° to either N-propionylhydroxyleucine-1 or N-acetyl-hydroxyhomoleucine-1. 
 
Figure 5-4: (A) Schematic structure of FR, FR-3 (3), and FR-4 (4). Peptide fragment ions are labeled in one-letter 
amino acid code, according to a nomenclature system described in Chapter 3.4.1.3. b° = b-ion with loss of water. 
L’ = N-acetylhydroxyleucine-1, L° = N-propionylhydroxyleucine-1, F’ = phenyllactic acid, A’’ = N-
methyldehydroalanine, A° = homoalanine, A = alanine, A’ = N-methylalanine, L’’ = hydroxyleucine, T’ = N,O-
dimethylthreonine, L’’’ =  N-propionylhydroxyleucine-2. (B) Comparison of first-generation, product-ion spectra 
of FR, 3, and 4; [M+H]+ . Compared to FR, 3 has a different acylation residue at L’; instead of an acetate residue 
(L’ in FR), 3 contains of a propionate residue (L°). 4 differs from FR in the amino acid alanine (A). A is substituted 
in 4 by homoalanine (A°). 
 
Compound 4 differs from FR concerning the alanine residue (A) (R3 in Scheme 5-6). Instead 
of alanine, 4 contains a residue with a 14.01 Da higher mass, i.e. homoalanine or alternatively 
a N-methylalanine building block, as revealed from the LCMS2 data (Supporting 
information). This was again evident from different Δm/z values resulting from sequential loss 
of amino acids. Compound 4, but not FR produced a fragment with m/z 470.22. Instead of a 
Δm/z 71.03 Da (alanine) loss as for FR, 4 loses a Δm/z 85.05 Da fragment (A° = homoalanine 
or N-methylalanine) leading to the same m/z 385.17 fragment. Analysis of further fragmentation 
pathways supported this assumption (see also Figure 5-4). Therefore we could reduce the 
number of possible structures for 3 and 4 to two reasonable structures for each compound. 
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Applying a further HPLC purification step we were finally able to isolate 3 as white powder 
only containing minor amounts of 4 (ratio 3 / 4 = 3 / 1). After recording 1H NMR and 1H-13C-
HSQC spectra, we were able to unambiguously assign the structures of 3 and 4 (Table 5-3, 
Appendix Scheme 10-5). 
Table 5-3: 1H and 13C NMR spectroscopic data of 3 (FR-3) and 4 (FR-4) in CDCl3 (1H: 600 MHz; 13C: 150 MHz). 
FR-3 (3)     FR-4 (4) 
Residue[c] 
No 
C/H[b] 
δC[a], mult δH[a] ( J [Hz]) Residue[c] 
No 
C/H[b] 
δC[a], mult δH[a] ( J [Hz]) 
Ala 1 172.6, C – Homo-Ala 1 172.2, C – 
 2 45.6, CH 
4.91 (dq, 9.1, 
6.7) 
 2 51.4, CH 4.69 (m) 
 2-NH – 8.52 (d, 9.1)  2-NH – 8.49 (d, 9.1) 
 3 18.0, CH3 1.41 (d, 6.7)  3a 26.4, CH2 a  1.78, m  
N-Me-Dha 4 164.0, C –  3b  b  2.00, m 
 5 145.5, C –  4 10.3, CH3 0.97 (t, 7.2) 
 6a 106.9, CH2 a 5.32 (d, 2.2) N-Me-Dha 5 164.4, C – 
 6b – b 5.07 (d, 2.2)  6 145.5, C – 
 7 36.3, CH3 3.16 (s)  7a 106.9, CH2 a 5.37 (d, 2.2) 
Pla 8 167.9, C –  7b – b 5.09 (d, 2.2) 
 9 72.8, CH 
5.19 (dd, 4.1, 
8.3) 
 8 36.3, CH3 3.20 (s) 
 10a 36.8, CH2 
a 3.11 (dd, 4.1, 
14.8)  
Pla 9 167.9, C – 
 10b – 
b 2.98 (dd, 8.3, 
14.8) 
 10 72.7, CH 
5.21 (dd, 4.1, 
8.3) 
 11 136.1, C –  11a 36.8, CH2 
a 3.11 (dd, 4.1, 
14.8)  
 12/16 129.4, CH 7.26[d]  11b – 
b 2.98 (dd, 8.3, 
14.8) 
 13/15 128.8, CH 7.32[d]  12 136.1, C – 
 14 127.2, CH 7.25[d]  13/17 129.7, CH 7.26[d] 
N-Pr-β-HyLeu-1 17 169.4, C –  14/16 128.7, CH 7.29[d] 
 18 50.3, CH 
5.30 (dd, 1.3, 
10.0) 
 15 127.1, CH 7.23[d] 
 18-
NH 
– 7.45, (d, 10,0) N-Ac-β-HyLeu-1 18 169.4, C – 
 19 77.8, CH 
5.12 (dd, 1.3, 
10.0) 
 19 50.5, CH 
5.26 (dd, 1.3, 
10.0) 
 20 29.1, CH 1.91 (m)  
19-
NH 
– 7.55, (d, 10,0) 
 21 18.9, CH3 1.01 (d, 6.8)  20 77.8, CH 
5.12 (dd, 1.3, 
10.0) 
 22 18.8, CH3 0.85 (d, 6.8)  21 29.0, CH 1.89 (m) 
 23 175.6, C –  22 19.1, CH3 1.01 (d, 6.8) 
 24a 28.7, CH2 2.59 (m)  23 19.0, CH3 0.85 (d, 6.8) 
 24b  2.53 (m  24 171.6, C – 
 25 10.3, CH3 1.24 (m)  25 22.6, CH3 2.26 (s) 
N,O-Me2-Thr 26 166.6, C – N,O-Me2-Thr 26 166.6, C – 
 27 64.4, CH 4.08 (d, 9.8)  27 64.6, CH 4.07 (d, 9.8) 
 28 72.3, CH 3.76 (m)  28 72.5, CH 3.75 (m) 
 29 16.2, CH3 1.18 (d, 4.8)  29 16.2, CH3 1.23, (d, 4.8)  
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 30 28.8, CH3 2.70 (s)  30 28.9, CH3 2.70 (s) 
 31 57.0, CH3 3.41 (s)  31 57.3, CH3 3.41 (s) 
β-HyLeu 32 171.4, C – β-HyLeu 32 171.4, C – 
 33 46.9, CH 5.36 (d, 9.9)  33 46.8, CH 5.38 (d, 9.9) 
 33-
NH 
 6.75, (d, 9.9)  
33-
NH 
 6.70, (d, 9.9) 
 34 77.1, CH 5.31 (m)  34 77.1, CH 5.31 (m) 
 35 30.4, CH 1.75 (m)  35 30.7, CH 1.72 (m) 
 36 19.3, CH3 1.10 (d, 6.7)  36 19.5, CH3 1.10 (d, 6.7) 
 37 18.3, CH3 0.83 (d, 6.7)  37 18.3, CH3 0.83 (d, 6.7) 
N-Me-Ala 38 170.1, C – N-Me-Ala 38 170.1, C – 
 39 56.5, CH  4.71 (q, 6.8)  39 56.4, CH  4.69 (q, 6.8) 
 40 14.2, CH3 1.41 (d, 6.8)  40 14.4, CH3 1.41 (d, 6.8) 
 41 31.3, CH3 2.90 (s)  41 31.5, CH3 2.88 (s) 
N-Pr-β-HyLeu-2 42 170.4, C – N-Pr-β-HyLeu-2 42 170.4, C – 
 43 56.8, CH 
4.57 (dd, 1.8, 
7.8) 
 43 57.0, CH 4.55 (m) 
 43-
NH 
– 7.25 (d, 7.8)  
43-
NH 
– 7.17 (d, 7.8) 
 44 78.3, CH 3.73 (m)  44 78.4, CH 3.73 (m) 
 44-
OH 
– 6.87 (d, 4.2)  
44-
OH 
– 6.81 (d, 4.3) 
 45 30.0, CH 1.99 (m)  45 30.1, CH 1.98 (m) 
 46 20.3, CH3 1.17 (6.7)  46 20.6, CH3 1.17 (6.7) 
 47 18.7, CH3 0.89 (6.7)  47 18.7, CH3 0.88 (6.7) 
 48 174.9, C –  48 174.9, C – 
 49a 28.8, CH2 
a 2.57 (dq, 14.9, 
7.5) 
 49a 28.8, CH2 
2.57 (dq, 14.9, 
7.5) 
 49b  
b 2.50 (dq, 14.9, 
7.5)  
49b  
2.50 (dq, 14.9, 
7.5) 
 50 10.0, CH3 1.19 (t, 7.5)   50 10.1, CH3 1.19 (t, 7.5) 
         
[a] Assignments are based on extensive 1D and 2D NMR measurements (HMBC, HSQC, COSY). 13C-NMR spectra were 
recorded at 150 MHz. [b] Numbers according to Scheme S1. [c] Residues: Ala = alanine, Homo-Ala = homoalanine N-Me-
Dha = N-methyldehydroalanine, Pla = 3-phenyllactic acid, N-Ac-β-HyLeu-1= N-acetylhydroxyleucine-1, N-Pr-β-HyLeu-1= N-
propionylhydroxyleucine-1 N,O-Me2-Thr = N,O-dimethylthreonine, β-HyLeu = hydroxyleucine, N-Me-Ala = N-
methylalanine, N-Pr-β-HyLeu-2 = N-propionylhydroxyleucine-2.[d] overlaying resonances. 
Evidence for the structure of 3 was provided from (i) the lacking NMR signals for an acetate 
moiety at δH 2.23 / δC 22.6 as observed for FR, (ii) the additional NMR signals for the methylene 
group CH2-24 and methyl group CH3-25, resulting in resonances at δH 2.55 / δC 28.7 and δH 
1.24 / δC 10.1, respectively (Table 5-3), as also, (iii) the COSY correlations of H2-24 and H2-
25 (Appendix Figure 10-29) and HMBC correlations (Appendix Figure 10-31) of H2-24 and 
H2-25 to the neighboring amide carbonyl group (C-23, δC 175.6 ppm). Thus, we finally 
concluded that compound 3 contains a N-propionylhydroxyleucine-1 (L°) instead of N-
acetylhydroxyleucine-1 (L’) in the cyclic backbone. Interestingly this means that FR-3 (3) 
would have the same planar structure as sameuramide, a compound previously isolated from a 
marine ascidian.29 After the assignment of 3, we could assign 4 from the NMR spectra of the 
1:1 mixture (Appendix Figures 10-32, 10-33). 
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Evidence for the homoalanine residue of 4 was provided from (i) the shifted methine αCH-2 δH 
4.69 / δC 51.4 as compared to δH 4.90 / δC 45.9 for FR (ii) the additional NMR signals for the 
methylene group CH2-3a/3b (δHa 1.78 / δHb 2.00  / δC 26.4) and methyl group CH3-4 (δH 0.97 / 
δC 10.3), respectively (Table 5-3), as well as (iii) the COSY correlations of H-2 to H2-3 and 
H2-3 and H3-4, and HMBC correlations of H2-4 to the neighboring methine αCH-2 (δH 4.69 / 
δC 51.4). Thus, we concluded for 4 to contain homoalanine (A°) instead of alanine (A) (Scheme 
5-6). 
 
Scheme 5-6: Structures of FR and isolated FR analogs 1-4 from Ardisia crenata. (Non-proteinogenic) amino acid 
building blocks colored and annotated for FR, including one-letter code. 
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 Synergistic effects of Ardisia crenata fractions towards FR activity 
Despite the activity of FR to perturb Gαq signaling, further Ardisia plant derived products may 
excert activity and/or interact with the bioactivity of FR. We (Tobias Benkel, MSc student, 
Kostenis lab) thus aimed to evaluate potential effects of other components in Ardisia leaves 
regarding the capability to blunt Gαq signaling and to interact with the activity of FR. For this 
purpose, we isolated and purified FR from dried leaves of A. crenata and collected all fractions 
received during the different extraction steps (Scheme 5-1). To confirm the potency of the 
isolated FR we applied the previously described functional assay (IP1 accumulation assay, 
Chapter 3.7.4). Agonist activation was completely inhibited by pre-incubation with isolated 
FR in a concentration-depended manner. The calculated LogIC50 values are in line with former 
reported potency of FR, which hereafter forms the basis of the following synergism trails. 
To determine the synergistic effects on FR we also applied the IP1 accumulation assay. All 
collected fractions have been tested in absence and presence of a non-active concentration of 
FR (10-7 M). All compounds have been tested once (n = 1) at first and repeated in case of any 
conspicuities (n = 2). For none of the tested compounds a synergistic effect on the potential to 
perturb the Carbachol induced IP1 production could be observed. Nonetheless, some Fractions 
(VLC 4, 5, 6 and S1, 5) revealed inhibitory potential on their own (Appendix Figures 10-34 to 
10-37).  
This should be further evaluated and might ultimately lead to novel compounds which could be 
superior to FR. 
 Detection of FR by molecular networking in several Ardisia species 
Ardisia is one of the largest genera within the family Primulaceae and comprises approximately 
500 species.197 Especially the subgenus Crispardisia is of interest, because all of these plants 
(e.g. A. crispa, A. hanceana, A. mamillata, and A. villosa) are known to have bacterial nodules 
that harbor endosymbiotic bacteria.3 
Leaves of several species belonging to Crispardisia, i.e. A. hanceana, A. villosa, and A. 
mamillata were collected in 2016 from tropical forest habitats in Hainan, China. Additionally, 
plants of A. crispa, and the non-nodulated species A. lucida and A. polycephala were cultivated 
in the Botanical Garden Bonn, Germany. In the butanolic extracts (derived from liquid-liquid 
separation of the methanolic extract with water) of A. crispa, A. hanceana, A. villosa and A. 
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mamillata, an ion with the same mass and retention time as FR was detected, although the 
respective concentration was significantly lower than in A. crenata. 
In A. lucida, and A. polycephala we could initially not detect such an ion. Thus, we further 
fractionated the butanolic extracts and could detect the signal in a subfraction of the A.lucida 
extract (Sephadex fraction AL-8-3-2) (Figure 5-5), but not in A. polycephala. 
 
Figure 5-5: Extracted ion chromatograms m/z 1002.54 ± 0.05 Da of extracts/fractions from different Ardisia 
species. 
The FR-containing samples were networked with the A.crenata extract to confirm the identity 
of FR by MS2 comparison and matching with an authentic FR standard uploaded to the GNPS 
database (Figure 5-1, 5-6).  
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Figure 5-6: Molecular network of the fractions from A. hanceana, A. lucida, and A. villosa leaves. Nodes display 
distinct m/z features, displaying their parent mass. Width of edges is proportional to cosine, labeled with delta m/z 
values. Sizes of the nodes correspond to sum of precursor intensities. Highlighted are nodes occurring only in A. 
hanceana (red), in A. hanceana and A. lucida (purple) and in all three species (blue). All m/z values display 0.03 
Da lower masses due to calibration error. 
The detection of FR in the non-nodulated A. lucida suggests the presence of an endosymbiont 
that is not located in the usual nodules, and may thus represent the very early stage of a plant-
bacterial symbiosis. Overall our results point toward a much broader distribution of FR in the 
genus Ardisia, than previously known, since all six analyzed Ardisia species do contain FR. 
Additionally, it is worthwhile to mention, that FR derivatives like YM-254890 and 
sameuramide were found in a in a soil bacterium28 and even a marine tunicate29, respectively. 
This again points to an even broader distribution of this molecule as currently anticipated. 
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 Isolation of FR from the cultivable Chromobacterium vaccinii MWU205, DSM 
25150 
The fact that YM analogs have before been found in free living bacteria, i.e. Chromobacterium 
sp. QS366628 makes it rather likely that biosynthetic genes for such molecules like YM and FR 
are present in other bacterial genomes. At this point it also has to be noted that up- and 
downstream of the frs cluster sequences for transposons were detected, and that the G/C content 
of the cluster is markedly different from that of the surrounding sequences. Horizontal gene 
transfer of the frs cluster is thus likely. Hence, it can be assumed that the ability to produce FR-
type molecules can be found in other bacteria as well. Under application of state-of-the-art 
similarity search algorithms, the multitude of bacterial genome sequences available were 
searched for biosynthetic genes related to the frs sequences. 
Using the BLAST similarity search tool,198 we took notice of Chromobacterium vaccinii 
MWU205, DSM 25150199,200, because the draft genome sequence apparently contains several 
small fragments of the frs gene cluster (>70% identity). This strain has been patented as 
potential biocontrol agent against mosquito (Aedes aegypti) larvae before199. As we already 
demonstrated the insecticidal properties of FR (Chapter 4.1.5), this fact made it an even more 
likely candidate for FR production.10 C. vaccinii had been isolated from soil and roots of 
Vaccinium macrocarpon (cranberry) in Massachusetts, USA and is a producer of violacein, a 
pigment with antibiotic properties.200 The putative chromobacterial frs gene cluster sequence 
was scattered on 11 contigs and incomplete and while we tried to close the gaps by resequencing 
of the strain and manual filling of the sequence gaps by PCR (performed by Dr. René Richarz, 
Institute for Pharmaceutical Biology, Univ. of Bonn), we planned to find direct evidence for 
FR production by cultivation and isolation procedures. 
We obtained C. vaccinii MWU205, DSM 25150 from the DSZM strain collection, grew it on 
liquid medium. After five days, we extracted the culture with butanol. LCMS measurements 
indicated the presence of FR and FR-2 (2) in almost equal quantities (Figure 5-7), but 
interestingly no FR-1 (1), being the most abundant FR analog in A. crenata extracts, could 
be detected. Subsequent purification via VLC, SEC and HPLC yielded pure white powders of 
FR (2.0 mg, 6.1 mg/L) and 2 (1.3 mg. 4.3 mg/L). Structures were confirmed by 1H NMR 
(Figure 5-7). As both isolated compounds displayed the same bioactivity profiles in the IP1 
accumulation assay as FR and FR-2 isolated from A. crenata, it was unequivocally shown that 
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the plants and C. vaccinii produce the same bioactive compounds, albeit in different ratios 
(Appendix Figure 10-38). 
 
Figure 5-7: (A) Extracted ion chromatograms of FR m/z 1002.54 ± 0.01 Da and FR-2 (2) m/z 988.52 ± 0.01 Da of 
butanolic extract from Chromobacterium vaccinii MWU205, DSM 25150. (B) Comparison of 1H NMR spectra 
(300 MHz CDCl3) of FR from A. crenata, FR from C. vaccinii and 2 from C. vaccinii. Spectral range of 2.7-2.2 
ppm is highlighted by black rectangle to demonstrate the differences between FR and 2. For 2 this is in essence 
the lacking resonances for a CH2 multiplet at 2.55 ppm and an additional resonance for a second acetate-CH3 
singulet at 2.24 ppm. 
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Altogether we can state that C. vaccinii contains the FR gene cluster frs and is cultivable. FR 
was produced at a rate of 6.1mg/L and compound 2 amounted to 4.3mg/L. In comparison, 
isolation from A. crenata supplies about 50 mg/kg dried leaves after about 6 month of plant 
cultivation. 
In order to investigate the biosynthetic production of FR and its analogs we acquired the growth 
curves of C. vaccinii via optical density measurements (Chapter 3.1.2, experiments performed 
by Wiebke Hanke, Institute for Pharmaceutical Biology, Univ. of Bonn). The stationary phase 
was reached after 36 hours. In parallel to the optical density measurements we also monitored 
the FR production via LCMS. The FR concentration peaked after 36 hours, thus upon transition 
from log- to stationary phase of bacterial growth. Interestingly, after 36-48 hours the FR 
concentration decreased possibly due to degradation and reached the level it has had during the 
lag phase after 228 hours. At the same time a molecular ion with the same m/z as FR increases 
at much lower retention times, possibly caused by ring-opening and re-esterification with the 
sidechain secondary alcohol of FR, altering the global conformation of FR. For determination 
of the conformation we need to isolate this degradation product and analyze it via NMR 
spectroscopy in future attempts. 
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Conclusion Chapter 5.1 
We demonstrated the usefulness of MS-based GNPS molecular networking for the detection of 
a family of FR derivatives in A. crenata. Based on the molecular network we were able to 
isolate and elucidate two new FR analogs, FR-3 (3) and FR-4 (4). The evaluation of these newly 
identified FR analogs and of the previously discovered FR-1 (1) and FR-2 (2) regarding their 
affinities to the Gq protein and their potential to inhibit Gq-mediated signaling will be described 
in Chapter 5.2.1. 
Based on our 1D and 2D NMR spectroscopic data analysis we conclude that small structural 
alterations of the acylation chains of L’ and L’’’ as observed for 1-3 have only marginal 
influence on the global conformation of the molecule. The same is true for the replacement of 
homoalanine for alanine in 4. 
Additionally, we were able to discover previously unknown FR producers, namely the 
nodulated A. crispa, A. hanceana, A. mamillata, and A. villosa and surprisingly also the non-
nodulated A. lucida. This finding together the newly discovered FR-producer 
Chromobacterium vaccinii MWU205, DSM 25150, and in conjunction with reports on the FR 
related compounds YM and sameuramide found in soil bacteria28 and a marine tunicate29, 
respectively, suggest an unexpected broad distribution of the FR molecular family in nature. 
This may implicate an important ecological role of the FR molecular family in nature, not only 
for Ardisia plants, but also in several other contexts. 
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 Towards the pharmacophore of FR – Structure-Activity 
Relationship studies of all currently known Gq inhibitors 
Direct targeting of intracellular Gα subunits is a challenging task in terms of finding chemical 
tools for mechanistic pharmacological studies and for developing novel therapeutic approaches. 
To date, the depsipeptides FR and YM have been established as Gq inhibitors, and it can be 
suggested that their activity correlates with a certain conformation, i.e. 3D shape. 
FR is a large molecule (MW 1002.17 Da), which adopts multiple conformations, as can easily 
be detected in NMR spectra showing resonances for major and minor conformers. Of special 
interest for the 3D shape of the molecule are cis amide bonds in the cyclic structure between 
alanine and N-methylalanine, as well as between hydroxyleucine and N,O-dimethylthreonine, 
as evidenced in an X-ray study30 and deduced from NOE data (see Figure 7-6). This applies to 
the major conformer, whereas the minor conformer may – according to our ROESY and 13C 
NMR data – has an additional cis amide bond between N-methyldehydroalanine and 
phenyllactic acid (see Table 5-5). Such cis amide bonds are generally energetically less favored 
(as compared to trans) and occur rather rarely. They clearly, however play a major role 
concerning the bioactivity of FR. To date, the 3D shape of FR may be envisaged as a wedge, 
where the phenyl ring of phenyllactic acid is forming the tip and dives deeply inside the G-
Protein/GDP complex. 
According to molecular modelling experiments many changes in the structure of FR seems to 
diminish its activity towards GDP-bound Gαq. X-ray studies of the Gαq/GDP/YM complex 
showed that especially the residues of YM (and in our case FR) targeting the linker 1 region of 
the protein may be important for the selectivity toward certain G-protein isoforms.53 
Thus, subsequent to the isolation and structure elucidation of new FR analogs from the above 
mentioned sources these compounds were analyzed in bioactivity assays such as IP1 and cAMP 
accumulation assays for determining their capabilities of interfering with Gq,- Gs,- and Gi-
mediated signaling, respectively. Additionally, analogs, which inhibited Gq-mediated signaling 
were assayed for their affinity to Gq proteins by competitive radioligand binding assays against 
tritiated FR, [³H]PSB-15900. Finally, in-depth analysis of the interaction of (i) simplified YM 
analogs provided by the Imhof lab (Pharmaceutical Chemistry I, Univ. of Bonn), (ii) molecular 
modelling studies by Dr. Daniel Tietze (TU Darmstadt) of all analogs provided (iii) and 
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molecular modelling of all so far described YM analogs in literature, were included in the 
present study in order to derive key molecular properties for binding to and inhibition of Gq. 
Altogether, these experiments should enable us to understand the relationship between the 3D 
shape of the molecule and its activity. The following questions shall be answered in Chapter 
5-2: 
1. Which influence do small structural changes of FR have on its 3D structure (i.e. 
conformation)? 
2. How does this correlate with its biological effects? 
3. Based on the results of 1) and 2): Can we derive the pharmacophore of FR and use the FR 
skeleton to develop inhibitors for other Gα subunits? 
 Bioactivity of FR analogs derived from A. crenata 
FR is characterized by its ability to inhibit Gq proteins and in this way the signal transduction 
of many GPCRs. In the context of the current study we wanted to assess whether in Chapter 
5.1 described, newly isolated FR analogs 1 - 4 (FR-1 to FR-4) differ in their affinity towards, 
and their effect on the downstream signaling of Gq proteins. For this reason, competitive 
radioligand binding studies (Markus Kuschak Pharmaceutical Chemistry I, Univ. of Bonn, 
Chapter 3.7.6) and IP1 accumulation assays (Nina Heycke, Suvi Annala, Tobias Benkel, 
Pharmaceutical Biology, Univ. of Bonn) were performed (Chapter 3.7.4). 
 
Due to the minute amounts of the 3:1 mixture (approx. 500 g from 2 kg of leaves) of 
compounds 3 and 4, we decided to biologically evaluate the mixture without further 
purification. Intriguingly, while most of the synthetic FR analogs published so far26,201 showed 
a dramatic decrease in potency, the here discovered FR analogs 1, 2, and 3/4 (3/1) are almost 
equipotent to FR in terms of inhibiting Gq-signaling as determined by IP1 accumulation assay 
(pIC50 ± SEM: FR = 6.10 ± 0.05, compound 1 = 5.97 ± 0.05, compound 2 = 5.63 ± 0.05, 
compounds 3/4 (3/1 = 5.96 ± 0.07, Figure 5-8A). 
Competitive binding assays, applying the tritiated FR-radioligand ([³H]PSB-15900) and 
purified membrane preparations of platelets allowed the comparison of affinities of FR, 1, 2, 
and 3/4 (3/1) towards the Gq protein (Figure 5-8B).54 All of the tested compounds show Ki and 
IC50 values in the low nanomolar range with the new discovered 3/4 (3/1) being the most Gq-
affine compounds so far discovered (Ki ± SEM =1.24 ± 0.06 nM). 
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In terms of Gq inhibition, no compound surpassed the activity of the parent substance FR. 
With data on Gq affinity and Gq mediated signaling of all three, respectively four (mixture 3/4 
(3/1)), naturally produced compounds (1, 2, and 3/4 (3/1)) in hand, it can be concluded that 
alterations in the length of the acylation chains at L’ and L’’’ as well as a substitution of alanine 
for homoalanine hardly affect Gq binding and inhibiting of downstream signaling. So, in 
contrast to most of the synthetically derived Gq-inhibitors26,201, all of the analogs provided by 
nature (1, 2, and 3/4 (3/1)) are potent and efficacious. 
 
Figure 5-8: Bioactivity of FR, 1, 2, 3/4 (3:1 ratio). (A) Inhibition of agonist-induced second messenger production 
in CHO cells expressing the Gq-sensitive muscarinic M1 receptor. Indicated analogs were evaluated against the 
muscarinic agonist Carbachol at its EC80. pIC50 ± SEM: FR = 6.10 ± 0.05, 1 = 5.97 ± 0.05, 2, = 5.63 ± 0.05, 3/4 
(3/1 = 5.96 ± 0.07. (B) Competition binding study of FR, 1, 2 and 3/4 (3:1 ratio) versus [³H]PSB-15900 (5 nM), 
the tritiated derivative of FR, at cell membrane preparations of platelets. Values represent means ± SEM of three 
independent experiments. pIC50 values ranging from 7.79 to 8.64 were determined. 
 
 Semisynthetic modification of FR 
As the so far isolated FR analogs demonstrated that there are several residues on the FR scaffold 
that can be altered without causing detrimental effects regarding inhibitory activity towards Gq 
(Figure 5-8) semisynthetic modification of FR was envisaged. Inspection of the FR structure 
reveals that it offers only few residues susceptible to modification, a secondary alcohol on the 
side chain L’’’ and a Michael acceptor, i.e. an exomethylene group in conjugation with a 
carbonyl group at A’’. 
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 Synthesis and analysis of FR-Hex (11) and FR-Cys (12) 
Synthesis of FR-Hex (11) 
The first residue we planned to modify was the secondary alcohol on the L’’’ side chain of FR 
(Scheme 5-6). Because this reaction proved to be sterically demanding, we applied a modified 
Steglich esterification202 with glacial acetic acid, pretreated with N-ethyl-N’-(3-
dimethylaminopropyl)carbodiimide (EDC), an water-soluble-byproduct-forming analog of 
N,N’-dicyclohexylcarbodiimide (DCC), and catalytic amounts of 4-dimethylaminopyridine 
(DMAP).203 Unfortunately, no detectable turnover rates towards the corresponding FR-acetate 
product were detected. Also the reaction with acetylchloride failed, but the reaction with acetic 
anhydride and catalytic amounts of DMAP, did lead to the formation of the desired product, 
according to LCMS measurements. However, we were not able to separate the assumed product 
from the educt FR, despite much effort. Consequently, we intended to couple a larger and more 
lipophilic residue to FR with the aim to improve the chromatographic separation of educt and 
product: The successful esterification of FR with hexanoic anhydride to the corresponding FR-
Hex (11, Scheme 5-7) is described in Chapter 3.5.1 in detail and was verified by MALDI-TOF 
(Appendix Figure 10-39), MSn (Figure 5-9) and LCMS² analysis (Figure 5-10) as previously 
described in Chapter 5.1.2. 
 
 
Scheme 5-7: Reaction scheme of the synthesis of FR-Hex (11). 
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Structural analysis of FR-Hex (11) 
The molecular formula of 11 was determined to be C55H85N7O16  (calcd. 1122.5945; obsd. 
1122.5952) for [M+Na]+. This result from an accurate mass measurement, which showed a 
mass difference of 98 Da between FR and compound 11, suggests the successful esterification 
of the secondary alcohol of the N-propionylhydroxyleucine2 (L’’’) residue of FR with hexanoic 
anhydride to the corresponding L+ = N-propionyl-(2S,3R)-3-(hexanoyloxy)-hydroxyleucine2 
moiety of 11. Mass spectrometric analysis, especially when comparing fragments from 
sequential fragmentation via collision induced dissociation of the depsipeptides FR and 11 
demonstrated that 11 differs from FR regarding the L’’’ moiety of FR, as expected. Indeed, the 
compounds can be distinguished by different Δm/z values of the modified amino acids. For 11 
this is evident from the second-generation mass spectra (MS³) of m/z 993.51 compared with the 
98 Da lower weight m/z 895.45 for FR. Loss of the side chain L’’’ (FR, Δm/z 185.11 Da) or L+ 
(11, Δm/z 283.17 Da), respectively leads for both compounds to the same fragment, i.e m/z 
710.34 Da (Figure 5-9, 5-10). 
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Figure 5-9: (A) Schematic structure of FR and 11 in one-letter amino acid code. L’ = N-acetylhydroxyleucine-1, 
F’ = phenyllactic acid, A’’ = N-methyldehydroalanine, A = alanine, A’ = N-methylalanine, L’’ = hydroxyleucine, 
T’ = N,O-dimethylthreonine, L’’’ = N-propionylhydroxyleucine-2, L+ = N-propionyl-(2S,3R)-3-
(hexanoyloxy)leucine2. (B) Comparison of second-generation (MS3), product-ion spectra of FR and 11; [M+Na]+. 
Comparison of the MS3 spectra of FR and 11 reveals the same pattern of signals and intensities for both 
compounds, except that all signals from 11, containing the hexanoate residue with a 98 Da higher m/z. Loss of the 
sidechain L’’’ (FR, Δ m/z 185.11 Da) or L+ (11, Δ m/z 283.17 Da), respectively leads for both compounds to the 
same fragment m/z 710.34 Da. (C) Fragmentation pathways of second-generation (MS³) product ions obtained 
from FR and 11. m/z 895.45 (FR) or rather m/z 993.51 (11) lose their distinctive side-chain amino acid N-
propionylhydroxyleucine-2 (FR) or N-propionyl-(2S,3R)-3-(hexanoyloxy)leucine-2 = L+ (11), resulting in the 
formation of the same fragment m/z 710.34 for both compounds. 
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Similar reactions with more bulky residues such as 1,8-naphthalic anhydride failed, most likely 
because of the steric hindrance of the secondary alcohol. 
Antibacterial activity of compound 11 
 
For analogs of the antibiotic drug and cyclic lipodepsipeptide daptomycin, it was evaluated that 
in vitro antibacterial activity increased with acyl chain length up to C-12 to C-13.204 Müller et 
al. proposed that the fatty acid tail of daptomycin inserts between the fatty acyl chains of the 
cell membrane bilayer und thus initiates its cellular uptake.205 To investigate whether this 
mechanism can be transferred to FR-related compounds we tested compound 11 for 
antibacterial activity, because it contains a hexanoate residue. However, neither FR, nor 
compound 11 showed any bactericidal effects on Arthrobacter assay (data not shown, Assay 
performed by Nils Böhringer, Univ. of Bonn). Possibly the C6-chain is too short to act as anchor 
into the cell membrane and the experiment should be repeated with a longer acyl residue such 
as decanoate. 
 
Synthesis of FR-Cys (12) 
The second reactive moiety on the FR scaffold is the exomethylene group of the N-
methyldehydroalanine moiety in conjugation to the peptide carbonyl group, which is a Michael 
acceptor with an expected reduced nucleophilicity due to the flanking amides. It is generally 
known that nucleophiles may attack α,β-unsaturated carbonyl groups via Michael addition. 
Before the synthesis of 12 was considered the reactivity of such a functional group in natural 
products was researched. In general, dehydroalanine moieties are common among peptidic 
natural products, especially for ribosomally synthesized lantibiotics.206 In contrast, the amino 
acid N-methyldehydroalanine is besides FR (and FR-related YM-254890, sameuramide) only 
known from the streptomycete-derived BE-22179207,208 and cyclic depsipeptides of several 
cyanobacterial genera, e.g. Microcystis aeruginosa. The latter produces numerous structurally 
diverse hepatotoxic microcystins.209 The mechanism of action of microcystins was reported to 
be a covalent linkage via Michael addition of the N-methyldehydroalanine to a cysteine 
(Cys273) residue and hence irreversible inhibition of human protein phosphatase 1 (PP1).210 
PP1 plays a crucial role in the regulation of blood-glucose levels in the liver and glycogen 
metabolism.211 On the other hand, microcystins immobilized to a sepharose bead through an 
aminoethanethiol (cysteamine) adduct retained inhibitory activity.211 These results imply that 
Results, Section II: Detection, Isolation and Structure Activity Relationship studies of new FR 
analogs 
99 
 
the N-methyldehydroalanine residue probably does not play a role in early enzyme–inhibitor 
interactions. Mechanistic studies by Craig and co-workers212 confirmed a two-step mechanism 
for irreversible inhibition by microcystins. In the first step, the rapid noncovalent binding and 
inhibition occurs, and then the slower covalent modification of a cysteine residue occurs over 
the course of hours.213 Notably, such adducts might not be resistant toward retro-Michael 
reaction in vivo, and reversible adduct formation may explain the observed biological activity. 
To test whether N-methyldehydroalanine is essential for Gαq/11 inhibitory activity of FR, the 
reactive moiety was removed by catalytic hydrogenation, complying with the procedure 
published for the hydrogenation of YM.52 For YM, Taniguchi et al. discovered that one of the 
two resulting diastereomers (epimers), YM-385781 (R)-epimer, was active, while the other one, 
YM-385780 (S-epimer), showed a 40-fold decrease in activity. These findings contradict a 
crucial role for N-methyldehydroalanine for the biological effect of YM by covalent binding to 
the Gαq/11 protein. The fact that the inactive (S)-epimer YM-385780 differs in its conformation 
from the active (R)-epimer YM-385781 and YM, emphasizes the dependence of the biological 
effect from the spatial arrangement of the molecules. Similar results were experienced for 
hydrogenated FR.54 
In general the Michael addition reaction is a versatile synthetic methodology for the efficient 
coupling of electron poor olefins with a vast array of nucleophiles. Due to the limited amount 
of FR available for reactions due time- and resource consuming planting, isolation and 
purification, literature was thoroughly screened for determination of optimal mild conditions, 
regarding base (strength), solvent, catalysts and also type of Michael reaction (carbon Michael 
addition vs aza- or thio-Michael additions). Besides solvent-free protocols214, the focus was put 
on reactions using model substrates similar to FR such as dehydropeptide derivatives215 and the 
previously mentioned microcystins.216 Naidu et al. reported on Michael addition reactions of 
several amines and thiols with triethylamine to dehydroalanine amides being significantly 
accelerated by water.217 Because of the excellent yields and the faster reactions we decided to 
perform a thio-Michael addition. As substrate 2-aminoethanethiol hydrochloride (cysteamine) 
was chosen. Hetero-Michael reactions usually require catalytic amounts of a strong base or a 
Lewis acid, resulting in many side reactions, apart from including toxic chemicals and 
hydrolysis may occur. Further the differential solubility of cysteamine and FR was a challenge 
to overcome. While cysteamine is a water-soluble salt, FR is only poorly soluble in aqueous 
media. Firouzabadi et al. published a procedure overcoming all these issues by using sodium 
dodecyl sulfate (SDS) in the critical micellar concentration.218 The protocol of Firouzabadi et 
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al. was demonstrated to be an effective method for the addition of thiols to α,β-unsaturated 
ketones under mild and neutral conditions.218 The accelerating effect of the SDS micelles was 
related to the concentrating of the hydrophobic species (in our case FR) into the micellar core 
(Scheme 5-8).218 We decided to generally follow the protocol of Firouzabadi et al. with slight 
modifications and successfully obtained 6 mg of the desired product FR-Cys (12) from 20 mg 
of FR. The reaction was performed under argon atmosphere to avoid cysteamine oxidation to 
the corresponding disulfide. 
 
Scheme 5-8: Reaction scheme of the synthesis of FR-Cys (12). The reaction is assumed to occur in the 
hydrophobic core of the sodium dodecyl sulfate (SDS) micellar droplets. 
 
Structural analysis of FR-Cys (12) 
The molecular formula of 12 was determined to be C51H82N8O15S  (calcd. 1079.5693; obsd. 
1079.5844) for [M+H]+. This result from an accurate mass measurement, which showed a mass 
difference of 77.03 Da between the molecular ions of FR and compound 5, suggested the 
successful addition of 2-aminoethanethiol to the N-methyldehydroalanine (A’’) moiety of FR. 
Mass spectrometric analysis, especially when comparing fragments from sequential 
fragmentation via collision induced dissociation of the depsipeptides FR and 12 indeed 
demonstrated that 12 differs from FR regarding the N-methyldehydroalanine (A’’) moiety, as 
expected (Appendix Scheme 10-6). Instead of the latter, compound 12 contains a N-methyl-3-
((2-aminoethyl)thio)-2-alanine moiety, which was revealed from comparison of the LCMS2 
data (Figure 5-10) of FR and 12. 
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For compound 12 a loss of Δm/z 77.03 Da referring to a 2-aminoethanethiol moiety is observed, 
e.g. fragmentation of the ion at m/z 309.13 (only occurring in 12) results in a loss of 77.03 Da 
to yield m/z 232.10. The latter represents the A’’-F’-dipeptide occurring in 12 and FR. 
Comparison of further MS fragments strengthened this assumption (Figure 5-10). 
 
Figure 5-10: (A) Schematic structure of FR, 11, and 12 in one-letter amino acid code. L’ = N-
acetylhydroxyleucine-1, F’ = phenyllactic acid, A’’ = N-methyldehydroalanine, A+ = 3-((2-aminoethyl)thio)-2-
alanine, A = alanine, A’ = N-methylalanine, L’’ = hydroxyleucine, T’ = N,O-dimethylthreonine, L’’’ = N-
propionylhydroxyleucine-2, L+ = N-propionyl-(2S,3R)-3-(hexanoyloxy)leucine-2. (B) Comparison of first-
generation, product-ion spectra of FR, 11, and 12; [M+H]+ . Nomenclature was used according to Chapter 3.4.1.3. 
Compared to FR, 11 has a different side chain; instead of L’’’ in FR, 11 contains after esterification with hexanoic 
anhydride L+. 12 differs from FR in the A’’ moiety. Via Michael addition a 2-aminoethanethiol moiety was added 
to the Michael acceptor functionality of A’’ leading to A+. This residue is evident from the 77.03 higher mass of 
the molecule ion of 12 and characteristic losses of this moiety, e.g. m/z 309.1286 (only occurring in 12) loses 77.03 
Da to yield m/z 232.10, which represents the A’’-F’-dipeptide. 
The conjugation of 2-aminoethanethiol to FR seems to give stereospecifically one epimer of 
the conjugate, deduced from of a single peak in the extracted ion HPLC chromatogram (Figure 
5-11), but the configuration at C-5 of compound 12 was not determined. The stereospecificity 
of Michael reactions were also described by similar conjugation reactions of N-
methyldehydroalanine moieties of microcystins.216,219,220 Miles et al. explained the 
stereoselectivity of the reaction with the steric effect of the N-methyl group of N-
methyldehydroalanine, which prohibits the attack of C-5 from two sides. Interestingly, LCMS 
data indicated that cysteamine was sensitive to oxidation and formed the corresponding 
disulfide. The primary amine of this disulfide was also able to react via aza-Michael addition 
to FR as revealed from the m/z 1154.58 molecular ion (Appendix Figure 10-40). 
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Figure 5-11: Extracted ion chromatograms of [M+H]+ and [M+2H]2+ of 12, demonstrating that only one epimer 
of the conjugate product of FR and 2-aminoethanethiol was formed. 
 
 Biological evaluation of FR-Hex (11) and FR-Cys (12) 
The depsipeptides 11 and 12 were tested for their inhibitory activity on second messenger-
generating Gq, Gs, and Gi signaling pathways, respectively (Figure 5-12). 
 
Figure 5-12: Carbachol-induced IP1 accumulation in CHO M1 stable cell line preincubated with or without 
potential Gq inhibitors FR, YM, 11, 12). Assays performed by Suvi Annala, Tobias Benkel and Nina Heycke Univ. 
of Bonn. 
 
Depsipeptide 11 only revealed an IC50 value of ~90 µM, while compound 12 was inactive at 
Gq. Exactly the same picture could be drawn from competitive radioligand binding studies 
(Figure 5-13), i.e both compounds showed only low affinity (11) or even no affinity (12) to 
Gq, respectively. In case of 11 this result was somehow expected, because the secondary 
alcohol of FR was reported to be involved in the complex hydrogen bond network of the 
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molecule. The crystal structure of FR had revealed this OH group to take part in three 
intramolecular hydrogen bonds, crucial for the conformation of FR.30 Further, according to the 
mode of action described for YM by Nishimura et al.53 the same OH group is responsible for 
refolding of the molecule upon target interaction with Gq, developing a new hydrogen bond to 
Glu 196 residue of the helicale domain of Gq. Regarding 12, the inactivity of the molecule was 
somehow unexpected and points towards having isolated the (S)-epimer (= (D)-epimer, because 
of the higher priority of the sulfur atom) corresponding to the (S)-epimer (= (L)-epimer) of YM-
385780, which was also shown to be inactive.26,52 Due to the stereoselectivity of the reaction 
we were not able to confirm this hypothesis, by testing the putatively active (R)-epimer. This 
hypothesis was supported by docking experiments (Chapter 6.1.3). 
 
Figure 5-13: Competition binding study of FR, 11, and 12 versus [³H]PSB-15900 (5 nM), the tritiated derivative 
of FR, at cell membrane preparations of platelets. Values represent means ± SEM of three independent 
experiments. Assay was performed by Markus Kuschak, Univ. of Bonn. 
In contrast to the natural FR derivatives 1-4 (Chapter 5.2.1), semisynthetic FR analogs 11 and 
12 were less active or devoid of activity, respectively. 
 
 YM-254890 and FR900359 – the ultimate Gq inhibitors designed by nature  
The natural FR analogs 1-4 and semisynthetically derived analogs 11 and 12 described in 
Chapters 5.1, 5.2.1 and 5.2.2 allowed for first structure-activity insights, though they do not 
suffice to determine the complete pharmacophore of FR. That is why we introduce a holistic 
approach, including the aforementioned FR analogs, but also YM analogs synthesized by us 
(Imhof lab, Univ. of Bonn) and others26,196,201,221 to devise a strategy for the elucidation of 
characteristics that determine interaction with Gq. Although a small number of analogs such as 
WU-07047,221 YM-280193,196 and YM1-YM1826,201 (Scheme 5-9) were reported earlier, a 
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detailed analysis of the SAR of these compounds with respect to Gq and other G proteins was 
still missing. The major reason for this is the lack of NMR structural analysis of suitable 
compounds together with a detailed in-silico analysis which enables the visualization of the 
recognition mode of ligand-Gq protein interaction. Here we report an in-depth analysis of the 
interaction of differentially active and inactive analogs of YM and FR. 
Therefore, we first grouped all 23 already published and further 14 new FR- and YM-derived 
compounds according to their potency, to identify tolerated, partially tolerated, non-tolerated 
minor, and non-tolerated major modifications in the original sequence(s) (Scheme 5-9, Table 
5-4). As we have 3 and 4 as mixture and only putative structure proposals for 5-10, these were 
not included in our study. Peptides 13-22 were synthesized in the Imhof lab, Univ. of Bonn (see 
Chapter 3.5.7-3.5.9, Appendix Table 10-3). These peptides were synthesized according to 
standard Fmoc-protocol on a solid support and cyclized by head-to-tail cyclization in solution 
using PyBOP as coupling reagent.222 Complexity and low yields of depsipeptide syntheses 
encouraged several other groups to provide simplified and more easily accessible analogs of 
YM or FR, which can be exemplified with WU-07047 (45),221 YM-280193 (36),196 and the 
recently reported 18 YM-analogs (23, 26–35, 38–44, Scheme 5-9).26,201 Biological activities 
for YM, FR and compounds 23–45 (Scheme 5-9) vary somewhat due to different methods used 
for determining biological activity in various laboratories. It is thus only referred to the herein 
determined values (Figure 5-14, Table 5-4).223 
A one letter amino acid code as shown in Scheme 5-9 is used in the following SAR studies. 
T’’ = N-acetylthreonine-1     (YM) 
L’ = N-acetylhydroxyleucine-1    (FR) 
L* = N-3-hydroxypropionyl-hydroxyleucine-1  (1 = FR-1) 
F’ = phenyllactic acid 
A’’ = N-methyldehydroalanine 
A+ = 3-((2-aminoethyl)thio)-2-alanine   (12 = FR-Cys) 
A = alanine 
A’ = N-methylalanine, 
L’’ = hydroxyleucine 
T’ = = N,O-dimethylthreonine,  
L’’’ = N-propionylhydroxyleucine-2    (FR) 
L^ = N-acetylhydroxyleucine-2    (2 = FR-2 + YM) 
L+ = N-propionyl-(2S,3R)-3-(hexanoyloxy)leucine-2 (11, FR-Hex) 
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Scheme 5-9: Compounds are listed based on their reported IC50 values determined by inhibition of carbachol-
induced IP1 production where available (Compounds measured with other assays are marked with an asterisk). 
aChemical modifications relative to FR and YM are given in brackets (R1–R15) for the corresponding compound. 
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SAR of natural and semisynthetic FR900359 analogs 
Compounds 1 (FR-1) and 2 (FR-0) differ from native FR with respect to their acylation pattern 
(for structure elucidation refer to Chapter 5.1).10 Semisynthesis yielded FR analogs 11 and 12 
(for structure elucidation refer to Chapter 5.2.1), in which the secondary alcohol of L’’’ was 
esterified with hexanoic acid (11) or Michael addition of cysteamine to the α,β-unsaturated 
double bond of FR (12). 
 
Table 5-4: Sequences of test compounds including FR900359, YM-254890 and analogs (FR analogs 1, 2, 11, 12) 
prepared in this study and their Gα inhibitory activity. 
No. Peptide sequence or name Gαq  
IC50 (µM) 
Gαi 
IC50 (µM) 
Gαs 
IC50 (µM) 
 FR900359 0.87 >100 >100 
 YM-254890 1.55 >100 >100 
1 cyclo-[L*-F’-A’’-A-A’-L’’(L’’’)-T’] 1.04 >100 >100 
2 cyclo-[L’-F’-A’’-A-A’-L’’(L^)-T’] 1.79 >100 >100 
11 cyclo-[L’-F’-A’’-A-A’-L’’(L
+
)-T’] 90 >100 >100 
12 cyclo-[L’-F’-A
+
-A-A’-L’’(L’’’)-T’] >100 >100 >100 
13 cyclo-[A6-A’7-Lys(Ac)-Thr(OMe)-Thr(OMe)-D-Phe-A’5] >100 >100 >100 
14 cyclo-[A-A’-Lys(Ac)-Thr(OMe)-Thr(OMe)-F-A’5] >100 >100 >100 
15 cyclo-[A-A-Lys(Ac)-Thr(OMe)-Thr(OMe)-DF-A5] >100 >100 >100 
16 cyclo-[A-A-Lys(Ac)-Thr(OMe)-Thr(OMe)-F-A5] >100 >100 >100 
17 cyclo-[A-A’-L-Thr(OMe)-Thr(OMe)-DF-A’5] >100 >100 >100 
18 cyclo-[A-A’-L-Thr(OMe)-Thr(OMe)-F-A’5] >100 >100 >100 
19 cyclo-[A-A-L-Thr(OMe)-Thr(OMe)-DF-A5] >100 >100 >100 
20 cyclo-[A-A-L-Thr(OMe)-Thr(OMe)-F-A5] >100 >100 >100 
21 cyclo-[Ahx-DF’-Ado-Dap(T’’)]  >100 >100 >100 
22 cyclo-[Ahx-DF’-Ado-β-HyLeu] >100 >100 >100 
DF, D-phenylalanine; DF’, N-methyl-D-phenylalanine; Thr(OMe), O-methylthreonine; Lys (Ac), N-acetyllysine; Dha, 
dehydroalanine; Pla, phenyllactic acid; Ahx, 6-aminohexanoic acid; Ado, 8-amino-3,6-dioxaoctanoic acid; Dap, 2,3-
diaminopropionic acid 
 
Inhibitory activity of FR900359-derived analogs and peptides 
The depsipeptides 1, 2, 11, 12 and peptides 13–22 were tested for their inhibitory activity on 
second messenger-generating Gq, Gs, and Gi signaling pathways, respectively (Figure 5-14, 5-
15). As described in Chapters 5.2.1 and 5.2.2 FR analogs 1 and 2 were in the same activity 
range as the lead compounds (Table 5-4, Figure 5-14), while surprisingly, depsipeptide 11 only 
revealed an IC50 value of ~90 µM, and compound 12 was inactive. Also peptides 13–22 (Figure 
5-15) were devoid of activity towards Gq inhibition. In addition, no Gs or Gi activity was 
observed as determined in second messenger cAMP accumulation assays for all compounds (1, 
2, 11-22). 
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Figure 5-14: Carbachol-induced IP1 accumulation in CHO M1 stable cell line preincubated with or without 
potential Gq inhibitors. Assays performed by Suvi Annala, Tobias Benkel and Nina Heycke Univ. of Bonn. 
 
 
Figure 5-15: Carbachol induced IP1 accumulation in CHO M1 stable cell line preincubated with or without 
potential Gq inhibitors. Assays performed by Suvi Annala, Tobias Benkel and Nina Heycke Univ. of Bonn. 
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Structural studies on FR and analogs by NMR spectroscopy 
In order to explain the differential activity of Gq inhibitors, 1H NMR-based characterization of 
the conformation of FR, FR analogs 1, and 2, and YM-inspired peptides 13 and 22 was 
accomplished in various solvents and temperatures (water, chloroform, and methanol/water). 
Additionally, solution structures were calculated from NOE intensities in water for FR and 
peptides 13 and 22 (Figure 5-17, Table 5-5, Appendix Table 10-3). Similar to YM, chloroform 
1H NMR spectra of FR showed two resolved sets of NMR signals, indicating a major and a 
minor conformation at a ratio of 10:1 at 293 K (Table 5-5).52 These two conformations are most 
likely caused by a cis/trans isomerization of the amide bond between A’’ and F’ with the major 
conformer exhibiting the trans amide bond. Apart from the major isomer, a large chemical shift 
separation of the two Hβ protons of A’’ (5.69; 3.73 ppm vs. 5.32; 5.07 ppm, CDCl3, Table 5-
5) was observed which is presumably due to the ring current effect of the nearby phenyl ring of 
F’ accounting for a cis amide bond. 
 
Table 5-5: 1H and 13C NMR spectroscopic data of FR900359 in CDCl3 (1H: 600 MHz; 13C: 150 MHz), H2O/D2O 
(v:v/ 9:1, 1H: 500 MHz), MeOH/H2O/D2O (v:v:v/ 1:1:0.2, 1H: 500 MHz). 
Isomer  major  minor Major major  
   CDCl3 
 
H2O/D2O 
MeOH
/H2O/
D2O 
Residue[c] No C/H[b] δC[a], mult δH[a] (mult, J in Hz) δH[a] (mult, J in Hz) δH δH 
A 1 172.6, C – –   
 2 45.9, CH 4.90 (m) 5.05 (m) 4.82 5.03 
 2-NH – 8.51 (d, 9.1) 7.65 (d, 9.5) 7.06 7.24 
 3 18.1, CH3 1.39 (d, 6.7) 1.29 (d, 6.5) 0.82 1.02 
A‘‘ 4 164.0, C – –   
 5 145.5, C – –   
 6a 106.9, CH2 a 5.32 (d, 2.2) 5.69 (d, 1.7) [e] 5.73 5.87 
 6b – b 5.07 (d, 2.2) 3.73 (m) 3.43 3.58 
N-Me 7 36.3, CH3 3.15 (s) 2.97 (s) 2.64  
F‘ 8 167.9, C – –   
 9 72.7, CH 5.21 (dd, 4.1, 8.3) 5.07 (dd, 9.0, 3.9) 5.42 5.61 
 10a 36.8, CH2 a 3.11 (dd, 4.1, 14.8)  3.41 2.91 3.11 
 10b – b 2.98 (dd, 8.3, 14.8) 2.74 (dd, 12.6, 4.4) 2.83 2.99 
 11 136.1, C – –   
 12/16 129.7, CH 7.26[d] 7.15 (m) 7.06 7.07 
 13/15 128.7, CH 7.29[d] n.d. 6.91 7.18 
 14 127.1, CH 7.23[d] 7.28 (m)   
L’ 17 169.4, C – –   
 18 50.5, CH 5.27 (dd, 1.3, 10.0) 5.17 4.68 4.89 
 18-NH – 7.55, (d, 10,0) 7.33 (d, 9.4) 8.81 8.63 
 19 77.8, CH 5.12 (dd, 1.3, 10.0) 5.15 (m) 5.22 5.38 
 20 29.0, CH 1.89 (m) 1.72 (m) 1.56 1.72 
 21 19.1, CH3 1.01 (d, 6.8) 1.14 (6.8) 0.55 0.75 
 22 19.0, CH3 0.85 (d, 6.8) 1.07 0.55 0.75 
Ac 23 171.6, C – –   
 24 22.6, CH3 2.23 (s) 2.15 (s) 1.80 1.96 
T‘ 25 166.6, C – –   
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 26 64.6, CH 4.07 (d, 9.8) 4.22 (d, 9.8) 3.72 3.81 
 27 72.5, CH 3.76 (m)  3.87 (m) 3.63 3.65 
 28 16.5, CH3 1.18 (d, 5.8) 1.23 (d, 6.1) 1.01 1.18 
N-Me 29 28.9, CH3 2.70 (s) 3.05 (s) 3.01 3.11 
O-Me 30 57.3, CH3 3.41 (s) 3.46 (s) 2.93  
L’’ 31 171.4, C – –   
 32 46.8, CH 5.36 (d, 9.9) 5.51 (d, 9.8)  4.92 5.13 
 32-NH  6.74, (d, 9.9) 6.65 (d, 9.8) 6.79 6.96 
 33 77.1, CH 5.31 5.04  4.66 4.84 
 34 30.7, CH 1.72 (m) ca. 1.90 1.82 1.61 
 35 19.5, CH3 1.09 (d, 6.7) 1.12 (d, 6.7) 0.71 0.95 
 36 18.3, CH3 0.83 (d, 6.7) 0.83 (d, 6.7) 0.67 0.66 
A‘ 37 170.1, C – –   
 38 56.6, CH  4.71 (q, 6.8) 4.76 (q, 6.8) 3.31 3.51 
 39 14.4, CH3 1.38 (d, 6.8) 1.45 (d, 6.8) 1.06 1.27 
N-Me 40 31.5, CH3 2.88 (s) 2.86 (s) 2.82 3.02 
L’’’ 41 170.4, C – –   
 42 57.0, CH 4.55 (dd, 1.4, 7.8) 4.60 (dd, 8.1, 1.3) 4.86 4.94 
 42-NH – 7.17 (d, 7.8) 7.27  7.86 7.77 
 43 78.4, CH 3.73 (m) 3.73 (m) 3.60 3.82 
β-OH 43-OH – 6.85 (d, 4.2) 6.43   
 44 30.1, CH 1.98 (m) 1.95 (m) 1.29 1.47 
 45 20.6, CH3 1.17 (6.7) 1.07 (d, 6.7)  0.66 0.84 
 46 18.7, CH3 0.88 (6.7) 0.92 (6.6) 0.66 0.81 
Pr 47 174.9, C – –   
 48a 28.8, CH2 2.57 (dq, 14.9, 7.5) 2.35 (m) 2.06 2.24 
 48b 
 2.50 (dq, 14.9, 7.5) 2.35 (m) 2.06 2.24 
  49 10.1, CH3 1.19 (t, 7.5) 1.19 (t, 7.5) 1.26 1.44 
[a] Assignments are based on extensive 1D and 2D NMR measurements (HMBC, HSQC, COSY). 13C-NMR spectra were recorded at 150 
MHz. [b] Numbers according to Scheme S1. [c] Residues: Ala = alanine, N-MeDha = N-methyldehydroalanine, D-Pla = D-3-phenyllactic acid, 
N-Ac-β-HyLeu= N-acetylhydroxyleucine, N-MeThr(OMe) = N,O-dimethylthreonine, β-HyLeu = β-hydroxyleucine, N-MeAla = N-
methylalanine, N-Pr-β-HyLeu = N-propionyl-β-hydroxyleucine.[d] overlaying resonances 
 
In contrast to the above observations, the minor conformer appears to be the major conformer 
in aqueous media as revealed by a series of 1H-NMR spectra at different temperatures in a 
water/methanol mixture (Figure 5-16). Moreover, this isomer was the only observable species 
at 275 K, while multiple minor conformations emerged with increasing temperature as 
concluded from the appearance of multiple additional signals in the 1H chemical shift region of 
6 to 9 ppm (Figure 5-16, Appendix Table 10-4). 
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Figure 5-16:. 1H spectra of the aromatic region of FR in MeOH/H2O/D2O (v:v:v/ 1:1:0.2, 1H: 500 MHz) at 
different temperatures. 
Finally, NMR structure calculations clearly confirmed that FR exclusively exists in a well-
defined global conformation (ensemble heavy atom RMSD 0.48 Å, Figure 5-17D) in aqueous 
solution, which indeed revealed a cis amide bond between F’ and A’’. 
All other amide bonds were identified to be in a trans conformation. In contrast, earlier NMR 
studies on YM-254890 in various organic solvents28 indicated cis amide bonds between T’/L’’, 
A’/A based on the presence of Hαi/Hαi+1 NOE crosspeaks, which were clearly missing in FR. 
Even though this amide bond was found to be in a trans conformation in Gq-bound YM (PDB 
ID 3AH8),53 the global backbone fold of the cyclic FR-core remained fairly similar. In contrast, 
the L’’’/L’’ tail was found to be in a different orientation and rotated along the L’’’/L’’ ester 
bond by approx. 150° (Figure 5-17D). 
In contrast to FR, analog 13 forms a rather flat cycle (ensemble heavy atom RMSD 0.83 Å, 
Figure 5-17B) folding into two equally populated conformations showing cis/trans isomerism 
between A’5 and A6. A second stable cis peptide bond was observed between A6 and A’7. In 
addition, although distinct parts of the structure of 13 (A’5, A6, A’7, and Ac-Lys1) are in good 
agreement with FR (A’’, A, A’), it deviates to some extent from the solution structure of FR 
(RMSD 7.1 Å, Figure 5-17E). Similarly, 22 also folds into a flat cyclic structure (ensemble 
heavy atom RMSD 0.71 Å, Figure 5-17C), which appears to be more flexible compared to 13 
(Figure 5-17B, C). The structural deviation of 22 from the global conformation of FR, however, 
is significant (RMSD 8.7 Å, Figure 5-17F). Thus, 13 and 22 do not reproduce the global fold 
of FR, which most likely accounts for their lack of biological activity. 
Results, Section II: Detection, Isolation and Structure Activity Relationship studies of new FR 
analogs 
111 
 
 
Figure 5-17: Solution NMR structures of FR (A) and its analogs 13 (B) and 22 (C) (presented as ensembles of 10 
lowest energy structures (coloring scheme: carbon - cyan, nitrogen - blue, oxygen - red). Superposition of the 
NMR solution structure of FR (carbon - purple) with (D) YM (PDB ID 3AH8,[14] all atom RMSD 2.41 Å, carbon 
- yellow), (E) 13 (all atom RMSD 7.14 Å, carbon - orange), and (F) 22 (all atom RMSD 8.67 Å, carbon - cyan). 
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Molecular modeling and docking studies 
Molecular modeling and docking studies were performed by Dr. Daniel Tietze, TU Darmstadt, 
Germany and applied to provide in-depth insight into inhibitor-Gq interactions and to 
characterize the binding mode of the most potent inhibitors. The YM-derived analogs 23, 26–
36, and 39–45, investigated herein were constructed from the Gq-bound conformation of YM-
254890 (PDB ID 3AH8).53,224 For FR-derived analogs 1, 2 11, 12, two conformations were built 
employing the solution NMR structure of FR and the Gq-bound conformation of YM. The 
structures obtained were then docked to the heterotrimeric Gq protein in the original 
conformation. Except of 31, which carries a backbone modification (A’ to A), these analogs 
contain side chain modifications at A’, A, L’’’/ Leu’’ or at the acetyl group of T’’ (YM)/L’ 
(FR). A closer look at the target-bound conformation of these analogs obtained from the 
docking runs revealed only minor alterations of the global fold of the inhibitor molecules 
retaining the intramolecular hydrogen bonds as observed in YM/FR (Figure 5-18). 
Consequently, the high-affinity analogs 1, 2, and 23–31 (Scheme 5-9) also share a similar 
orientation in the Gq binding pocket resulting in almost identical hydrogen bond interactions 
with Gq (Figure 5-18A+B). Moreover, similar orientations within the Gq binding pocket in 
comparison to the orientation of YM were observed when the alternative NMR-derived 
structures for FR and 1 (named FR cis and 1 cis thereafter) were employed in the docking 
experiments (Figure 5-19A-C). A marginally different Gq-bound orientation was found for the 
NMR derived structure of 2 (named 2 cis thereafter, Figure 5-19D). 
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Figure 5-18: Docking results (a) Superposition of reference structures YM-254890 (PDB ID 3AH8, carbon - 
purple) and FR900359,54 carbon - navy blue) on the left, separate views of their individual binding modes on the 
right (coloring scheme: nitrogen - blue, oxygen - red, hydrogens are omitted for clarity, hydrogen bonds are shown 
as yellow dashed lines; Gαq surface - gray, hydrogen bond interacting residues - labeled and highlighted by 
element color, Gβ - dark yellow). (b) Superposition of FR900359 (carbon - navy blue) with the docked 
conformation of two selected high-affinity analogs 30 (YM-18) and 1 (carbon - cyan) (left) as well as separate 
views of their individual resulting binding modes (right); particular modifications are tagged by orange circles or 
arrows. (c) Superposition of FR900359 (carbon - navy blue) and the docked conformation of the selected medium-
affinity analog 39 (YM-3) (carbon - cyan) (left) as well as separate view of its individual binding mode (right) (d) 
Superposition of FR900359 (carbon - navy blue) and the docked conformation of two selected low-affinity analogs 
44 (YM-2) and 11 (carbon - cyan) (left) as well as separate views of their individual binding modes (right). 
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Figure 5-19: (A) Superposition of FR and cis FR bound to Gq as revealed from the docking studies. Orientation 
of (B) cis FR (C) cis 1 and (D) cis 2 bound to the Gq-YM binding pocket. 
 
In conclusion, this strong orientation towards linker 1 and β sheet 2 of the Gα subunit, mainly 
represented by the hydrogen bonds to Arg60 and Glu191 and hydrophobic interactions towards 
segments α1 (I56, K57), αA (F75), switch I (V184), and β sheet 2 (I190, Y192, P193), 
complement intrinsic features of powerful Gq inhibitors (Figure 5-20). 
 
 
Figure 5-20: (A) and (B) Illustration of key interactions of high affinity inhibitors with Gq (residue numbers – 
regular, bold), exemplarily shown for YM (residue numbers – italic, coloring scheme: carbon - cyan, nitrogen - 
blue, oxygen – red). Hydrogen bonds are indicated by magenta dotted lines. Hydrophobic interactions between Gq 
and YM are indicated by blue arrows between the interacting atom pairs (thickness of arrow indicates interaction 
strength). Gq residues are colored according to the sum of their hydrophobic interaction energy with YM, ranging 
from yellow (1 kJ/mol - weak) to red (10 kJ/mol - strong). 
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In case of the medium-affinity analogs 36–39, each compound appears to be conformational 
more flexible compared to YM/FR as revealed by our MD simulations (Figure 5-21). Thus, 
these would result in different global conformations compared to the original conformation 
(Figure 5-18C) and, in turn, in different orientations in the Gq binding pocket compared to YM 
(Figure 5-18C). 
 
Figure 5-21: Overview of MD simulations of (A) YM, (B) 31 (YM-1), (C) 38 (YM-9), (D) 39 (YM-3) and (E) 
37 (YM-385780). RMSD time trace of Cα atoms and per residue RMSF (first two panels from left) and structural 
ensemble (third panel, 10 structures, coloring scheme: carbon - cyan, nitrogen - blue, oxygen - red, hydrogens are 
omitted for clarity, hydrogen bonds are shown as yellow dashed lines) derived from the time interval indicated 
(blue line) at the Cα RMSD-time trace. Fourth panel: Superposition of YM-254890 (carbon – light purple) and 
energy-minimized representative structure (carbon – orange/yellow) extracted from the simulation after a certain 
time, which is indicated by yellow/orange label at the Cα RMSD-time trace and which was used for docking. 
Results, Section II: Detection, Isolation and Structure Activity Relationship studies of new FR 
analogs 
116 
 
Regarding the low-affinity or inactive compounds 11–22 and 40–44 an increased structural 
flexibility as assessed by NMR analysis and MD simulation (except of 11 and 12 significantly 
altered the global conformation, resulting in highly dissimilar structures compared to YM/FR 
(Figure 5-22). Taking a closer look at the orientation of the low-affinity compounds in the Gq 
binding pocket, except of 43, the phenyl ring of F’ resides in the hydrophobic cleft as already 
observed for the high- and medium-affinity YM/FR analogs. Another common feature among 
this group of YM analogs is the tendency of hydrogen bond formation with the switch I region 
or residues of the Gβ subunit as shown for 11 and 44 in Figure 5-18D. However, with the 
exception of 11 and 40, Arg60 was no longer linked via hydrogen bonding by any of these 
analogs. Instead, Arg96 of the Gβ subunit became a major hydrogen bonding partner. In any 
case, the modifications introduced into the low-affinity YM/FR analogs significantly altered 
the conformation of the inhibitor molecule and thus the ability to correctly access the rather 
deep binding pocket. This interpretation becomes even more valid with respect to the different 
conformations of the inactive peptides (13–22). 
 
Figure 5-22: Superposition of the protein-bound conformation of YM (color scheme: carbon - light purple, 
nitrogen - blue, oxygen - red, PDB ID 3AH8) with the conformation of the protein-bound YM/FR analog (carbon 
- yellow) (A) 40, (B) 41, (C) 42 (D) 43 (E) 44 (F) 11, and (G) 12 as revealed by the docking experiments. 
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Deviation of recognition determinants for inhibitor binding to Gαq 
FR and YM represent small to medium-sized compounds with a high degree of chemical 
complexity, specific three-dimensional conformations, and consequently precise orientation of 
backbone and side chain atoms through intrinsic rigidity. Our attempt focused on characterizing 
features accounting for the high inhibitory activity of YM/FR towards Gq and on sampling 
chemical space to identify possible sites for further optimization. This analysis revealed how 
changes in three distinct categories affect inhibitory potency compared to the lead compounds, 
namely I) backbone conformation, II) backbone conformation influencing the intramolecular 
hydrogen bond network, and III) side chain constitution and orientation (Scheme 5-10). In 
analogs belonging to categories I and II, which are based mainly on backbone modifications, 
most drastic effects or even complete loss of activity were observed in derivatives 44, 43, 42, 
and 40, in which only single atoms or small groups were changed at T’, (T’’ in YM), (A’’), or 
(A) relative to YM/FR (Scheme 5-9, 5-10). Considering structural alterations within backbone 
modifications, two different types need to be taken into account: a) sole conformational changes 
(category I), e.g. evoked by inversion of configuration as in 42, and b) functional impairment 
of intramolecular hydrogen bonding (category II), as occurring in 40, 43, and 44 (Figure 5-22). 
Exploring their individual binding modes revealed perturbations on the individual molecule’s 
integrity with respect to YM/FR and their binding behavior. Substitution of an ester by an amide 
bond as in 40 was also introduced in a further compound (39) at a different position (F’ to DF), 
which turned out to result in a moderately active derivative compared to the inactive 40, 42–
44. This demonstrates that the ester bond linking T’ and L’ (or T’’ for YM respectively) is more 
important concerning the macrocycle’s bioactive conformation than the bond between L’ (T’’) 
and F’. There was one further modification in the backbone associated with a change in the 
hydrogen bond network, namely compound 31 (A’ to A), which, however, did not significantly 
change the inhibitory activity compared to YM/FR (Scheme 5-10A). Finally, concerning 
backbone modifications only the reduction of A’’ to A’ led to a strong effect on activity, which 
induced stronger changes to the backbone conformation than the N-Me-D-Ala substitution. All 
further alterations as found in 35, 31, 28, 27, and 25, including changes such as an increase in 
flexibility (e.g. A to G, 35) or the inversion of configuration (A’ to N-Me-D-Ala, 28), were 
tolerated (Scheme 5-10A). 
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Scheme 5-10: Structural classification of compounds with modifications at one side of FR and/or YM according 
to their impact on (A) backbone and intramolecular hydrogen bonds and (B) side-chain modifications. Colored 
bars next to compounds indicate acceptance of modifications (red - inactive compounds with minor, non-tolerated 
substitutions, yellow - moderately active compounds with partially tolerated substitutions, green - active 
compounds with tolerated substitutions). *Nomenclature refers to YM-254890. A*, dehydroalanine; T’’, N-
acetylthreonine; T^, 2,3-diaminobutyric acid; T’’’, O-methylthreonine; DA, D-alanine; DA’, N-methyl-D-alanine; 
DF, D-phenylalanine; F’’, N-methylphenylalanine; L^^, N-acetylleucine; L^^^, N-
methylthioacetylhydroxyleucine52; Sar, sarcosine; V’, N-methylvaline. 
Thus, it is obvious that the surface region of the YM/FR molecule comprising residues A’ and 
A accepts such changes, whereas in the region between A’’ to T’ not even marginal 
modifications are tolerated, most likely due to their direct interaction with the protein surface.  
A more detailed analysis of category III comprising primarily side chain modifications and 
functionalities apart from the backbone atoms revealed a rather different picture. While 
molecules with acyl-modifications in the side-chain, e.g. such which occur in natural YM 
analogs 23, 24, and natural FR analog 2, displayed equivalent potency compared to YM and 
FR, respectively, the Gαq/11 protein did not tolerate a complete absence of an acylated side 
chain.26,52 This observation was confirmed by Kaur et al., who succeeded in the total synthesis 
of YM-280193, a YM analog lacking of the previously mentioned side-chain.196 The 
corresponding FR analog, compound 6, isolated from A. crenata and also detected in C. 
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vaccinii, was introduced in Chapter 5.1. First biological data revealed also significant reduced 
potency towards Gq-inhibition (IC50 about 20 µM, data not shown). Acylation of the secondary 
alcohol, performed in our laboratory, caused a dramatic loss of biological activity, probably by 
destroying the intramolecular hydrogen network, resulting in conformational change (11 = FR-
Hex, Chapter 5.2). Further the side-chain seems to be important for the stabilization of the 
biologically active conformation of FR. Figure 7-6 shows that the side chain is closely bound 
to the cyclic backbone of FR, and 1H-NMR spectroscopic data of compound 6 (= FRSC, FR 
lacking the side chain) shows that much more conformations appear, if the side chain is missing. 
The equipotency of compounds 1, 2, 23, and 24 can be attributed primarily to the fact that the 
aforementioned backbone-related criteria are retained in these analogs. 
In addition, regarding the protein-facing side in YM/FR no alterations were made or identified 
at F’, L’ (T’’), T’, whereas at both ends spanning the sequence between residues A’’) and L’’’, 
L’’ modifications maybe critical as can be proven with compounds 11, 12, 36, and 38 (Scheme 
5-10). For 11, 36 and 38, important hydrogen bond interactions between the hydroxyl function 
of L+ (or L^) and the Gq backbone at Ile190 and Glu191 are missing, while in case of 12 the 
bulkiness of semisynthetically prolonged A’’ to A+ avoids interactions at the binding site of F’. 
If more than one amino acid substitution was introduced at the same time, effects were even 
more striking. In case of 41, simultaneous exchange of L^ and L‘‘ for T’’ led to complete loss 
of activity at Gq most likely due to their smaller size. With respect to our simulations, this 
would allow for a reorientation of the two tail residues towards Arg96 at the Gβ subunit not 
only resulting in the loss of hydrogen bond interaction with Ile190 and Glu191 similar to 
compounds 11, 36 and 38 but also loosing hydrophobic contacts in this region. In case of 32 
and 34, in which each of the L‘‘ residues was mutated to T’’ independently, the steric reductions 
were not sufficient to allow for such reorientations, thus preserving the hydrogen bond 
interactions with the protein.  
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Conclusions Chapter 5.2 
Together with the analysis of the backbone (categories I and II) it becomes apparent that except 
of two residues, N-Me-Ala and Ala, the remaining part of the YM/FR molecule represents the 
“pharmacophore” for this specific Gq binding pocket (Figure 5-18). In addition, both molecules 
obviously represent optimal, highly efficient and specific compounds for Gq inhibition, since 
none of the natural as well as the artificial modifications yielded more potent analogs so far. 
 
It is known that natural products represent structures validated from millions of years of 
coevolution with their specific target exploiting precision in complementary chemical 
design.225–227 Hence, it seems unlikely that a significant improvement regarding Gq-inhibitors 
can be obtained with the limited opportunities provided by the YM/FR template(s). Also, there 
was no effect detected at Gi and Gs proteins for the compounds analyzed herein. These 
observations for artificial YM-analogs together with our results on the native derivatives of FR 
(1, 2) strongly indicate that the lead molecules already seem to be optimized for Gq inhibition. 
In terms of perspective, one conceivable task thus could be the implementation of strategies to 
target other Gα protein subunits based on the YM/FR template(s). 
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 Results, Section III: Development of the first fluorescent Gq 
protein inhibitor 
In Chapter 5 SAR of FR and its derivatives in the context of Gq inhibition were extensively 
studied. The gained insights are considered also as useful to assist in the development of a 
fluorescent FR probe. Such a probe would possibly allow monitoring of trajectories of 
individual fluorescently labelled receptors and thus would provide additional information 
concerning the molecular receptor dynamic and interaction with FR, given that fluorescence-
labeling does not perturb its biological activity. These experiments could help to get deeper 
insights into the interaction of FR and Gq on a molecular basis and enlighten the mechanism of 
action. For technical reasons, many of the ligand-receptor affinities published in the literature 
have been derived using purified cell membranes assayed at 4 °C.228 Conclusions from such 
experiments, however refer to receptors in live cells at 37 °C.228 This may be problematic. A 
fluorescent FR analog could be applied for real-time imaging in living cells to study, e.g. the 
mechanism of cell membrane permeation of FR. Furthermore, BRET assays were envisaged to 
characterize binding kinetics of cold (non-fluorescent) ligands. 
According to the gained SAR insights (Chapter 5.2), N-Me-Ala and Ala are the residues of 
choice for derivatization as also suggested by Zhang et al.201 However, these residues are only 
accessible in total synthesis approaches. Alternatively, we put our main focus on the 
development of fluorescent probes via isolation of FR and subsequent semisynthetic 
modification. Hence, we planned to utilize the exomethylene group of FR to add further 
substituents, since this part of the molecule interacts with the linker 1 region and is chemically 
feasible for reactions (compare Chapter 5.2). Thus, it was planned to use thiols to perform 
hetero-Michael additions,220 e.g. using cysteamine as substrate (described for 12 in Chapter 
5.2.2, which after addition to the exomethylene residue will yield a thioether with a primary 
amine. The latter can be further derivatized to obtain a fluorescent molecule. This approach is 
regarded as very versatile, since other thiols could be applied like cysteine or glutathione. This 
was successfully done for N-methyldehydroalanine containing microcystins. These 
microcystin-conjugates showed comparable properties to unconjugated microcystins, regarding 
conformation and toxicity, but the formation of epimers has to be taken into account.216,219 In 
the case of microcystins, the exomethylene group was also taken for the addition of a 
fluorophore, e.g. first cysteine was attached and subsequently fluorescein (FITC) via its 
isothiocyanate group.229 
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As a fluorophore BODIPY630/650-X-NHS was envisaged due to its relatively low molecular 
weight, high fluorescent intensity, and its low photobleaching rate. A further advantage of 
BODIPY fluorophore-linked fluorescent ligands is the fact that they are heavily quenched in 
aqueous solution and are brighter in a non-aqueous environment, that is, when receptor 
bound.230 These was desired by us as G proteins signal via membrane-bound GPCRs. 
BODIPY630/650-X-NHS contains a seven-atom aminohexanoyl ("X") spacer between the 
fluorophore and the NHS ester group. This spacer helps to separate the fluorophore from its 
point of attachment, potentially reducing the interaction of the fluorophore with FR or Gq 
respectively. 
The main focus of Chapter 6 is addressed to answer the following questions (taking account 
on the results of Section II): 
1. Can we modify FR toward a fluorescent probe? 
2. If so, is the fluorescent FR analog still able to inhibit Gq signaling? 
3. If so, can we apply the fluorescent probe for, e.g. real-time imaging in living cells? 
 Synthesis and biological evaluation of the first fluorescent Gq 
protein inhibitor FR-RR-BP 
 Synthesis of FR-RR-BP (46) 
A first fluorescent FR analog was synthesized in a two-step process. In the first step FR-Cys 
(12, see Chapter 5.2.2) was made to introduce a primary amine into the molecule. In a second 
step served to couple the primary amine to commercially available N-hydroxysuccinimide 
(NHS) ester containing fluorophores. 
Regarding the first step, i.e. thio Michael addition of cysteamine to FR in micellar media, an 
increase in yields as compared to the procedure of compound 12 synthesis was attempted by 
using DL-α-tocopherol methoxypolyethylene glycol succinate (TPGS-750-M), a 2nd generation 
designer surfactant developed by the Lipshutz Group (Scheme 6-1).231 TPGS-750-M was 
reported to have superior properties compared to SDS like (i) it is nonionic, (ii) the stabile ester 
residues make it relatively inert, (iii) it was designed to produce optimal sized nanomicelles, 
(iv) it was engineered to be water-soluble such that it cannot be extracted with most organic 
solvents (anything except chlorinated solvents) and (v) it is non-frothing. However, in our hands 
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the reaction using TPGS-750-M (2 wt %) in aqueous media led to even lower production yields 
of 12 (7.5 mg from 30 mg FR, 25%) as compared to using SDS (6 mg from 20 mg FR, 30%), 
inter alia due to laborious work-up procedure for TPGS-750-M (similar retention times like FR 
under standard conditions). The reaction was performed under argon atmosphere to avoid 
cysteamine oxidation to the corresponding disulfide. 
 
Scheme 6-1: Reaction scheme of FR-RR-BP synthesis. 
In general, the second step of the reaction was performed according to the manufacturer’s 
instructions (http://www.thermofisher.com/order/catalog/product/D10000). 7.5 mg (1 eq) of 
compound 12 were dissolved in DMSO and trimethylamine was added to ensure that the amine 
was deprotonated. Next, the amine-reactive dye BODIPY630/650-X-NHS (5 mg, about 1.1 eq) 
was added to the reaction mixture. The mixture was stirred at room temperature for 4 hours, 
protected from light. Subsequently to freeze-drying and purifying the conjugate via HPLC the 
desired conjugated FR-RR-BP (46) was obtained in moderate yields (3 mg from 7.5 mg 12, 
40%). 
 Analysis of FR-RR-BP (46) 
The molecular formula of compound 46 was determined to be C80H108BF2N11O18S2 (calcd. 
1624.7449; obsd. 1624.7438) for [M+H]+. This result from an accurate mass measurement 
suggests the successful conjugation between BODIPY630/650-X and compound 12 (Figure 6-
2). Interestingly, when comparing the LCMS² data of FR, 12 and 46, for compound 46 a 
molecular ion m/z 1640.7 was much more abundant than the expected [M+H]+ =1624.7 and 
pointing to an oxidation of the thioether to the sulfoxide catalyzed by DMSO. Oxidation of 
thioethers (sulfides) of various amino acids, peptides and proteins by DMSO have been reported 
earlier232,233, however required acidic conditions. Lushington et al. speculated these reactions 
to occur also under physiological conditions in vivo.234,235 In contrast to an achiral thioether 
sulfur atom that can be described as sp3 -hybridized, with two lone electron pairs and two alkyl 
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groups occupying points of a distorted tetrahedron, the pyramidal sulfur center of a sulfoxide, 
with an oxygen atom replacing one of the lone pairs of electrons of the thioether is chiral, when 
the two organic residues are dissimilar as in compound 46. The additional chiral center 
complicates analysis and made clear assignment of NMR resonances unfeasible. 
 
Figure 6-1: LCMS analysis of FR-RR-BP reaction mixture after 4h. (A) UV spectrum at 254 nm and extracted 
ion chromatograms for 46 [M+H]+  m/z 1624 (yellow), [M+2H]2+  m/z 812 (green), [M+H]+ oxidized  m/z 1640 
(black). (B) MS spectrum for the peak of compound 46 tR 4.0-4.2 min. 
 
 Bioactivity of FR-RR-BP 
To determine the properties of 46 to inhibit Gq-mediated signaling the IP1 accumulation assay 
could not be applied, because it is a fluorescence-based competitive immunoassay and the 
emission wavelength interferes with the emission of compound 46. Hence, we applied dynamic 
mass redistribution (DMR) to measure signaling of GqPCRs noninvasively in living cells 
(HEK293) as described by Schröder et al. (see also Chapter 3.7.5)236. 
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The DMR measurements were performed by Tobias Benkel and Nina Heycke, Institute for 
Pharmaceutical Biology, Univ. of Bonn). Clearly, compound 46 was able to completely inhibit 
Gq-mediated signaling in a concentration-dependent manner, while the precursor compound 12 
was inactive (Figure 6-2A). However, compound 46 was about 20 times less active when 
compared to FR. Similarly, competitive radioligand binding assays revealed low-affinity 
binding of compound 46 to Gq(Figure 6-2B). 
 
 
Figure 6-2: (A) DMR biosensing in HEK293 cells expressing endogenous Gq-coupled M3 receptors, preincubated 
with (potential) Gq inhibitors FR, 12, 46 normalized to 30 µM carbachol. Experiments were performed by 
performed by Tobias Benkel and N. Heycke, Institute for Pharmaceutical Biology, Univ. of Bonn. (B) Competition 
binding study of FR, 12, 46 versus [³H]PSB-15900 (5 nM), the tritiated derivative of FR, at cell membrane 
preparations of platelets. Values represent means ± SEM of three independent experiments. Experiments were 
performed by performed by Markus Kuschak, Institute for Pharmaceutical Chemistry I, Univ. of Bonn. 
 
 Molecular modelling studies of compounds 12 and 46 
It was considered, whether the inactivity of 12 could be explained by the positive charge of the 
primary amine, which is masked upon conjugation with the BODIPY dye. This would be a 
possible explanation for the recovered activity. This assumption was investigated via in-silico 
binding studies, performed by Dr. Daniel Tietze, TU Darmstadt. The results suggest that 12 
cannot bind to Gq due to repulsing effects of positively charged arginine residue R202 in Gq 
(Figure 6-3). 
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Figure 6-3: (A) Schematic representation of the Gαq subunit “bound” to 12 derived from docking by Dr. Daniel 
Tietze, TU Darmstadt. Surface charge distribution (red, negative; gray, neutral; blue, positive). (B) Zoomed-in 
view of (A). 
In order to understand the significantly different binding affinities of FR-Cys (12) and FR-RR-
BP (46) with respect to Gq, Dr. Tietze performed docking and molecular dynamics simulations 
(see Chapter 3.6.4. for detailed descriptions of methodology). For a holistic approach, he had 
to take into consideration D/L-epimers of both compounds (12 and 46), because the absolute 
configuration of the modified alanine residue is not known. Gq-bound conformations of FR-
(D/L)-Cys and FR-(D/L)-RR-BP were derived from molecular docking employing a flexible 
docking protocol using VINA. The best scoring complex conformations (Figure 6-4A and 6-
5A) showing the FR core structure in a similar conformation as found for YM in pdb3ah8 (taken 
from53) were subjected to further analysis and all-atom MD and steered MD simulations. 
Binding energies calculated from the docking (Appendix Table 10-5) runs unveiled the lowest 
binding affinities for the D-isomers of FR-Cys and BODIPY-functionalized FR (33.8 kJ/mol 
and 31.6 KJ/mol). In contrast, binding energies for the L-isomers of FR-Cys and FR-BODIPY 
were about 6 kJ/mol higher (40.3 kJ/mol and 37.3 kJ/mol) whereas the binding energy of FR-
L-Cys was almost at the level of FR and YM (40.8 kJ/mol and 41.2 kJ/mol, Appendix Figure 
10-41). With respect to the slightly different orientation of the FR-L-Cys and FR-D-Cys (I) we 
re-scored the high affinity FR-L-Cys complex conformation inverting the respective stereo 
center (FR-D-Cys (II), Appendix Table 10-6) in order to test if the low FR-D-Cys affinity 
against Gq would be artificial. Remarkably, the resulting binding energy for FR-D-Cys (II) 
(33.4 kJ/mol) derived from the VINA re-scoring was almost at the same level as for FR-D-Cys 
(I) (33.8 kJ/mol). Despite this small difference, both FR-D-Cys complex conformations were 
Results, Section III: Development of the first fluorescent Gq protein inhibitor 
127 
 
further analyzed through regular and steered MD simulations. Interestingly, ligand un-binding 
was observed for both FR-D-Cys conformations within less than 20 ns during all-atom MD 
simulations which were run for up to 500 ns on the best scoring complex conformations from 
the VINA dockings (Figure 6-4B). Again, FR-L-Cys was much stronger bound to Gq starting 
to un-bind at 420 ns which confirmed the higher receptor affinity predicted from the docking 
results (Figure 6-4B). 
 
Figure 6-4: (A) Gq-bound FR-(D/L)-Cys (12) derived from molecular docking with the switch I (yellow), linker 
1 (magenta) and β2 (red) region of the Gαq subunit. Gβ of the helical domain is indicated in green. 12 (I and II, 
see below) are shown as stick models (color code: carbon – cyan, nitrogen – blue, oxygen – red, sulfur – green) 
(B) ligand RMSD (root mean square deviation – black trace) and relative distance of two ligand atoms (Cα HF6 – 
blue trace, Cβ Maa9 – red trace) with respect to their starting (bound) position during all-atom MD simulation. 
(C) Steered MD profiles of ligand unbinding showing the time required to separate FR (black trace and squares), 
FR-L-Cys (red trace and squares) and FR-D-Cys (light and dark blue traces and squares) from the protein. Two 
alternative Gq bound conformations for FR-D-Cys were simulated whereas I. was derived from docking and II. 
(dotted lines) was derived from the docked conformation of FR-L-Cys by interconversion of the respective stereo 
center. Experiments performed by Dr. Daniel Tietze, TU Darmstadt. 
However, FR-(D/L)-RR-BP as well as FR and YM did not show any ligand un-binding during 
the regular MD simulation (Figure 6-5B) resulting into stable complex conformations with Gq 
after 5 to 10 ns (40 and 100 ns for FR-L-Cys and FR-D-RR-BP). In order to have an additional 
estimate on the binding affinities of the FR derivatives presented in this study, steered MD 
simulations at various accelerations were conducted enforcing ligand un-binding by pulling the 
complex apart measuring the time (tdiss), which is needed to separate the ligand from the 
complex as a direct measure for the ligand binding affinity. Therefore, steered MD was 
performed starting from an equilibrated complex conformation taken from the regular MD runs 
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(Appendix Table 10-5). During the steered MD simulations a nearly linear dependence of tdiss 
on the acceleration was observed for all tested ligands (Figure 6-4C and 6-5C, Appendix 
Figure 10-41). Extrapolated complex dissociation times at zero acceleration tdiss
0 (Appendix 
Table 10-6) of FR-D-Cys (~0.2 ns) confirmed its very low Gq binding affinity. Again, FR-L-
Cys and FR-L-RR-BP revealed much longer tdiss
0 times (~ 2.3 ns and ~ 1.8 ns, Appendix Table 
10-5) compared to the D-isomers being even longer than for FR and YM (~ 0.9 ns and ~ 1.1 ns, 
Appendix Table 10-6) thus suggesting a significantly higher Gq affinity. Moreover, ligand 
binding affinities estimated from the sMD results also agree well with the ligand binding 
energies calculated from additional 10 ns MD simulations (Appendix Table 10-5) which were 
performed at a higher level of precision than the afore mentioned regular MD runs. 
 
Figure 6-5: (A) Gq-bound FR-(D/L)-BODIPY (46) derived from molecular docking with the switch I (yellow), 
linker 1 (magenta) and β2 (red) region of the Gαq subunit. Gβ subunit is indicated in green. FR-(D/L)-BODIPY 
(46) are shown as stick models (color code: carbon – cyan, nitrogen – blue, oxygen – red, sulfur – green, fluorine 
– orange, boron - yellow) (B) ligand RMSD (root mean square deviation – black trace) and relative distance of 
two ligand atoms (Cα HF6 – blue trace, Cβ Maa9 – red trace) with respect to their starting (bound) position during 
all-atom MD simulation. (C) Steered MD profiles of ligand unbinding showing the time required to separate FR 
(black trace and squares), FR-L-BP (red trace and squares) and FR-D-BP (blue trace and squares) from the protein. 
Experiments performed by Dr. Daniel Tietze, TU Darmstadt. 
From the molecular docking and dynamic simulations we concluded that (i) FR-L-Cys and FR-
L-RR-BP should be highly bioactive or at least should strongly bind to Gq, (ii) FR-D-Cys shows 
much lower affinity for Gq than all other compounds, which might agree with inactivity. 
Therefore most likely compound 12 is FR-D-Cys (= S-epimer) as also discussed in Chapter 
5.2, (iii) FR-D-RR-BP revealed an intermediate Gq affinity, which might agree with low 
experimentally found activity. Therefore most likely compound 46 is FR-D-RR-BP. 
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 Synthesis of FR-Cys-Boc (47) 
In Chapter 6.1.3.1 we tried to explain the complete loss of activity of compound 12 with 
repulsing effects from neighboring arginine residues of Gq via molecular modelling. To verify 
this hypothesis we intended to create a FR derivative where the positive charge of compound 
12 was masked. Hence, we coupled FR to an N-Boc-protected cysteamine. In general we 
applied the protocol from the synthesis of compound 12 (see Chapter 6.2) with small changes. 
We reacted 35 mg of FR with 20 eq N-Boc-cysteamine in methanol. The crude product was 
purified by liquid-liquid separation, flash chromatography and HPLC to yield 27 mg of 
compound 47 (FR-Cys-Boc) again as mixture of oxidized and unoxidized product (Scheme 6-
2). 
 
Scheme 6-2: Reaction scheme of FR-Cys-Boc (47) synthesis. 
The molecular formula of the unoxidized compound 47 was determined to be C56H90N8O17S 
(calcd. 1179.6217; obsd. 1179.6187) for [M+H]+. This result from an accurate mass 
measurement suggests the successful conjugation between FR-Cys-Boc and FR (Figure 6-6). 
 
Figure 6-6: LCMS measurement of FR-Cys-Boc (47) product after Flash purification. (A) UV Chanel at 254 
nm shows only one broad product peak. (B) Mass spectrum from tR 17-17.8 min. m/z range 650-1800 shows that 
the dominant signals of the sample are[M+H]+ ions of unoxidized compound 47 (m/z 1179.61). 
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First bioactivity measurement show that it is completely inactive regarding Gq inhibition up to 
100 µM (n = 2, personal communication, Nina Heycke). This result is surprising and would 
contradict our former assumption that compound 12 is most likely inactive due to its positive 
charge (Chapter 6.1.3.1). Another explanation was that there is no space for the bulky Boc 
group close to the FR backbone. A long flexible linker as applied in the active fluorescent FR 
analogs 46, 48, and 49 might not have these spatial demands and the bulky fluorogenic groups 
are possibly sufficient apart from the Gq protein. However, these results have to be confirmed 
before drawing final conclusions. 
 Application of FR-RR-BP (46) 
After demonstrating Gq-inhibiting properties of the first reported fluorescent FR analog 
compound 46 we tried to visualize its interaction with Gq via fluorescence correlation 
spectroscopy (FCS). FCS, developed inter alia by Elliot Elson,237 is widely applied to study 
membrane and protein dynamics, intracellular transport and cellular uptake,238 protein-protein 
and ligand–receptor interaction.239 FCS experiments were performed by Dr. Thomas Sorkalla, 
Dr. Stefan Franken, Stefan Aatz, Häberlein lab, Institute for Biochemistry and 
Molecularbiology, Univ. of Bonn on either HEK293 wildtype (wt) or HEK293 Gq/knockout 
(Ko) cells. First, HEK293 wt cells were incubated with compound 46, then pictures were taken 
after 1 min, 15 min, and 30 min (Figure 6-7A). Afterwards the outcome was compared with 
the same setting, but using HEK293 cell where Gq proteins had been genetically depleted via 
CRISPR/Cas9240 (Figure 6-7B). No significant differences between both cell lines could be 
observed, so it was concluded that compound 46 is unspecifically distributed and that direct 
specific binding to Gq could not be visualized. To examine whether the staining pattern 
observed in Figure 6-7A+B was due to solely the fluorescent dye or to FR coupled to the dye 
we repeated the experiment with BODIPY-630/650 conjugated with tris 
(hydroxymethyl)aminomethane (Tris), a common buffer component. Interestingly, while 
compound 46 entered cell membranes immediately after 1 min, it took the BODIPY-Tris 
conjugate about 30 min to be present in the cell membranes for both HEK wt cells and Gq/Ko 
cells (Figure 6-7C+D). 
We concluded from these experiments that compound 46 is unspecifically distributed in 
HEK293 wt as well as HEK293 Gq/Ko cell lines and further that 46 rapidly binds to cell 
membranes and that the FR-part of 46 is responsible for cellular uptake. 
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Figure 6-7: Comparative Life Cell imaging of FR-RR-BP in HEK293 wt and HEK293 Gq/Ko cells. (A) 50nM 
FR-RR-BP, HEK293 wt cells, (B) 50 nM FR-RR-BP, HEK293 Gq/Ko cells (C) 50 nM BP-TRIS, HEK293 wt 
cells, (D) 50nM BP-TRIS, HEK293 Gq/Ko cells. Exposure time = 300 ms. Experiments performed by Dr. Thomas 
Sorkalla, Dr. Stefan Franken, Stefan Aatz, Häberlein lab, Institute for Biochemistry and Molecularbiology, Univ. 
of Bonn. 
A similar result could be observed by fluorescence microscopy (experiments performed by 
Belma Hot, Schulte lab, Karolinska Institute). We tried to show co-localization of FR-RR-BP 
with Gαq-Venus (labeled Gq) and wanted to compare it to cells expressing Gαi-GFP, but there 
were not observable differences (data not shown.). However, when treating the cells with 
compound 46 and Rab5-GFP, a marker of early endosomes241 there was a clear indication of 
vesicle formation, implying endocytic uptake of compound 46 (Figure 6-8). 
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Figure 6-8: Fluorescence microscopy imaging of FR-RR-BP (46) in HEK293 cells. Rab5-GFP was used as 
endosomal marker. Compound 46 was found in vesicles, highlighted by white arrows. Experiments performed by 
Belma Hot, Schulte lab, Karolinska Institute. 
Conclusions 
We concluded that FR-RR-BP (46) is the first fluorescent selective Gq-signaling inhibitor. 
Applications like fluorescence microscopy & FCS measurements are at present unsuccessful 
due to lost specify. Compound 46 rapidly binds to cell membranes and enters cells most likely 
via endocytic uptake. 
 Development of a fluorescent FR probe with reduced 
hydrophobicity 
FR analog 46 was determined to be a selective Gq-signaling inhibitor, though with moderate 
activity, and FCS experiments demonstrated that 46 unspecifically accumulates and sticks to 
biomembranes. To prevent the interaction with membranes and at the same time localize the 
fluorophore far away from the FR core structure we planned the synthesis of a fluorescent FR 
analog containing a prolonged and more hydrophilic linker. Dr. Daniel Tietze did in silico 
binding studies for the so far developed fluorescent FR analog 46 and also for an putative 
fluorescent probe containing an optimized linker (FR-JK-BP, 49) towards Gq, Gq- NanoLuc® 
and Gq-RLuc (Figure 6-9). According to his calculations compound 49 should be suitable for 
bioluminescence resonance energy transfer (BRET) studies with Gq- NanoLuc®, because the 
NanoLuc® moiety and the BODIPY moiety are only 6-8 Å apart from each other (RET is 
detectable < 10 Å between donor and acceptor). 
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Figure 6-9: Structures of (A) FR-RR-BP (46) docked to Gq, (B) FR-JK-BP (49) with hydrophilic linker docked 
to Gq, (C) Gq-49- NanoLuc®, the NanoLuc® unit is shown in purple (D) Gq-49-RLuc8, the RLuc8 unit is shown 
in blue, structures of 46 and 49 (plus molecular surface colored in red for (C) and (D) are given in stick 
representation (atom color scheme: carbon – cyan, nitrogen – blue, oxygen – red, sulfur – green, fluorine – brown, 
boron – yellow). In silico binding experiments were performed by Dr. Daniel Tietze, TU Darmstadt. 
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The main reason for establishing a BRET assay was to characterize (binding kinetics) of cold, 
i.e. non-fluorescent, ligands. Firstly, for detectable RET to occur, the BRET luciferase/substrate 
combination needs to emit with sufficient intensity within the excitation wavelength range of 
the chosen fluorophore. As red fluorophores such as BODIPY 630/650 can be distinguished 
most readily from cellular autofluorescence and are therefore generally considered most 
desirable for binding assays, this was potentially a problem as luciferases emit largely at blue 
wavelengths that are sub-optimal for exciting red fluorophores.242 Secondly, a BRET ligand 
binding assay requires extracellular fusion of the BRET donor luciferase to the receptor of 
interest.242 Unfortunately, as G proteins are synthesized inside the cell and need to be trafficked 
and inserted into the plasma membrane, appropriate expression of such a fusion protein is not 
trivial. Both of these issues have been addressed by utilizing NanoLuc®. As a consequence of 
its very high luminescence intensity, NanoLuc®, although having an emission peak at 460 nm, 
has sufficient emission at longer wavelengths to enable transfer of resonance energy to red 
fluorophores such as BODIPY 630/650 to be readily detected.228 The native luciferase from 
which NanoLuc® is derived is secreted by the shrimp in bright luminescence bursts as a defense 
mechanism to deter predators.243–245 The fused Gq- NanoLuc® construct was kindly provided 
by Celine Galés, French Institute of Health and Medical Research, Paris. 
 Syntheses of FR-JK-Boc (48) and FR-JK-BP (49) 
The proposed linker from Dr. Daniel Tietze was synthesized and provided by Jim Küppers 
(Gütschow lab, Institute for Pharmaceutical Chemistry I, Univ. of Bonn) and contained two 
ethyleneglycol units with a terminal tert-butyloxycarbonyl (=Boc)-protected amine on the one 
side and a free terminal thiol group on the other side (Scheme 6-3). The Boc-protecting group 
was used to prevent by-products in which the amino group attacked the Michael acceptor of 
FR. 
In general we applied the synthesis protocol of compound 12 (see Chapter 5.2) with small 
changes. As LinkerJK was soluble in methanol we waived the micellar media and performed 
the reaction with 40 mg of FR (about 40 µM) and 120 mg LinkerJK (370 µM) under argon 
atmosphere in 1 mL hypergrade methanol containing 10 % milli-Q water (for details see 
Chapter 3.5.4). The crude reaction mixture was processed via liquid-liquid separation with 
butanol and flash chromatography (Appendix Figure 10-1) to yield 15 mg of the desired FR-
Linker conjugate (FR-JK-Boc, 48). Flash fractions 32-38 was controlled via LCMS² and 
afterwards in the second step, the acid-labile Boc group of compound 48 was cleaved with a 
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mixture of DCM/TFA = 5/1, controlled by TLC sprayed with ninhydrin, to obtain FR-JK-NH2 
intermediate product, which was not isolated, but directly further reacted. After removal of 
residual TFA, BODIPY630/650-X-NHS ester was coupled to the primary amine of FR-JK-NH2 
in DMSO and trimethylamine as catalyst. The reaction was stirred over night at room 
temperature and protected from light. 
 
Scheme 6-3: Reaction scheme of FR-JK-BP (49) synthesis. 
After HPLC purification of 10 mg reaction mixture, we finally obtained merely 1.4 mg of the 
desired product FR-JK-BP (49). 
 Analysis of FR-JK-BP (49) 
The molecular formula of 49 was determined to be C86H119BF2N12O21S2 (calcd. 1769.8188; 
obsd. 1769.8254) for [M+H]+. This result from an accurate mass measurement suggests the 
successful conjugation between BODIPY630/650-X and compound 48 (Figure 6-10). Mass 
spectrometric analysis. As observed earlier for compound 46, a molecular ion + m/z 16 Da was 
also abundant for compound 49 (m/z 1785.82), pointing to an oxidation of the thioether to the 
corresponding sulfoxide, also supported by the slightly lower retention time for the oxidized 
product (Figure 6-10). That is why we exposed 49 to air until complete conversion. 
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Figure 6-10: LCMS measurement of FR-JK-BP (49) product after HPLC purification. (A) UV Chanel at 254 
nm shows only one broad product peak. (B) Mass spectrum from tR 4-11 min. (C) Mass spectrum m/z 865-890 
shows that the dominant signals of the sample are [M+2H]2+ ions of 49 (m/z 875.41)and oxidized 49 (m/z 883.41). 
(D) Mass spectrum m/z 1630-1950 shows the [M+H]+ ions of 49 (m/z 1769.82) and oxidized 49 (m/z 1785.82). 
 
 Application of FR-JK-BP (49) 
Unfortunately, when we tested compound 49 no change in BRET signal was detectable and 
therefore, the elongated linker might still be too short to render the fluorophore out of the 
binding pocket, not allowing for resonance energy transfer (personal communication with 
Tobias Benkel, Institute for Pharmaceutical Biology, Univ. of Bonn). 
 Development of FR probes with different fluorophores 
The current developed fluorescent FR analogs 46 and 49 were demonstrated to be selective Gq-
signaling inhibitors, though with moderate activity. Unfortunately, they seem to unspecifically 
accumulate in biomembranes. Further, establishment of BRET assays failed with both 
compounds. Therefore we intended to change the fluorophore to TAMRA, because this dye 
was also demonstrated to work well in BRET studies of GPCR-related research.228 
In general, we applied the synthesis protocol of compound 47 (see Chapter 6.2) with small 
changes. We reacted 25 mg of FR with 25 mg TAMRA-thiol (2 eq) under argon atmosphere in 
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1 mL hypergrade methanol containing 10 % milli-Q water; deprotonation of the thiol was 
achieved by addition of 2 eq TEA. The reaction was stirred vigorously for 2.5 h at 40 °C, 
protected from light. Next, we added 10 ml milli-Q water and extracted three times with 15 mL 
butanol each. Afterwards the raw product was purified by flash chromatography and HPLC to 
yield 1.1 mg of compound 50 (FR-TAMRA, Scheme 6-4). 
 
Scheme 6-4: Reaction scheme of FR-TAMRA (50) synthesis. 
 
 Analysis of FR-TAMRA (50) 
The molecular formula of 50 was determined to be C76H102N10O19S (calcd. 1491.7116; obsd. 
1491.9372) for [M+H]+. This result from an accurate mass measurement suggests the successful 
conjugation between TAMRA-thiol and FR (Figure 6-11). 
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Figure 6-11: LCMS measurement of FR-TAMRA (50) product after HPLC purification. (A) UV Chanel at 
245 nm shows only one broad product peak. (B) Mass spectrum from tR 4-11 min. (C) Mass spectrum m/z 300-
3000 shows that the dominant signals of the sample are [M+2H]2+ ions of 50 (m/z 746.40) and the [M+H]+ ions of 
50 (m/z 1491.94). 
BRET assays with FR-TAMRA (50) are in progress. 
 Semisynthetic approach towards a coumarin-containing fluorophore 
Besides the already used BODIPY and TAMRA fluorophores, we further intended to test the 
influence of the fluorophore moiety on the Gq activity. That is why we also tried to couple FR 
to a coumarin343-thiol derivative, synthesized and provided by Jim Küppers, Gütschow lab, 
Univ. of Bonn (Scheme 6-5).246 Unfortunately, the coumarin-thiol was difficult to dissolve in 
micellar media as well as in methanol and after 24 hours only trace amounts of the desired 
compound could be detected via LCMS measurements. Hence, we were not able to isolate the 
product in quantities sufficient for further testing. 
Results, Section III: Development of the first fluorescent Gq protein inhibitor 
139 
 
 
Scheme 6-5: Reaction Scheme of FR-Coumarin synthesis. Coumarin-SH was synthesized by Jim Küppers 
(Gütschow lab, Univ. of Bonn). 
 
 Alternative synthetic approach towards a fluorescent FR probe 
Evaluation of compounds 12, 46-50 showed that alteration of the planar sp²-hybridized 
(Michael acceptor of the dehydroalanine moiety) to a sp³-hybridized system was demonstrated 
to impede with biological effect. Thus, to keep the sp²-hybridized methylene group unchanged, 
a cross-metathesis reaction was conceived applying a 2nd generation catalyst developed by 
Nobel prize awardee Robert Grubbs247 and a BODIPY derivative containing a terminal alkene, 
synthesized in the lab of Prof. Christa Müller, Univ. of Bonn (Scheme 6-6). The advantages of 
such a compound would be numerous; (i) the stereochemistry and conformation of the peptide 
backbone would remain intact, including the sp² hybridized exomethylene group (ii) the 
coupling product would have a relatively low molecular weight (iii) one-step synthesis. In 
natural product chemistry cross-metathesis is commonly used for ring-closing reactions.248,249 
However, there are also examples for late stage modifications of cyclic peptides via cross 
metathesis, and also reactions where BODIPY dyes were coupled to the molecule of interest 
via this type of reaction and reactions in micellar media were reported.250–254 
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Scheme 6-6: Reaction Scheme of putative FR-BODIPY-CM synthesis. Terminal-Alkene was synthesized in 
the Müller lab (Univ. of Bonn). 
 
Regrettably, pretesting with simplified structures, (performed by Jim Küppers, Gütschow lab, 
Univ. of Bonn) failed. That is why we did not follow this reaction type further. 
Conclusions Section III 
The so far developed fluorescent FR probes 46, 49, and 50 turned out to still inhibit Gq-
mediated signaling. However, unspecific binding to biomembranes so far prevent their 
application as tools in fluorescence-based assays. Nevertheless, together with the failed 
reactions (Chapter 6.3.2, 6.4) compounds 46, 49, and 50 build a solid foundation for 
development of fluorescent FR analogs with improved applicabilities. 
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 Discussion 
 Ecological considerations concerning the leaf nodule symbiosis and 
FR900359 
It is assumed that symbiotic microbes of plants often function as biological defense for the host 
to combat phytopathogens. The protective functions of such endophytes are exerted often 
directly by releasing metabolites suitable to attack any antagonists, or indirectly by, either 
inducing host defense mechanisms or promoting growth.11,12 We examined ecological aspects 
for the specialized leaf nodule symbiosis, occurring between bacteria of the genus Burkholderia 
and plants of Primulaceae, especially A. crenata as described in Chapters 1.1 and 4.1. 
 Burkholderia symbioses with plants and insects: Considerations about the 
origin of the leaf nodule symbiosis 
The genus Burkholderia, proposed by Yabuuchi et al.,255 is an ecologically very diverse 
bacterial group. To date, the ever-growing genus Burkholderia comprises over 100 species.256 
The genus Burkholderia occupies diverse ecological niches as there are several human, animal 
and plantpathogenetic species, including members of the Burkholderia cepacia complex 
(BCC)257 and the B. pseudomallei group258. Some Burkholderia strains are, on the other hand, 
beneficially associated with their host organisms. These include nodule symbionts of 
leguminous plants, endophytic bacteria of diverse crops, mycelium and spore symbionts of 
fungal species, symbionts in the farming symbiosis of slime molds and gut symbionts of 
heteropteran insects.256 Based on molecular phylogeny, the genus Burkholderia is grouped into 
three distinct clades (Appendix Figure 10-42). The first clade consists of many human, animal 
and plant pathogens, including B. cepacia, B. pseudomallei, B. mallei and their allied species, 
designated as the “Burkholderia cepacia complex and Burkholderia pseudomallei (BCC&P)” 
clade.257 The second includes a number of plant growth-promoting rhizobacteria and nodule 
symbionts, assigned as the “plant-associated beneficial and environmental (PBE)” clade, i.e. 
Ca. B. crenata belongs to this clade. The third clade mainly consists of environmental species 
and gut symbionts of stink bugs, referred to as the “stinkbug-associated beneficial and 
environmental group (SBE)” or the Burkholderia glathei clade (BGC).257 Although the 
Burkholderia symbionts of stink bugs in the SBE/BGC are genetically diverse (Appendix 
Figure 10-42), recent deep sequencing analyses revealed that the gut microbiota of each bean 
bug (Riptortus pedestris) individual was remarkably simple and consisted of one or a few 
SBE/BGC taxa.257 Kikuchi et al. found the Riptortus-Burkholderia gut symbiosis to be an ideal 
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model system as the symbiont is easily culturable, genetically manipulatable, and the host can 
be reared free of symbionts.256,259,260 Although the Burkholderia symbiont of R. pedestris is not 
essential for the host’s survival, aposymbiotic insects exhibit retarded growth, smaller body size 
and weight and lower fecundity.256 Unlike typical insect-microbe symbioses, rearing 
experiments have demonstrated that the bean bug does not vertically transmit the symbiont. 
Instead, the Burkholderia symbiont inhabits the ambient soil on which the host insect lives and 
Riptortus acquires the symbiont from the environment at every generation. The specific 
acquisition of the Burkholderia symbiont is speculated to occur via a specialized intestinal 
organ for sorting the symbiont from various non-symbiotic microorganisms.256 Interestingly, 
many phytophagous insects are consistently associated with the “plant-associated beneficial 
and environmental (PBE)” group of Burkholderia and the symbiotic association with 
Burkholderia is speculated to be evolved at the common ancestor of at least the three 
superfamilies Coreoidea, Lygaeoidea, and Pyrrhocoroidea.260,261 
 Endosymbiotic Burkholderia – double agents, switching hosts between plants and 
insects and vice versa? 
Development of insecticide resistance has become a serious concern worldwide. The resistance 
mechanisms have been attributed to evolutionary changes in pest insect genomes such as 
alteration of drug target sites, up-regulation of degrading enzymes, and enhancement of drug 
excretion. Recently, Kikuchi et al. reported an interesting new mechanism of insecticide 
resistance that is selection and cultivation of insecticide-degrading strains of Burkholderia by 
the bean bug R. pedestris, conferring insecticide resistance to the latter.262–265 Further, they 
found evidence for a quick establishment of resistance within a single insect generation, and 
they assume that resistance moves around horizontally between different pest insects and other 
organisms. 
A hint toward the mechanism of symbiont transmission between plants and insects comes from 
the nested clade of the plant endosymbionts Ca. B. punctata, Ca. B. kirkii and Ca. B. 
schumanniana, which form a sister group with stinkbug R. pedestris symbiont (B. sp. 
RPE64).185 The same sister group also contains soil Burkholderia isolates with pesticide-
degrading capabilites.185 B. sp. RPE64 has been isolated from stinkbugs.266 This group of 
Burkholderia species, to which the leaf nodule symbionts of Rubiaceae belong, live freely in 
soil or are associated with plants and insects. Hence, one can envision that the ancestor of the 
leaf nodule symbionts was a Burkholderia species with a remarkably broad host range.185 It is 
therefore conceivable that some of the leaf nodule species have retained the ability for transient 
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association with insects, which could act as potential vectors (whereas non-vector insects may 
be targets of the insecticidal activity of kirkamide7 or FR7,10, respectively).185 
 
Figure 7-1: Figure modified after Pinto-Carbo et al.185 Evolutionary history hypothesis for the leaf nodule 
symbiosis. Ancestors of modern Ardisia sp. were probably in transient association with endophytic, or possibly 
epiphytic commensal bacteria. About 10 Mya, the bacteria acquired genes for the production of protective 
secondary metabolites such as FR, thereby giving a net fitness benefit to the association. As more effective 
symbionts were selected, the symbiotic bacteria became vertically transmitted, making the symbiosis permanent. 
A consequence of this permanent association is the increased dependency of the host on the leaf nodule bacteria, 
possibly through the loss of redundant metabolic pathways. All described modern nodulated Ardisia species are 
locked in the relationship with the leaf nodule bacteria, regardless of the production of protective metabolites. 
Intermediate stages shown in dashed lines (mutualistic Burkholderia symbionts, nodulated Primulaceae with 
facultative symbionts) are hypothetical. 
 
The obligate interaction between leaf nodule symbionts and their host plant (Ardisia sp.) could 
have evolved from an initial facultative and commensal association (Figure 7-1). The 
acquisition of secondary metabolite synthesis by the symbiotic bacteria via horizontal gene 
transfer is likely due to the flanking transposable elements in case of FR and kirkamide, 
respectively. This may likely have been essential for the transition to a mutualistic interaction 
and the establishment of the leaf nodule symbiosis. Subsequently, the association became 
permanent and the bacterial genomes started to erode.185 
 Burkholderia-Ardisia lucida: A pre-form of leaf nodule symbiosis? 
The Burkholderia-Crispardisia leaf nodule symbiosis is considered to be obligate,139 because 
neither the host nor the endosymbiont can survive outside the symbiotic interaction.15,140–142 
Seeds cured of the symbionts by antibiotic or heat treatment do germinate ordinary, but the 
resulting bacteria-free plants fail to reach maturity and die within two years.17,146 We tried to 
replicate these results, however, our antibiotic treatment was unsuccessful (see Chapter 4.1.1). 
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In contrast, Nakahashi et al. clipped the nodules from mature seedlings of A. crenata, which 
had no detrimental effects on the plants.143 One could hypothesize that the benefit, provided by 
the bacteria could be limited to another life stage of the plant. Considerations that the 
Burkholderia profits from nutrients and vitamins provided by the plant in return, turned out as 
possible, because Ca. B. crenata seems to possess a very eroded genome lacking of some 
necessary genes for the biosynthesis of its cellular components.22 In this point it differs from 
closely related Psychotria-symbiont Ca. B. kirkii, which seems to be particularly self-sufficient 
for amino acids, nucleotides and vitamins, despite the younger age of the Ardisia leaf nodule 
symbiosis compared with the Psychotria-symbiosis (approximately 5 Mya versus 10 Mya).146 
In Chapter 5.1 we reported on the surprising occurrence of FR in the non-nodulated plant A. 
lucida. When investigating the leaves of A. lucida, modified stomata can be observed that we 
suspected to be a “pre-form” of the above mentioned leaf nodule symbiosis (Figure 7-2, 
pictures provided by Dr. Aurelièn Bailly, Eberl lab, Univ. of Zurich). Interestingly, these 
structures that resemble to nodules display heterogeneity in their color. Some nodules are black 
whereas others are green (Figure 7-2C). The structures are highly autofluorescent in areas that 
could describe cell wall (see Figure 7-2D), which could be indicative of the presence of lignin. 
 
Figure 7-2: (A) Ardisia lucida leaf. The arrows are pointing on potential nodule structures. (B, C) Close-up picture 
on modified stomata similar to the ones observed in Psychotria kirkii, displaying heterogeneity in their color. (D) 
Close-up picture with eGFP-filter, highlighting autofluorescence in areas that could describe cell wall. Pictures 
were taken and provided by Dr. Aurelièn Bailly, Eberl lab, Univ. of Zurich. 
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In order to determine the location of the bacteria, Marta Pinto-Carbo (Eberl lab, Univ. of Zurich) 
performed a PCR in two different locations of the leaf, i.e. part of the leaf close to the main vein 
where the “nodules” are located, and of the margin of the leaf. Indeed, bacterial endophytes 
were detected within A. lucida leaves. In contrast to A. crenata, where the endosymbionts were 
concentrated in the nodules at the leaf rim, the endosymbiotic Burkholderia of A. lucida seem 
to be equally distributed around the whole leaf. Further PCR results indicated that there is more 
than one endophytic bacterium and a PCR product for the frs gene cluster was found. (Appendix 
Table 10-8). 
These preliminary results may indicate a pre-form of the leaf nodule symbiosis, where host and 
endophytic Burkholderia are not in an obligate relationship, yet. Thus, cultivation and 
sequencing of the endosymbiotic bacteria could be considered to get deeper insights in the 
development of symbioses. Further, MALDI imaging of leaves, berries, and seeds could be 
performed in comparison to A. crenata to track FR as indirect marker for the bacteria. 
 
 Ecological function of leaf nodule symbiosis 
Heritable symbiosis may have long-term consequences for the fitness of the host. It is predicted 
that co-dependence between host and symbionts may evolve over evolutionary time beyond the 
initial benefits of the symbiosis, e.g. through streamlining of redundant pathways or 
immunological susceptibilities. Some possible functions of the leaf nodule symbiosis are 
depicted in Figure 7-3. 
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Figure 7-3: Figure taken from Pinto-Carbo et al.7 Reduced set of plant-endophyte interaction pathways in leaf 
nodule symbionts. Items barred with red crosses indicate functions important for plant colonization of facultative 
endophytic bacteria, which are not conserved in leaf nodule symbionts. A general host-symbiont recognition 
mechanism not relying on protein secretion systems could be based on surface components such as 
lipopolysaccharides or exopolysaccharides. Secondary metabolites production is a common feature of all leaf 
nodule symbioses characterized so far and appears to provide the basis of the symbiotic alliances. The structure of 
the FR produced by the symbiont of A. crenata is shown, as well as the structure of cyclitols found in Rubiaceae 
species. For kirkamide, R1 = OH and R2 = N-Acetyl. ROS detoxification mechanisms are also conserved and 
likely represent adaptation to oxidative conditions in the leaf or provide resistance to host defenses. A putative 
ammonium transporter is conserved in the genomes of all leaf nodule symbionts and putative efflux transporters 
of secondary metabolites are associated with their respective biosynthetic clusters. 
FR, known for inhibiting Gαq-signalling in mammalian cells, is produced by Ca. B. crenata 
living in symbiosis with A. crenata as we demonstrated in Chapters 4.2, 4.3. Hence, we 
wondered whether A. crenata utilizes this molecule to regulate their own G signalling. This 
idea is supported by the structural similarity of mammalian G proteins to the plant G protein 
AtGPA1.148–150 Plant G proteins differ from mammalian G proteins in that they are self-
activating, which means that they do not G protein-coupled receptors to promote GDP-GTP 
need exchange. Therefore, regulation of G protein activation in plants occurs at the deactivation 
step.149,150 Plants may also utilize a GDP dissociation inhibitor (GDI) like FR, which slows 
down nucleotide exchange. However, FR was not able to interfere with AtGPA1 (Chapter 
4.1.2), but it could still be possible that FR plays a role in host-symbiont communication. 
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FR is found in all parts of A. crenata, but in different concentrations, thus vice versa, the 
bacterium could use FR to regulate primary metabolism of the plant according to the demands 
of the bacterium via plant G protein signaling. In this regard, it is noteworthy that the 
cyanobacterium Nostoc punctiforme, known to live in symbioses with plants, produces the 
cyclodepsipeptide nostopeptolide, which excerts vastly different effects on cellular 
differentiation and the direction of motility of N. punctiforme, depending on its 
concentration.267 Furthermore, this peptide is down-regulated in symbiosis or altered by plant 
cells in the direct proximity to the bacterium, while it is expressed under all conditions in the 
free-living state of the cyanobacterium.267 Maybe the nostopeptolide-signaling cascade is 
mediated via plant G proteins (other than AtGPA1). This would be in accordance with Urano 
& Jones et al., who declared the primary function of G signaling in plants to be nutrient sensing, 
and this information impacts signaling by several plant hormones, light, pathogen-associated 
molecular patterns, and probably other signals.150 
 Insecticidal properties of FR via inhibition of insect GqPCR signaling 
We provided first evidence for FR as a chemical protective agent for its host plant (Chapter 
4.1.5). The interaction of FR with its molecular target, i.e. Gq proteins has been demonstrated 
to be very selective.54,55,58,62 The resulting biological effect in cells, however, is pleiotropic due 
to the ubiquitous presence of GPCR signaling cascades. In essence, signal transmission by a 
huge number of GqPCRs is blocked. These features make FR a unique defense chemical with 
an unprecedented mode of action. As we have shown in this study10, FR is, unexpectedly, orally 
bioavailable and causes a drastic physiological effect in mammals. Insects, however are 
probably the biggest threat for plants, and are likewise affected (all tested R. pedestris 
individuals died after a delay of several days). Furthermore, molting of the R. pedestris nymphs 
was completely prevented in the two highest concentrations applied. 
Most intriguing in this context is that Gαq was proven to be essentially important for molting 
and metamorphosis in a lepidopteran insect, Helicoverpa armigera via an insect steroid 
hormone (20-hydroxyecdysone).168,268 Moreover, the 20-hydroxyecdysone-signaling pathway, 
including Gαq, is highly conserved among different insects, such as D. melanogaster, B. mori, 
and Culex quinquefasciatus. These data suggest a possible explanation of the observed molting-
inhibiting effect of FR towards R. pedestris (Chapter 4.1.5).  
Discussion 
148 
 
 Potential of FR as crop protection chemical 
Another studied insect GqPCR is the diapause hormone receptor (DHR) of Bombyx mori. 
Diapause is a delay in development with minimizes metabolic activity adopted by insects to 
survive regularly and recurring periods of adverse environmental conditions.269 This unique 
process is regulated by diapause hormone (DH), which is a neuropeptide hormone that induces 
egg diapause in B. mori and is involved in terminating pupal diapause in heliothis moths.163,270 
Jiang et al. figured out that FR was able to completely inhibit DH-signaling. Thus, FR has great 
potential as crop protection chemical, as it is able to inhibit both initiation and termination of 
diapause in different stages (egg and pupal), an essential strategy of insects to survive and 
develop. As there are most likely many further insect GqPCRs, obligate for many insects, 
resistance development can be suspected as difficult.271 First evidence that diapause of 
Helicoverpa zea and likely many other pest insects is indeed susceptible to manipulation was 
provided by Zhang et al., who used a synthetic DHR-antagonist to significantly reduce diapause 
termination.272,273 However, the currently applied antagonists suffer from poor cell-
permeability.272 FR has besides its capabilities of cell-penetration, other superior properties 
such as high potencies and affinities to different insect Gq proteins and a broad spectrum of 
effects due to its unique mechanism of action. Interestingly, the DH receptor (DHR) exhibits a 
high level of similarity to the receptors of mammalian neuromedin U. For the latter, application 
of FR helped to discover participation of neuromedin U receptors in innate immune responses 
of mammals.55 A drawback, however is the toxicity of FR to mammalians. 
 Discovery of putatively FR-resistant scale insects on A. crenata 
For the supply of FR to members of the Research Unit FOR2373 we cultivate several hundred 
A. crenata plants in the green house of the Botanical Garden, Bonn. While they are robust to 
most plant pathogens, our gardener Dirk Schmitz found some plants, heavily infected with scale 
insects (Figure 7-4). Most scale insects are parasites of plants, feeding on sap drawn directly 
from the plant's vascular system. Other scale insect species evolved symbiotically with some 
ant species.274 Dr. Danièle Matile-Ferrero, an entomologist from the Muséum National 
d'Histoire Naturelle in Paris, determined the species attacking our Ardisia plant to be Saissetia 
coffeae, belonging to the family of soft scales (Coccidae). Interestingly, the colony of scale 
insects theirself were heavily attacked by a Hymenoptera parasite (parasitoid wasp), which is a 
natural enemies of S. coffeae. 
In future efforts we want to investigate the resistance mechanism of S. coffeae towards FR. One 
possibility would be the selective uptake of insecticide-degrading Burkholderia from the soil 
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(see Chapter 7.1.1.1). Intriguingly, again obligatory Burkholderia have been described from 
species of the superfamily Coccidea to be transovarially, thus vertically, transmitted from the 
mother to offspring.275 The complete genome sequencing of several obligatory symbionts of 
sap-feeding insects showed that their genomes are much smaller than the ones in their free 
living relatives, e.g. they lost mobile elements, most of the regulatory genes and pseudogenes, 
as we also observed for Ca. Burkholderia crenata.22 These endosymbionts could also provide 
mechanism to escape FR exposure. It would be interesting to see whether the endosymbionts 
of the scale insects are closely related to Ca. Burkholderia crenata, because it is possible that 
Crispardisia sp. gained their endosymbionts by scale insects infecting them with their own 
Burkholderia. Another possibility would be that the scale insects lack or have mutated Gαq 
proteins and thus they are not affected by FR. 
 
Figure 7-4: Ardisia crenata, infected with scale insects (Saissetia coffeae). (A) Non-infected leaf (8 cm) of A. 
crenata. (B) Picture of infected A. crenata plant. (C) Zoomed view of infected A. crenata plant. Red circle 
highlights transparent immobile female 2nd instar nymphs of S. coffeae. (D) Zoomed view of infected A. crenata 
plant. Blue circle highlights mobile, white female 1st instar nymphs (crawlers). Red circle highlights immobile 
female adult scale insect with a brown waxy shield. Dimensions of berries are 1 cm in diameter. 
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 General considerations about symbiotic relationships between bacteria of the genus 
Burkholderia, - plants, - and insects 
It is becoming plausible that the long-term persistence of symbiotic relationships such as 
Burkholderia-Ardisia, Burkholderia-Psychotria, Burkholderia-Riptortus, and Burkholderia-
Coccidea could be prevalent not only in two-party interactions, but also in more complex 
systems comprising three or more associates. The common ancestor of Burkholderia symbionts 
is suspected to have had a notable broad host range from plants to insects, and its descendants 
served as a kind of double agents, sometimes killing former host insects and then defecting back 
to the insect, degrading the same insecticides for its former enemy. Thus, the complex 
relationship could be imagined as war between plants and insects in favor of the best 
Burkholderia endosymbionts for their purposes. In that way the bacteria always benefit unless 
they develop to close relationships to one host, as e.g. described for Ca. B. crenata. This 
endosymbiont has lost its independency due to ongoing genome erosion and needs its host plant 
A. crenata to survive. 
An alternative option is that insects and plants are not necessarily enemies using bacteria as 
weapons, but they are all part of a bigger symbiotic network. A frequently encountered 
phenomenon in tropical forests is the association between ants (Crematogaster), plants 
(Macaranga trees) and Coccus scale insects.276 The plants are protected against lianas and 
herbivores by the ants that in turn gain residence in domatia created by hollow stems and food 
bodies secreted by the plants. In addition, the ants are able to further extract nutrients from the 
plants indirectly via the exudates of Coccus scale insects feeding on Macaranga sap and 
cohabiting with the ants in the confines of the Macaranga stem domatia. 
Concluding, the plant A. crenata and its obligate symbiotic bacterium Ca. B. crenata are a 
fabulous ecological system, where the host plant is protected from a big range of enemies and 
the metabolically very limited bacterium profits from primary metabolites of the plant. Further 
work is required to decipher the mutual benefits, possible biased effects depending on the 
concentration of signaling molecules and further molecular mechanisms underlying these 
benefits of this captivating type of symbiosis. 
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 Biosynthetic considerations concerning FR and its analogs 
Cyclic depsipeptides like FR are usually produced by fungal or bacterial microorganisms.23,277 
In this study we could prove via in-depth biosynthetic analysis and heterologous expression that 
FR is made by NRPSs encoded by the frs gene cluster of Ca. B. crenata, the endosymbiont of 
the vascular plant A. crenata (Chapters 4.2, 4.3).  
The structure of FR is unusual in that it contains hydroxylated amino acids, allowing for the 
construction of two adjacent ester bonds, which is rarely observed among natural products. The 
cyclodepsipeptide skyllamycin derived from Streptomyces sp. Acta 2897 contains, like FR three 
β-hydroxylated amino acids, serving as a further example for the complex nature of NRPS-
related biosynthesis.278 Thus a few features of skyllamycin biosynthesis are noteworthy to 
mention. The hydroxylations in this case and supposedly also in FR biosynthesis are catalyzed 
by a single cytochrome P450 monooxygenase (P450sky), which selectively accepts substrates 
bound to a peptidyl carrier protein (PCP) domain. Furthermore, the enzymatic system is able to 
distinguish between those PCPs on which the respective building blocks are hydroxylated in 
skyllamycin biosynthesis, and those PCPs where even the same amino acid building block is 
not hydroxylated. This reveals a new route of precursor production in NRPS biosynthesis, one 
which works in parallel with peptide synthesis.279 Through modification of precursors and their 
supply in vivo, novel peptides could be generated that possess alternate properties to the 
unmodified skyllamycin. 
 Generation of new FR analogs via molecular biology-based approaches 
 Generation of new FR analogs by genetic engineering – a glimpse to future studies 
The cyclodepsipeptide synthetases show a relatively broad tolerance for α-hydroxy acids and 
have been applied for in vitro syntheses of new cyclodepsipeptides, simply by adding synthetic 
α-hydroxy acids to those enzymes.280 Maybe this lack of absolute substrate specifity of the 
synthetases is also the reason for the appearance of newly described compounds 1-4 in this 
study (Chapter 5.1) and also the reported YM analogs, most of which are NH-acylation 
products of β-Hle moieties. 
After confirmation that the frs gene cluster is sufficient for FR production (Chapters 4.2, 4.3), 
now new FR analogs derived by targeted manipulation of the frs gene cluster are envisioned. 
Currently, we are exploring other hosts such as the cultivable endosymbiont of R. pedestris 
(Burkholderia RP64) that is closely related to leaf nodule symbionts (see Chapter 7.1.1.1). 
Discussion 
152 
 
Further, investigations of other expression plasmids to increase heterologous production yields 
of FR are planned. Finally, FR analogs with altered amino acids by genetic engineering of the 
A domains should be obtained. These derivatives will reveal new structure-activity 
relationships regarding the Gq binding pockets and may lead to development of at time 
unknown and urgently needed inhibitors of Gs or G12/13 proteins, that harbor a similar binding 
pocket. 
Phenyllactate is a relatively rare, but prominent acid building block in depsipeptides. PF1022A, 
a cyclooctadepsipeptide possessing strong anthelmintic properties and being produced by the 
filamentous fungus Rosellinia sp. PF1022 contains inter alia two D-phenyllactate building 
blocks (FR contains one D-phenyllactate).281 Yanai et al. produced unnatural PF1022A 
derivatives in which the two benzene rings were modified specifically at the para-position with 
amino and nitro groups by metabolic engineering. This approach is not limited to amino- and 
nitro-derivatives, and might be also transferred to approximately 100 secondary metabolites 
that may be biosynthesized via phenylpyruvate or p-hydroxyphenylpyruvate.282 
In the case of FR the introduced amino group would be apart from the cyclic backbone and thus 
may not interfere with its conformation. Most strikingly, the phenyllactate moiety is thought to 
be responsible for the extreme selective inhibition of Gαq subunits. Via subsequent modification 
of the para-amino group, susceptible to a vast number of reactions, new FR analogs with altered 
Gα-subunit profile could be obtained. 
 Optimization of FR production in Chromobacterium vaccinii 
As described in Chapter 5.1.5, FR was isolated from extracts of the cultivable bacterium C. 
vaccinii. In future, we plan to upscale the cultivation of C. vaccinii, and optimize the strain for 
FR production (by varying temperature, media, and genetic engineering). Further, we intend to 
diminish the violacein production, because this purple pigment impedes the purification process 
of FR. Khan et al. reported that clove oil (essential oil from Syzigium aromaticum) is a potent 
inhibitor of violacein in C. violaceum.283 Indeed, we were able to completely prevent violacein 
production when treating the C. vaccinii cultures with glove oil (0.01% - 1% v/v). While in 
higher concentrations from 0.25%-1% glove oil FR could no longer be detected via LCMS 
measurements, lower concentrations (0.1% and less) retained FR and FR-2 (2) production. The 
glove oil experiments were performed by the Master student Wiebke Hanke, Pharmaceutical 
Biology, Univ. of Bonn. 
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 Generation of new FR analogs by feeding experiments of Chromobacterium vaccinii 
In parallel to optimization of FR production we plan feeding experiments with altered (and also 
with 13C-labeled) precursors that may lead to novel derivatives of FR and novel insights into 
the biosynthesis of FR, respectively. First experiments were done with different carboxylic 
acids, because the starter-C domains of FR have demonstrated broader substrate specifity, 
proven by the existence of FR analogs such as FR-1 (1), FR-2 (2), and FR-3 (3). 
We are especially interested in the production of compound 1, because (i) it is originally not 
produced by C. vaccinii and (ii) its primary alcohol function may be the ideal anchor for 
derivatization with fluorescent dyes. Feeding of azido amino acids could also be envisaged. 
They can be subsequently coupled to alkyne-containing fluorophores via “Click-
Chemistry”.284,285 Docking experiments revealed much more space around the primary alcohol 
for a fluorophore, when bound to Gq. Further, succinic acid was proposed for feeding studies 
by Dr. Daniel Tietze, because according to in-silico modelling the new acidic moiety could a 
form salt bridge with the neighboring arginine R202 residue (Figure 7-5).  
 
Figure 7-5: In-silico modelling of a putative FR analog, containing a succinate in place of a propionate 
residue to Gq. Hydrogen bonds and salt bridges are labeled in pink dashed lines. Experiment was performed by 
Dr. Daniel Tietze, TU Darmstadt. 
 
Unfortunately, LCMS measurements indicated that none of the used substrates (3-OH-
propionate, succinic acid, glutaric acid, β-alanine, γ-aminobutyric acid, D-tyrosine added after 
1 week of cultivation) were incorporated into the FR molecule (Appendix Figure 10-43). But 
regarding the growth curve of C. vaccinii (Chapter 5.1.5) the bacterium reaches the stationary 
phase after two days. Therefore the experiments should be repeated with earlier addition of the 
substrates. 
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 Generation of new FR analogs by chemoenzymatic assays 
Chemoenzymatic methods offer additional approaches towards new FR derivatives. The 
Actinoplanes utahensis-assay gained our attraction, because it was applied to deacylate 
secondary amide residues of daptomycin and echinocandin B, two approved antiinfective and 
cyclic depsipeptide drugs.204,286–289 The resulting amino functionalities offer new SAR insights 
and more importantly can be easily further derivatized or functionalized towards e.g. 
fluorescent dyes. 
 Structure-activity considerations of FR and analogs 
A main goal of the study was the in-depth chemical examination of FR and structurally related 
cyclic depsipeptides provided by the plant A. crenata. Therefore, the isolation and identification 
of such peptides from the plant extract was optimized.  
FR and its new discovered analogs 1-4 isolated from A. crenata are structurally closely related 
cyclic depsipeptides. Such peptides are not easily analyzed by NMR and MS due to different 
conformations and - concerning MS - their cyclic nature. This project, especially Chapter 5 
revealed that a combination of mass spectrometric approaches, including MS², Tandem-MS, 
and GNPS analyses of FR and analogs is a suitable, fast, sensitive, and specific method for 
analyzing amino-acid composition of FR and related compounds. 
Conformational aspects seem to play an important role for the biological activity of FR. Several 
N-methylations reduce the number of possible hydrogen bonds and force the peptide into a 
certain conformation. This conformation also allows for the existence of peptide bonds in the 
generally unfavored cis-conformation. 
 Conformational analysis of FR with emphasis on the influence of N-methylation 
and cis-trans isomerization 
In Chapter 1.3, the unusual structural features of FR were described, inter alia, the multiple 
N-methylations, offering several advantages regarding pharmacodynamic and pharmacokinetic 
parameters. Thus, structural modification of the peptide backbone via N-methylation is a 
powerful tool to modulate the pharmacokinetic profile and biological activity of peptides. Wang 
et al.290 used temperature coefficients measured by NMR to identify and specifically N-
methylate those amides being exposed to solvent. These capped amides resulted in a higher 
membrane permeability and consequenced in a distinctly increased oral bioavailability. Wang 
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et al further concluded that N-methylations of cyclic peptides improve their oral bioavailability 
without significantly modifying their biological activity and selectivity. 
In my opinion, these considerations might be true for some compounds, but should not be 
generalized. Including the fact that FR already obtains several methylations, we think that its 
methylation pattern affects and determines its conformation and hydrogen bonding potential. 
X-Ray analysis of Myamae et al.30 and our 2D-NMR experiments, especially ROESY 
measurements suggest that all free amide and hydroxyl protons of FR are involved in hydrogen 
bonds. NOE correlations (see Figure 7-6, Appendix Figure 10-11, and Table 10-8) add further 
evidence for the observation of Myamae30 that the side-chain seems to be tightly bound to the 
cyclic backbone by these hydrogen bonds. Furthermore, the hydroxyl group at C-43 seems to 
play a key function in the hydrogen network.  
 
Figure 7-6: Key NOE correlations of FR derived from ROESY measurements: Red arrows highlight multiple 
long-range NOE correlations between protons of the side-chain and the peptide backbone deduced from ROESY 
experiments. This indicates that the side-chain is bound close to the backbone via hydrogen bonds. Black arrows 
show NOE correlations important for structure elucidation. 
It is probable that the biological effect of FR will be substantially decreased by altering the 
number of N-methylations. An increased number of N-methylations would destroy the 
hydrogen bonds directing the side-chain and backbone spatially close together. The side-chain 
would point away from the backbone and possibly disturb target interactions. Decreasing the 
number of N-methylations would enhance the flexibility and hydrophilicity of the molecule. In 
accordance with these assumptions, the dramatic effect resulting from alterations of the N-
methylation pattern of YM was demonstrated by Xiong et al.26 They synthesized three 
compounds in which backbone modifications of N-Me amides were introduced. YM-2, where 
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N-Me-Dha was replaced for Dha, a 630-fold decrease in potency was observed. Similarly, for 
YM-5 (N,O-Me2-Thr was replaced for OMe-Thr) a 465-fold decreased potency was displayed. 
YM-1 (N-Me-Ala was replaced for Ala), however, was nearly equipotent when compared to 
YM, indicating that effects due to altered methylations are hard to predict and cannot be 
generalized. Further, these analogs underline that not the number of N-methylations is 
important, but the specific pattern, contributing to a bioactive folding of the molecule. 
In this regard, the dramatic effects upon alteration of the N-methylation pattern could be due to 
a completely altered H-bonding network and thus an altered global conformation, when 
introducing additional NH groups. Thereby many additional conformations regarding the side-
chain and the backbone, e.g. the cis-peptide bonds could be changed to their trans counterparts. 
The cis-conformation, which occurs in nature very rarely, except on proline or tyrosine residues, 
can occur in FR, because the complex hydrogen bond network contributes to its overall stability. 
Furthermore, it is commonly known that N-methylation promotes trans–cis isomerization of 
amide bonds.291,292 Thus, N-methylation affects not only the conformation of the modified 
amino acid but also of the preceding residue.293 In addition, the α,β-double bond of N-Me-Dha 
has a profound effect on the conformational properties of the dehydroamino acid residue and, 
in consequence, on the conformation of the whole peptide molecule.294 Altogether, loss of these 
features by destroying its unique conformation would possibly lead to a decreased selectivity 
and efficacy of FR for its target as observed for e.g. Michael addition conjugates 12, and 46 - 
50 (Chapter 5.2). 
Considering application of FR as drug lead, it remains debatable if the conformational analysis 
by NMR measurements, recorded in unnatural media, like CDCl3, can be transferred one-to-
one to physiological milieus. To date, the transferability of the reported conformation of YM 
by Taniguchi et al.28 is supported by the study of Nishimura et al.53 who did a biochemical 
characterization of YM using purified G proteins in vitro and determined the X-ray crystal 
structure of the heterotrimeric Gq protein complexed with YM. They found that YM in this 
complex exhibits a combination of cis-and trans-amide bond conformations identical to the 
major conformer suggested by a previous NMR analysis in solution of Taniguchi.28 Taniguchi 
et al.28 proposed the occurrence of two conformers for YM. The same phenomenon was 
observed for FR in the present work. Comparing the chemical shifts and NOE correlations, it 
attracts attention that the same NOE correlations were noticed in the minor conformer, except 
that no NOE correlation between the α-proton of Pla and the N-methyl protons of N-Me-Dha 
was observed. This indicated that the distinction between major and minor conformers may lie 
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in the geometry of the amide bond between Pla and N-Me-Dha. The chemical shift of β-carbon 
of N-Me-Dha 6-CH2 (major: δC 106.9; minor: δC 121.8) was much different between both 
conformers, implying that it was influenced by the steric hindrance caused by the geometry of 
the amide bond. In the minor conformer, the high-field chemical shift (d, δH 3.73) of 6b-H of 
N-Me-Dha, compared to (d, δH 5.07) in the major conformer, suggested that the proton of the 
minor conformer might sit just above or below the plane of the benzene ring of Pla and be 
affected by an anisotropic shielding effect (for NMR spectroscopic data see Table 5-5). 
 FR and analogs adopt different conformations in aqueous medium compared to CDCl3 
In contrast to the above mentioned assumption of Nishimura et al. that YM (and FR) will adopt 
the same conformation as measured in CDCl3 upon Gq binding
53, we observed strikingly 
different conformations for FR, YM, and compound 1 when recording NMR spectra in more 
physiological media (H2O/D2O = 9/1) (Appendix Figures 10-44 to 10-55). The major 
conformer in water of all three compounds contains a single cis amide bound between N-Me-
Dha/Pla. This conformation fits much better in the Gq binding pocket than the previously 
published crystal structure.53 Further it can better explain why the N-Me-Dha residue does not 
tolerate any modifications. When the major conformer of the NMR structure measured in water 
is docked to Gq, the N-Me of Dha residue strongly interacts with Tyr192, Arg60, and K57. 
Interestingly, the ratio between major and minor conformers for YM (obtained in H2O/D2O = 
9/1) was 3:1, while the ratio for FR and compound 1 was 10:1. The increased conformational 
flexibility of YM could be an explanation for its much higher off-rate kinetics, observed in 
radioligand binding assays (PhD thesis Markus Kuschak, Univ of Bonn, manuscript in 
preparation). If our proposed structure for FR is indeed the biological active conformation this 
would force us to revise all so far drawn SAR insights and would also have huge impact on 
mutational studies towards other Gα subunits. That is why in-depth NMR studies with labeled 
Gq protein in physiological medium are urgently needed for verification or falsification of these 
assumptions. 
 Implications of the N-methyldehydroalanine moiety of FR 
Another interesting feature of FR is the unusual amino acid N-Me-Dha, which besides in FR 
and BE-22179207,208 only occurs in microcystins that are, like FR, cyclic heptadepsipeptides, in 
this case produced by cyanobacteria. It is known that nucleophiles may attack α,β-unsaturated 
carbonyl groups (occurring in N-Me-Dha) via Michael addition, and indeed we successfully 
applied this reaction for semisynthetic modifications of FR as described in Chapters 5.2 and 
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6.1, 6.2, 6.3. For microcystins, mechanistic studies by Craig and co-workers212 revealed a two-
step mechanism for irreversible inhibition of target proteins under physiological conditions. In 
the first step, the rapid non-covalent binding and inhibition occurs, and then the slower covalent 
modification of a cysteine residue takes place over the course of hours. 
Thus, in analogy, the mechanism behind the biological activity of FR could be assumed as rapid 
non-covalent interaction, which is sufficient to block GDP release and simultaneously direct 
the dehydroalanine moiety towards a cysteine residue nearby, followed by a thereby possible 
slowly occurring covalent modification afterwards. This two-step-mechanism could explain 
both, the remaining activity of the hydrogenated YM-385780 and the irreversible, covalent 
binding mode of FR to the Gαq/11 protein. 
In a previous study Schrage et al. performed wash-out experiments in both ex vivo (mouse tail 
arteries) and in vitro (HEK-293 cells expressing Gq-sensitive muscarinic M3 receptors).54 They 
observed in both systems retained Gq inhibition after washout, indicating the formation of a 
covalent complex or, alternatively, very tight association of FR with Gq. As also a hydrogenated 
FR derivative displayed potent Gq inhibition and this effect remained after washout Schrage et 
al. concluded that the α,β-unsaturated carbonyl group within FR is not crucial for Gq/11 
inhibition and that FR and Gq do not interact in a covalent way.54 
These experiments were repeated in CHO-M1 cells, incubated with FR or compound 1 (FR-1) 
for 1 h, followed by extensive washing, before activation of Gq-sensitive muscarinic M1 
receptors with carbachol (CCh) (Figure 7-7). The experiments were performed by Tobias 
Benkel and Nina Heycke (Institute for Pharmaceutical Biology, Kostenis lab, Univ. of Bonn). 
In all four trials the inhibitory effect of compound 1 could not be reversed through Cch after 
washing. In contrast to the former published data (Schrage et al.54) the effect of FR seems to be 
compromised to about half of the initial value after washing and exaggerated stimulation of 1 
mM Cch. Regarding the putative discrepancies compared to the former published data, one has 
to keep in mind that we achieved a shift in the x-axis of about 1.5. This might be due to the 
cellular background. Instead of HEK293 M3 cells, we used CHO M1 cells. As seen below, 
adjusting the x-axis by 1.5, leads to a quite similar result, indicating that the former data 
achieved for FR, could be confirmed for compound 1. This data is congruent with our 
assumption that FR and 1 adopt similar conformations (Chapter 7.3.1.1). In this context, it 
would be interesting to repeat the wash-out experiments with YM to see whether it is easier to 
remove. 
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Figure 7-7: Muscarinic M1 receptor-mediated production of IP1 induced by Cch in CHO cells in presence 
and absence of FR and FR-1, with or without wash-out. 
 
We posit that a slow off-rate may contribute significantly to the high affinity of FR to Gq, 
accounting for both pseudo-irreversible inhibition and resistance to washout in ex vivo vessel 
preparations as well as in intact cells in culture. An experimental set-up that could be used to 
confirm the slow off-rate kinetics of FR and analogs compared to YM and analogs was reported 
by Deng et al., using label-free whole cell dynamic mass redistribution (DMR) assays under 
both persistent and duration-controlled stimulation conditions.295 Furthermore, the implication 
that the non-covalent interactions are essential for a successful secondary covalent conjugation 
is a possible explanation for the selectivity of FR. Otherwise, if the N-Me-Dha moiety was 
freely accessible and solvent exposed, it would react in an unspecific way with many proteins. 
As consequence, one could postulate that the N-Me-Dha moiety is either not reactive enough 
or sterically hampered for covalent binding to cysteine residues under physiological conditions. 
Nevertheless, this residue is important for the global conformation of FR, which is closely 
connected to the biological activity as most modifications in this residue led to dramatic loss in 
potency (e.g. YM-2, FR-Cys, FR-RR-BP, FR-JK-BP, and FR-TAMRA). 
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 Application of FR and its derivatives as tools to study Gq-signaling 
and as therapeutic agents 
 Application of FR as tool to study Gq-signaling 
Schrage et al. pointed out the value of FR towards the scientific community for the investigation 
of numerous physiological processes.54 The data from Klepac et al. indicate that Gq signaling 
regulates brown/beige adipocytes and that inhibition of Gq signaling might be a novel 
therapeutic approach to combat obesity.55 Klose et al. demonstrated the participation of 
neuromedin U in immune response and inflammation via its Gq-coupled neuromedin U receptor 
1.55 
Application of FR has not only become diagnostic of the involvement of Gq proteins in 
biological processes, but has the potential for initiating paradigm shifts as lately outlined by 
Grundmann et al.299 G protein-independent, arrestin-dependent signaling has been such a 
paradigm that broadened the signaling scope of G protein-coupled receptors (GPCRs) beyond 
G proteins for numerous biological processes.300,301 Only recently, Grundmann et al. provided 
evidence that arrestin signaling in the collective absence of functional G proteins does not 
occur, but that arrestins were essential mediators of internalization when G protein activation 
was inhibited. This highlights and expands the role of arrestins from desensitizers of G protein-
dependent signaling to regulators of GPCR surface abundance under conditions when receptors 
are active but G proteins are not.299 
To improve the tool box we lately developed fluorescent FR probes 46, 49, 50 that should have 
served to get deeper insights into the interaction of FR and Gq on a molecular basis and to 
enlighten the mechanism of action by real-time imaging of Gαq family members in living cells.  
Apart from being useful for SAR studies, the semisynthetically derived FR analogs FR-RR-BP 
(46), FR-JK-BP (49), FR-TAMRA (50) are the first fluorescent selective Gq-inhibitors and 
display increasing potencies concerning Gq-inhibition from 46 to 50 (Chapter 6). They also 
serve as basis for further investigations on the mechanism of cellular uptake of FR. 
Further we wanted to establish a BRET assay between fluorescent compounds 46, and 49 and 
Gq protein coupled to NanoLuc® for the characterization (binding kinetics) of cold ligands at 
physiological conditions. However, no BRET signal was detected for compound 46 and also 
no change in BRET signal was detectable for compound 49 and therefore, the elongated linker 
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might still be too short to render the fluorophore out of the binding pocket, not allowing for 
resonance energy transfer.302 
The pharmacology of the developed fluorescent ligands was influenced by both the linker 
(prolonged hydrophilic linker of compound 49 resulted in higher Gq activity) and the associated 
fluorophore. Furthermore, it can be assumed that the physicochemical properties of the 
fluorophore/linker pairing determine where in the environment of the target protein the 
fluorophore is placed, and this, together with the environmental sensitivity of the resulting 
fluorescence, may finally decide its utility as a fluorescent probe.242 A possible explanation for 
the finding that all fluorescent probes are still active Gq protein inhibitors, but do not display 
RET signals could be that the fluorescent moieties point away from the NanoLuc® part of Gq 
or are hidden behind secondary structural elements of the Gq protein. That is why in future 
efforts the following concepts are proposed to obtain fluorescent FR analogs with superior 
properties, applicable for use in fluorescence-based assays. 
 
 Application of different attachment points of the fluorophore (fluorescent analogs of 
FR-1) 
The so far developed fluorescent FR analogs 46, 49, and 50 are all Michael adduct products 
coupled to FR via a thioether. This thioether might me partially cleaved under physiological 
conditions to FR, which would explain their residual activity on the one hand and the non-
applicability as fluorescent probes on the other hand. Further, the conformation of the FR 
peptidic backbone is altered by Michael additions, because the sp² hybridized exomethylene 
group is reacted to a sp³ hybridized system, generating diastereomers (epimers). Deduced from 
the results of this study it is highly recommended to have an intact N-Me-Dha residue. As the 
other functionality of FR that can be chemically modified (secondary alcohol of the side chain), 
has also been demonstrated to be crucial for biological activity, it is planned to modify the 
primary alcohol of compound 1 (FR-1). Altering this moiety would remain the stereochemistry 
and keep an intact conformation of the backbone. Further, the point of modification is the 
optimal derivatization side as predicted by molecular modelling (personal communication Dr. 
Daniel Tietze). However, only few milligrams of compound 1 have been isolated after four 
years, limiting the number of attempts. The idea is to first selectively oxidize the primary 
alcohol of compound 1 to the corresponding carboxylic acid derivative catalyzed by 2,2,6,6-
Tetramethylpiperidin-1-yl)oxyl (TEMPO) under mild conditions.303,304 In a second step the FR-
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1-COOH should then be activated by EDC/DMAP and coupled to an amine-containing 
fluorophore (Scheme 7-2). 
 
Scheme 7-1: Reaction scheme of FR-1-BODIPY synthesis. 
 
The intermediate product FR-1-COOH can also be used for SAR studies. It could be a first step 
in the direction of a Gαs inhibitor, due to a possible interaction of the carboxylic acid with a 
lysine residue in Gs (the corresponding residue in Gq is F75). 
 Application of regioselective reactions followed by Click-Chemistry 
An interesting approach to obtain regioselective precursors from N-Me-Dha residues, which 
could be reacted in a second step with a fluorescent dye was proposed by Zemskov et al.219 In 
a first step they reacted microcystins with a nucleophile (glutathione) in a similar way as it was 
described in Chapter 5.2 for compound 12. They obtained a single diastereomer with high 
selectivity as Michael addition product. To drive the cleavage to completion they added 
propargylamine to trap the Michael acceptor. In that way they observed the formation of two 
diastereomeric forms of propargylamine conjugates. Further, the formed propargylamine 
conjugates had improved stability relative to the thioether and N-Me-Dha derivatives under 
basic conditions. 
The great advantage of this approach is that two diastereomeric propargylamine-containing FR 
derivatives can be obtained and subsequently coupled to azide-containing fluorophores or 
photoswitches305–308 via click chemistry, which are chemical reactions that are rapid, selective 
and high-yielding.284,309–311 Click reactions are biorthogonal, that is, non-interacting with 
biological functionality while proceeding under physiological conditions in vivo.310 
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 Application of click chemistry as proof of principle for BRET assays between Gq- 
NanoLuc® and FR-binding pocket 
More recently, novel methods have been used to incorporate click reaction partners onto and 
into biomolecules, including the incorporation of unnatural amino acids containing reactive 
groups into proteins and the modification of nucleotides.312–316 These techniques represent a 
part of the field of chemical biology, in which click chemistry plays a fundamental role by 
intentionally and specifically coupling modular units to various end. Therefore we could apply 
click-chemistry to examine, whether the applied Gq- NanoLuc® is generally suitable for BRET 
assays with fluorescent FR probes being located in their Gq binding pocket. To achieve that a 
single mutation in (or next to) the Gq binding pocket alanine to an fluorescent azido amino acid 
has to be introduced into the Gq- NanoLuc® as described before in other contexts.316 BRET 
assays could be used to determine the best location of the fluorogenic amino acid and luminous 
Gq proteins would be generated. Thus also insights are gained about the preferred position of 
fluorophore coupled to FR. The in Chapter 7.4.1.2 described FR-propargylamine 
diastereomers could then be applied separately. First they should be tested for Gq activity and 
their conformations determined by NMR spectroscopy to see whether in the former approaches 
(compounds 12, 46, 47, 48, 49, 50) always the unfavorable diastereomer was generated as 
anticipated, which would explain their decreased activity as well their non-suitable application 
in FCS and BRET studies. The superior diastereomer should then be applied to Gq- NanoLuc®-
containing cells, harboring the fluorescent azido amino acid. In that way, the Gq proteins should 
be coupled to FR in a covalent manner. Afterwards, covalently inhibited and not-inhibited 
luminous Gq proteins could be compared via fluorescence microscopy and FCS, shedding light 
on the life cycle G proteins in active and inactive states. 
 
 Applications of FR as potential drug lead 
Great therapeutic interest exists for modulation of GPCR-promoted signal transduction. 
Although most current therapies utilize receptor agonists or antagonists, manipulation of GPCR 
signaling at steps distal to receptors, such as on the level of heterotrimeric G proteins, is an 
attractive alternative, particularly for diseases with complex pathologies, involving multiple 
receptors and signaling pathways.127 FR is an inhibitor of Gαq/11/14-mediated signaling. 
Therefore, it is well suited to investigate contribution of Gq-input in complex biological 
processes in vitro and ex vivo. Remarkable, thermal and chemical stability of the peptide FR, 
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are extraordinary properties for a peptide. The activity remained for at least 8 days proven by 
Ca2+ mobilization assay54 and no degradation was observed after stirring for 24h in a water bath 
of 60°C, followed by HPLC and NMR analysis. 
 Targeted inhibition of Gq with FR for the treatment of pulmonary diseases 
Because a tremendous number of physiological processes are controlled and regulated by Gq 
signaling and the resulting pleiotropic effects, it is consistent that application of FR cannot 
occur systemically. In contrast, the local treatment of FR against pulmonary diseases is 
conceivable. Matthey et al. demonstrated that FR specifically inhibited Gq-dependent signaling 
in airway smooth muscle cells and that this compound strongly reduced airway tone in rodent, 
pig, and human airways ex vivo.62 In addition, inhalation of FR effectively and persistently 
prevented airway constriction in both healthy and allergen-sensitized mice without causing 
acute cardiovascular side effects.62 Despite the fact that effective medicinal therapy with low 
rates and weak adverse effects for diseases like asthma and COPD are available, additional 
benefit provided by FR can be anticipated, because of (i) the superior bronchiorelaxing activity 
when compared with the gold standard salbutamol, (ii) a single drug relieves several symptoms 
simultaneously and (iii) long-lasting effects. Furthermore, for incurable diseases with presently 
inadequate treatments, like pulmonary hypertension, FR could offer significant relief of 
symptoms. The new mechanism of action could cause vasodilatation of the constricted 
pulmonary arteries, independently of nitrogen monoxide (NO), whose production is disturbed 
at persons suffering from pulmonary hypertension.  
 FR has potential as first-in-class agent treatment of GNAQ/11-driven cancers 
The notion that numerous GqPCRs regulate cell proliferation, but also motility and thereby 
invasive potential of cancer cells led us (Schrage et al.54) to posit that inhibition of Gq proteins 
rather than their linked receptors may be an efficient molecular intervention to target oncogenic 
signaling on the level of a postreceptor signaling hub where all cellular GqPCR input converges 
to eventually produce additive effects on cell behavior.54 
In uveal melanoma, the most common ocular cancer of the adult eye, about 85% of patients 
carry mutations in their heterotrimeric Gαq/11 proteins. Precision molecular therapies to target 
the oncogenes behind these mutations directly are lacking at present and current treatment 
options rely on radiation or surgery. First experiments indicate that FR potently silences 
mitogenic over canonical phospholipase Cβ (PLCB) signaling driven by these oncogene and 
Discussion 
165 
 
thus has potential as first-in-class agent to treat GNAQ/11-driven cancers in patients harboring 
Q209 pathway mutations (personal communication Suvi Annala).317–319 
Concluding, FR has been demonstrated to be a fascinating molecule not only as selective 
pharmacological tool and potential drug lead candidate, but also in a biochemical point of view. 
Its suggested ecological role as chemical defense compound offers an answer to the question, 
how first beneficial bacterial-plant associations may have developed to obligate leaf nodule 
symbioses. Future interdisciplinary research of the FOR2372 and others will certainly expand 
our knowledge of human GqPCR-signaling in physiological and pathophysiological contexts 
as well as Gq-contribution to ecological aspects among different kingdoms of life. 
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 Summary 
Plant-derived natural products possess an astonishing diversity of structures and bioactivities. 
Such compounds play a prominent role, not only as drugs for a wide array of therapeutic 
indications, but also as pharmacological tools to unravel fundamental biological processes. 
The DFG-funded research unit FOR2372 uses the cyclic depsipeptide FR900359 (FR) from 
Ardisia crenata as a molecular tool for investigations of Gαq-mediated signaling of G protein-
coupled receptors (GqPCRs). Additionally, FR has potential as a lead structure for the 
development of novel therapeutics to treat conditions, in which multiple GqPCRs contribute to 
pathology such as asthma, COPD or at present “undruggable” uveal melanoma. 
A majority of Ardisia species harbor bacteria of the genus Burkholderia within specialized leaf 
nodules. We sequenced for the first time the genome of Candidatus Burkholderia crenata (Ca. 
B. crenata), the uncultured leaf nodule symbiont of A. crenata. The genome of Ca. B. crenata 
is the second smallest Burkholderia genome to date (2.85 Mb). We identified unique genes with 
a predicted role in secondary metabolism in the genome of Ca. B. crenata. Specifically, 
evidence is provided for the FR nonribosomal peptide synthetase (frs) gene cluster. To confirm 
the link between FR and the symbiotic bacteria, we quantified FR in the leaf nodules versus the 
leaf lamina and visualized the result via MALDI imaging. This gives a clear indication that 
synthesis of FR is concentrated in the leaf nodules (Figure 8-1A). Further, an in-depth 
investigation of the frs biosynthetic gene cluster and the successful heterologous expression 
now provides the basis for future biotechnological FR production, as well as engineering 
experiments. 
The current project discovered FR as the first defense chemical applying inhibition of Gq 
proteins, a most effective and unique mode of action, that is suspected to act on a multitude of 
organisms based on the fact, that G proteins are highly conserved in the evolution of metazoans. 
FR is, unexpectedly, orally bioavailable and causes a drastic physiological effect in mammals. 
Insects, probably the biggest threat for plants, were likewise affected and all investigated bean 
bugs died when FR-concentrations of 40µM and higher were applied (Figure 8-1B-D). The 
plant A. crenata and its obligate symbiotic bacterium Ca. B. crenata are thus a fabulous 
ecological system, where the host plant is protected from a large range of enemies, and the 
metabolically very limited bacterium profits from primary metabolites of the plant. 
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Figure 8-1: Evaluating the ecological function of FR. (A) MALDI imaging mass spectrometry of an Ardisia 
crenata leaf. The potassium adduct of the molecular ion of FR (m/z 1040.49) is highlighted according to intensity. 
(B) Statistical analysis of in vivo blood pressure recordings in mice revealed a strong reduction of systolic arterial 
pressure (SAP) in the aorta one hour after oral FR application. (C) Competition binding study of FR versus 
[3H]PSB-15900 (5 nm), the tritiated derivative of FR, at Sf9 insect cell membranes, and at Gq proteins of Bombyx 
mori and Bemisia tabaci expressed in Gq-knockout HEK cell membrane preparations. Values represent means: 
SEM of three independent experiments. pIC50 values of 8.13–9.27 were determined. (D) Exposure of nymphs of a 
bean bug (Riptortus pedestris) to different concentrations of FR; the survival rate was measured. 
Additionally, we were able to find new FR producers, namely the nodulated A. crispa, A. 
hanceana, A. mamillata and A. villosa, and unexpectedly also the non-nodulated A. lucida. Only 
recently, we were successful in isolating FR from a cultivable bacterium. These findings 
together with reports on the FR related compounds YM-254890 (YM) and sameuramide found 
in soil bacteria and a marine tunicate respectively, suggest a very broad distribution of the FR 
molecular family in nature and supports an important ecological role for this natural product 
and its congeners. 
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The mechanism of action of FR on the molecular level was investigated by examining the 
structural elements of the depsipeptide, responsible for biological activity. In that way 
information concerning the FR pharmacophore was gained. Structure activity relationship 
studies (SAR) of FR analogs were conducted using semisynthetically modified FR and natural 
variants, the latter obtained by in-depth investigation of A. crenata. For the latter project part, 
the usefulness of Global Natural Product Social (GNPS) molecular networking for the detection 
of a family of FR derivatives in the TCM plant A. crenata could be demonstrated. The new 
cyclic depsipeptides FR-1 (1), FR-2 (2), FR-3 (3), and FR-4 (4), all of them structurally closely 
related to FR (Scheme 8-1) were isolated and elucidated. 
 
Scheme 8-1: Structures of FR900359 and isolated “natural” FR analogs FR-1 to FR-4 (1-4). Scheme was 
taken from Reher et al., submitted. 
 
Isolation was guided by bioactivity and GNPS molecular networking. Structure elucidation was 
done by extensive 1D- and 2D-NMR analyses in combination with Tandem MS analysis. 
Evaluation of biological activities of the FR analogs 1-4 showed high affinities to the Gαq 
protein with IC50 values in the low nanomolar range, even exceeding the affinity of the parent 
compound FR (16.8 ± 3.20 to 2.3 ± 0.12 nM for 1, 2, 3, and 4 compared to 18.5 ± 4.55 for FR). 
Similarly, downstream effects mediated by Gq proteins were equipotent inhibited by 1-4 as 
compared to FR (Figure 8-2). 
In contrast, FR analogs obtained by semisynthetic modification of the secondary alcohol of FR 
(FR-Hex, 11) or of the exomethylene group, respectively (12, 46, 47, 48, 49, 50), as well as 
most of the literature known YM analogs derived by total synthesis (Zhang, Xiong et al.), 
displayed a dramatic loss of efficacies, or were even found to be inactive (Scheme 8-2, Figure 
8-2). 
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Scheme 8-2: Structures of FR900359 and semisynthetically derived FR analogs. 
 
Apart from being useful for SAR studies, the semisynthetically derived FR analogs FR-RR-BP, 
FR-JK-BP, FR-TAMRA are the first fluorescent selective Gq-inhibitors and display increasing 
potencies concerning Gq-inhibition. Thus they serve as basis for further investigations on the 
mechanism of cellular uptake of FR and characterization of unlabeled FR analogs via BRET 
assays. 
 
Figure 8-2: SAR studies of FR and analogs. FR-3/FR-4 was tested in a 3/1 mixture. (A) IP1 accumulation assay 
of FR and analogs. Untransfected cell lines (CHO-M1R) were analyzed in the IP1 accumulation assay. All data are 
means of three experiments performed in triplicates and were performed by Suvi Annala, Nina Heycke, and Tobias 
Benkel (Kostenis lab, Institute for Pharmaceutical Biology, Univ. of Bonn). (B) Radioligand binding assay of FR 
and analogs, performed at human platelet membranes at 37 °C. All data are means of three experiments and were 
performed by Markus Kuschak (Müller lab, Institute for Pharmaceutical Chemistry, Univ. of Bonn).  
 
Concluding from this in-depth SAR study of the currently isolated and synthesized FR and 
YM analogs by us and others, it can be suggested that nature has optimized FR and YM for 
the specific inhibition of Gαq in a long-term co-evolutionary process.  
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Figure 10-1: Flash chromatography of FR-JK-Boc crude product. 15 mg pure FR-JK-Boc (47)  was obtained 
from fractions 32-38. 
 
Figure 10-2: Flash chromatography of FR-TAMRA (49) crude product. 4 mg FR-TAMRA was obtained 
from tR 17-27 and further purified by HPLC. 
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Figure 10-3: Flash chromatography of FR-Cys-Boc (50) crude product. 32 mg compound 50 was obtained 
from fractions 19-28 and further purified by HPLC. 
 
Figure 10-4: FR-concentration (µg/ml) in different plant tissues of A. crenata determined by LCMS 
measurements. Calibration curve with 4 different concentration (1 µg/ml, 10 µg/ml, 100 µg/ml, 1 mg/ml),of 
standard FR was applied. 
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Scheme 10-1: Structure and numbering of C-atoms of FR900359 (FR). 
 
 
Figure 10-5: 1H NMR spectrum (600 MHz CDCl3) of FR900359 (FR). Assignments see Table 10-1. 
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Figure 10-6: 13C NMR spectrum (150 MHz CDCl3) of FR900359 (FR). Assignments see Table 10-1. 
 
Figure 10-7: DEPT-135 NMR spectrum (150 MHz CDCl3) of FR900359 (FR). Assignments see Table 10-1. 
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Figure 10-8: 1H-1H-COSY NMR spectrum (600 MHz CDCl3) of FR900359 (FR). 
 
Figure 10-9: 1H-13C HSQC NMR spectrum (600 MHz CDCl3) of FR900359 (FR). 
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Figure 10-10: 1H-13C HMBC NMR spectrum (600 MHz CDCl3) of FR900359 (FR). 
 
Figure 10-11: ROESY NMR spectrum (600 MHz CDCl3) of FR900359 (FR). 
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Figure 10-12: TOCSY NMR spectrum (600 MHz CDCl3) of FR900359 (FR). 
 
Figure 10-13: HSQC-TOCSY NMR spectrum (600 MHz CDCl3) of FR900359 (FR). 
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Table 10-1: 1H and 13C NMR spectroscopic data of FR900359 (FR) in CDCl3 (1H: 600 MHz; 13C: 150 MHz). 
Residue[c] No C/H[b] δC[a], mult δH[a] (mult, J in Hz) 
Ala 1 172.6, C – 
 2 45.9, CH 4.90 (m) 
 2-NH – 8.51 (d, 9.1) 
 3 18.1, CH3 1.39 (d, 6.7) 
N-Me-Dha 4 164.0, C – 
 5 145.5, C – 
 6a 106.9, CH2 a 5.32 (d, 2.2) 
 6b – b 5.07 (d, 2.2) 
 7 36.3, CH3 3.15 (s) 
Pla 8 167.9, C – 
 9 72.7, CH 5.21 (dd, 4.1, 8.3) 
 10a 36.8, CH2 a 3.11 (dd, 4.1, 14.8)  
 10b – b 2.98 (dd, 8.3, 14.8) 
 11 136.1, C – 
 12/16 129.7, CH 7.26[d] 
 13/15 128.7, CH 7.29[d] 
 14 127.1, CH 7.23[d] 
N-Ac-β-HyLeu-1 17 169.4, C – 
 18 50.5, CH 5.27 (dd, 1.3, 10.0) 
 18-NH – 7.55, (d, 10,0) 
 19 77.8, CH 5.12 (dd, 1.3, 10.0) 
 20 29.0, CH 1.89 (m) 
 21 19.1, CH3 1.01 (d, 6.8) 
 22 19.0, CH3 0.85 (d, 6.8) 
 23 171.6, C – 
 24 22.6, CH3 2.23 (s) 
N,O-Me2-Thr 25 166.6, C – 
 26 64.6, CH 4.07 (d, 9.8) 
 27 72.5, CH 3.76 (m) 
 28 16.5, CH3 1.18 (d, 5.8) 
 29 28.9, CH3 2.70 (s) 
 30 57.3, CH3 3.41 (s) 
β-HyLeu 31 171.4, C – 
 32 46.8, CH 5.36 (d, 9.9) 
 32-NH  6.74, (d, 9.9) 
 33 77.1, CH 5.31 
 34 30.7, CH 1.72 (m) 
 35 19.5, CH3 1.09 (d, 6.7) 
 36 18.3, CH3 0.83 (d, 6.7) 
N-Me-Ala 37 170.1, C – 
Appendix 
197 
 
 38 56.6, CH  4.71 (q, 6.8) 
 39 14.4, CH3 1.38 (d, 6.8) 
 40 31.5, CH3 2.88 (s) 
N-Pr-β-HyLeu-2 41 170.4, C – 
 42 57.0, CH 4.55 (dd, 1.4, 7.8) 
 42-NH – 7.17 (d, 7.8) 
 43 78.4, CH 3.73 (m) 
 43-OH – 6.85 (d, 4.2) 
 44 30.1, CH 1.98 (m) 
 45 20.6, CH3 1.17 (6.7) 
 46 18.7, CH3 0.88 (6.7) 
 47 174.9, C – 
 48a 28.8, CH2 2.57 (dq, 14.9, 7.5) 
 48b 
 2.50 (dq, 14.9, 7.5) 
  49 10.1, CH3 1.19 (t, 7.5) 
[a] Assignments are based on extensive 1D and 2D NMR measurements (HMBC, HSQC, COSY). 13C-NMR spectra were recorded at 150 MHz. [b] 
Numbers according to Scheme S1. [c] Residues: Ala = alanine, N-Me-Dha = N-methyldehydroalanine, Pla = 3-phenyllactic acid, N-Ac-β-HyLeu= N-
acetylhydroxyleucine-1, N,O-Me2-Thr = N,O-dimethylthreonine, β-HyLeu = hydroxyleucine, N-Me-Ala = N-methylalanine, N-Pr-β-HyLeu = N-
propionylhydroxyleucine-2.[d] overlaying resonances. 
Compound FR900359 (FR), 50mg/kg dried A. crenata leaves (all spectroscopic data as reported in Fujioka et al1, 
Crüsemann and Reher et al.10). 
 
Scheme 10-2: Structure and numbering of C-atoms of 1 (FR-1). 
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Figure 10-14: Structure and 1H NMR spectrum (600 MHz, CDCl3) of 1 (FR-1). Assignments see Table 10-2. 
 
Figure 10-15: 13C NMR spectrum (150 MHz CDCl3) of 1 (FR-1). Assignments see Table 10-2. 
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Figure 10-16: DEPT-135 NMR spectrum (150 MHz CDCl3) of 1 (FR-1). Assignments see Table 10-2. 
 
Figure 10-17: 1H-1H-COSY NMR spectrum (600 MHz CDCl3) of 1 (FR-1). 
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Figure 10-18: 1H-13C HSQC NMR spectrum (600 MHz CDCl3) of 1 (FR-1). 
 
Figure 10-19: 1H-13C HMBC NMR spectrum (600 MHz CDCl3) of 1 (FR-1). 
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Figure 10-20: ROESY NMR spectrum (600 MHz CDCl3) of 1 (FR-1). 
Scheme 10-3: Structure and numbering of C-atoms of 2 (FR-2). 
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Figure 10-21: 1H NMR spectrum (300 MHz CDCl3) of 2 (FR-2).Assignments see Table 10-3. 
 
Figure 10-22: 13C NMR spectrum (75 MHz CDCl3) of 2 (FR-2). Assignments see Table 10-3. 
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Figure 10-23: DEPT-135 NMR spectrum (75 MHz CDCl3) of 2 (FR-2). Assignments see Table 10-3. 
 
Figure 10-24: 1H-1H-COSY NMR spectrum (300 MHz CDCl3) of 2 (FR-0). 
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Figure 10-25: 1H-13C HSQC NMR spectrum (300 MHz CDCl3) of 2 (FR-2). 
 
Figure 10-26: 1H-13C HMBC NMR spectrum (300 MHz CDCl3) of 2 (FR-2). 
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Scheme 10-4: Structures of FR900359 (FR), FR-1 (1), FR-2 (2), FR-3 (3), and FR-4 (4); putative structures of 
FR-5 (5), isomeric to 2. (Putative) differences are highlighted (blue box). For 2 complete 1D and 2D NMR data 
exist, but are in submission process of another manuscript. Due to the limitations of LCMS² analysis for 5 we can 
only determine the residue N,O-dimethylthreonine to be modified by one missing methyl group. Hence, three 
chemically and biosynthetically reasonable structures remain.  
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Figure 10-27: 1H NMR spectrum (600 MHz CDCl3) of FR-3 (3) and FR-4 (4), 1:1 mixture. 
 
Figure 10-28: 13C NMR spectrum (150 MHz CDCl3) of FR-3 (3), and FR-4 (4), 1:1 mixture. 
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Figure 10-29: 1H-1H-COSY NMR spectrum (600 MHz CDCl3) of FR-3 (3) and FR-4 (4), 1:1 mixture. 
 
Figure 10-30: 1H-13C HSQC NMR spectrum (600 MHz CDCl3) of FR-3 (3) and FR-4 (4), 1:1 mixture. 
Appendix 
208 
 
 
Figure 10-31: 1H-13C HMBC NMR spectrum (600 MHz CDCl3) of FR-03 (3) and FR-4 (4), 1:1 mixture. 
 
Figure 10-32: 1H NMR spectrum (600 MHz CDCl3) of FR-3 (3) and FR-4 (4), 3:1 mixture. 
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Figure 10-33: 1H-13C HSQC NMR spectrum (600 MHz CDCl3) of FR-3 (3) and FR-4 (4), 3:1 mixture. 
 
 
Scheme 10-5: Structures and numbering of FR900359 (FR), FR-1 (1), FR-2 (2), FR-3 (3), and FR-4 (4). 
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Figure 10-34: Results of the second messenger assays. Agonist induced IP1 production of CHO M1 cells after 
pretreatment with either vacuum liquid chromatography fractions VLC1 to VLC4 alone or in combination with a 
subliminal concentration of FR900359. Mean values ± s.e.m. of up to two independent experiments. Experiments 
performed by Tobias Benkel, Kostenis lab, Institute for Pharmaceutical Biology, Univ. of Bonn. 
 
Figure 10-35: Results of the second messenger assays. Agonist induced IP1 production of CHO M1 cells after 
pretreatment with either vacuum liquid chromatography fractions VLC5 to VLC9 alone or in combination with a 
subliminal concentration of FR900359. Mean values ± s.e.m. of up to two independent experiments. Experiments 
performed by Tobias Benkel, Kostenis lab, Institute for Pharmaceutical Biology, Univ. of Bonn. 
 
Figure 10-36: Results of the second messenger assays. Agonist induced IP1 production of CHO M1 cells after 
pretreatment with either Sephadex fractions S1 to S4 alone or in combination with a subliminal concentration of 
FR900359. Mean values ± s.e.m. of up to two independent experiments. Experiments performed by Tobias Benkel, 
Kostenis lab, Institute for Pharmaceutical Biology, Univ. of Bonn. 
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Figure 10-37: Results of the second messenger assays. Agonist induced IP1 production of CHO M1 cells after 
pretreatment with either Sephadex fractions S5 to S9 alone or in combination with a subliminal concentration of 
FR900359. Mean values ± s.e.m. of up to two independent experiments. Experiments performed by Tobias Benkel, 
Kostenis lab, Institute for Pharmaceutical Biology, Univ. of Bonn. 
 
Figure 10-38: Results of the second messenger assays. Agonist induced IP1 production of CHO M1 cells after 
pretreatment with FR either isolated from A. crenata or C. vaccinii. Mean values ± s.e.m. of two independent 
experiments. Experiments performed by Nina Heycke, Kostenis lab, Institute for Pharmaceutical Biology, Univ. 
of Bonn. 
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Figure 10-39: MALDI-TOF measurement of FR-Hex (11). α-cyano-4-hydroxycinnamic acid (HCCA) was used 
as matrix material. 
 
 
Scheme 10-6: Fragmentation pathways of first-generation (MS²) product ions obtained from 12. The modified m/z 
309.13 (12) loses phenyllactic acid Δm/z 148.04 Da or only the modified 2-aminoethanethiol residue Δm/z 77.03 
Da, resulting in the single modified amino acid N-methyl-((2-aminoethyl)thio)-2-alanine m/z 161.09 only 
occurring in 12 (not in FR) or A’’-F’ dipeptide residue, m/z 232.10, respectively. 
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Figure 10-40: FR-Cys-Disulfide Michael addition product indicated by mass spectrometry. (A) LCMS 
measurement of compound 12 crude reaction mixture. (B) MS² spectrum of m/z 1154.58 = putative [M+H]+ ion 
of FR-Cys-Disulfide. 
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Table 10-2: Analytical data of depsipeptides and peptides used in this study. 
Peptide 
No. 
Peptide sequence Mw / (Mw 
calc.) 
[g/mol] 
preparative 
HPLC 
tr [min] 
analytical 
HPLC 
tr [min]* 
TLC  
 
Rf 
1 cyclo-[OHCH2CH2CO-β-HyLeu-D-Pla-
N-MeDha-Ala-N-MeAla-β-HyLeu(Pr-
β-HyLeu)-N-MeThr(OMe)] 
1032.54[a] 
(1031.54) 
23.73[d] 58.16[k] 0.80[o] 
0.87[p] 
2 cyclo-[Ac-β-HyLeu-D-Pla-N-MeDha-
Ala-N-MeAla-β-HyLeu(Ac-β-HyLeu)-
N-MeThr(OMe)] 
988.51[a] 
(987.52) 
23.01[d] 60.01[k] 0.78[o] 
0.89[p] 
11 cyclo-[Ac-β-HyLeu-D-Pla-N-MeDha-
Ala-N-MeAla-β-HyLeu(Pr-β-
HyLeu(OCO(CH2)4CH3))-N-
MeThr(OMe)] 
1120.60[b] 
(1090.61) 
13.12[e] 62.25[k] 0.87[o] 
0.87[p] 
12 cyclo-[Ac-β-HyLeu-D-Pla-N-Me-
D/L-(CαCH2S(CH2)2NH2)-Gly-Ala-N-
MeAla-β-HyLeu(Pr-β-HyLeu)-N-
MeThr(OMe)] 
1079.57[a] 
(1078.56) 
27.21[f] 49.34[l] 0.82[o] 
13 cyclo-[Ala-N-MeAla-Lys(Ac)-
Thr(OMe)-Thr(OMe)-D-Phe-N-MeAla] 
789.44[a] 
(788.44) 
71.56[g] 14.11[l] 0.58[o] 
0.77[p] 
14 cyclo-[Ala-N-MeAla-Lys(Ac)-
Thr(OMe)-Thr(OMe)-Phe-N-MeAla] 
789.45[a] 
(788.44) 
81.59[h] 16.54[l] 0.59[o] 
0.79[p] 
15 cyclo-[Ala-Ala-Lys(Ac)-Thr(OMe)-
Thr(OMe)-D-Phe-Ala] 
761.42[a] 
(760.41) 
93.79[i] 12.46[l] 0.55[o] 
0.75[p] 
17 cyclo-[Ala-Ala-Lys(Ac)-Thr(OMe)-
Thr(OMe)-Phe-Ala] 
761.44[a] 
(760.41) 
73.67[h] 15.32[l] 0.55[o] 
0.72[p] 
18 cyclo-[Ala-N-MeAla-Leu-Thr(OMe)-
Thr(OMe)-D-Phe-N-MeAla] 
732.44[a] 
(731.42) 
78.56[i] 24.28[l] 0.68[o] 
0.76[p] 
19 cyclo-[Ala-N-MeAla-Leu-Thr(OMe)-
Thr(OMe)-Phe-N-MeAla] 
732.43[a] 
(731.42) 
87.16[h] 24.19[l] 0.54[o] 
0.75[p] 
20 cyclo-[Ala-Ala-Leu-Thr(OMe)-
Thr(OMe)-D-Phe-Ala] 
704.40[a] 
(703.39) 
88.69[h] 19.40[l] 0.55[o] 
0.76[p] 
21 cyclo-[Ala-Ala-Leu-Thr(OMe)-
Thr(OMe)-Phe-Ala] 
704.39[a] 
(703.39) 
98.96[h] 42.8[m] 0.55[o] 
0.76[p] 
22 cyclo-[Ahx-N-Me-D-Phe-Ado-
Dap(Ac-Thr)]  
647.32[c] 
(648.35) 
65.15[g] 20.67[m] 0.64[o] 
0.75[p] 
23 cyclo-[Ahx-N-Me-D-Phe-Ado-β-
HyLeu] 
549.32[a] 
(548.32) 
71.16[j] 36.04[n] 0.73[o] 
0.63[p] 
MS-peaks were detected as [a][M+H]+, [b][M+Na]+, or [c][M-H]-. Peptides were detected with LC-ESI-MS. Purification was performed using 
semipreparative RP-HPLC: [d]75% eluent D isocratic for 20 min, then 75-100% in 15 min, [e]70-100% eluentF in 30 min, [f]57% eluent D 
isocratic for 35 min, [g]10–60 % eluent B in 120 min, [h]0–50 % eluent B in 120 min, [i]20–70 % eluent B in 120 min, and [j]15–65 % eluent B 
in 120 min. For analytical RP-HPLC the following gradients were used: [k]0–80 % eluent B in 80 min, [l]0–60 % eluent B in 60 min, [m]10–50 
% eluent B in 40 min, and [n]0–50 % eluent B in 60 min. TLC was performed with systems containing: [o]n-butanol/acetic acid/water (48:18:24, 
v/v) and [p]n-propanol/25% NH3  (7:3).  *All peptides were >95 % HPLC pure. 
 
Table 10-3: Energy and structural statistics of the NMR ensembles of FR900359, 13, and 22 (10 lowest energy 
structures). Maximum distance restraints violations were < 0.026 Å for 13, < 0.043 Å for 22 and < 0.07 Å for FR. 
Peptide FR900359 5 13 
Distance restraints 100 40 38 
Dihedral angle restraints 11 9 3 
Structure statistics    
Violations in kJ/mol   
Total restraint violation energy 1.266 0.439 0.411 
Distance restraints 1.266 0.080 0.411 
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Dihedral angle restraints 0 0.360 0 
Total Force field energy (Yasara) -51 -904 -938 
Internal solute energy 574 -209 -290 
Electrostatic solv. energy -415 -511 -518 
Van der Waals solv. energy -212 -184 -131 
Mean RMSD (Å) Mean (s.d.)   
Backbone global  
0.18 
(± 0.10) 
0.74 
(± 0.25) 
 
Heavy atoms  
0.48 
(± 0.14) 
0.83 
(± 0.20) 
0.71 
(± 0.18) 
 
Table 10-4: Temperature coefficients for FR900359 in MeOH/H2O/D2O (v:v:v/ 1:1:0.2, 1H: 500 MHz). 
NH of residue Temperature coefficient 
Δδ/ΔT (-ppb/K) 
N-Ac-β-HyLeu-1 12.31 
N-Pr-β-HyLeu-2 7.62 
β-HyLeu -0.003 
 
  
Appendix 
216 
 
Table 10-5: Overview of inhibitor binding energies and inhibitor dissociation times tdiss calculated from 
docking, regular MD and steered MD (n.o. – not observed) 
 Ebind (kJ/mol) 
Vina 
Ebinding (kJ/mol) 
MD 
tdiss (ns) 
MD 
tdiss0 (ns) at 0 
acceleration  
sMD 
FR 40.8 135 n.o. 0.9 
YM 41.2 142 n.o. 1.1 
FR-L-Cys 40.3 174 425 2.3 
FR-D-Cys (I) 33.8 98 12 0.17 
FR-D-Cys (II) 33.4 61 20 0.23 
FR-L-BP 37.3 189 n.o. 1.8 
FR-D-BP 31.6 330 n.o. 0.7 
Binding energies were calculated with Yasara from a separate 10 ns molecular dynamics simulation using the 
following formula: 
𝐸𝑏𝑖𝑛𝑑𝑖𝑛𝑔 = (𝐸𝑖𝑛𝑡𝑒𝑟𝑛𝑎𝑙
𝑝𝑟𝑜𝑡𝑒𝑖𝑛 + 𝐸𝑖𝑛𝑡𝑒𝑟𝑛𝑎𝑙
𝑖𝑛ℎ𝑖𝑏𝑖𝑡𝑜𝑟 + 𝐸𝑠𝑜𝑙𝑣𝑎𝑡𝑖𝑜𝑛
𝑝𝑟𝑜𝑡𝑒𝑖𝑛 + 𝐸𝑠𝑜𝑙𝑣𝑎𝑡𝑖𝑜𝑛
𝑖𝑛ℎ𝑖𝑏𝑖𝑡𝑜𝑟) − (𝐸𝑖𝑛𝑡𝑒𝑟𝑛𝑎𝑙
𝑐𝑜𝑚𝑝𝑙𝑒𝑥 + 𝐸𝑠𝑜𝑙𝑣𝑎𝑡𝑖𝑜𝑛
𝑐𝑜𝑚𝑝𝑙𝑒𝑥 + 𝐸𝑠𝑢𝑟𝑓𝑎𝑐𝑒
𝑎𝑐𝑐𝑒𝑠𝑠𝑖𝑏𝑙𝑒 × 0.65)  
where E – energy, A – area in Å2, and 0.65 is a guestimate of the entropic cost of exposing one Å2 to the solvent. 
Ebind was calculated as an average value derived from the individual simulation snapshot. Each individual 
simulation snapshot was energy minimized before the Ebind calculation using the Amber14 force field parameters. 
Starting structures were the same as for the sMD simulations. Integration time steps for intra-molecular and inter-
molecular forces were 1.25 fs and 2.5 fs, respectively. All other parameters were identical with the simulations 
described above. 
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Table 10-6: Overview of simulation times of the regular MD runs used to generate the starting structures 
for sMD simulations 
 time 
FR 5 ns 
YM 5 ns 
FR-L-Cys 40 ns 
FR-D-Cys (I) 5ns 
FR-D-Cys (II) 5ns 
FR-L-BP 10 ns 
FR-D-BP 100 ns 
 
 
Figure 10-41: (A) Gq-bound FR and YM (pdb 3ah8) derived from molecular docking with the switch I (yellow), 
linker 1 (magenta) and β2 (red) region of the Gαq subunit. Gβ subunit is indicated in green. FR and YM are shown 
as stick model (color code: carbon – cyan, nitrogen – blue, oxygen – red, sulfur – green) (B) ligand RMSD (root 
mean square deviation – black trace) and relative distance of two ligand atoms (Cα HF6 – blue trace, Cβ Maa9 – 
red trace) with respect to their starting (bound) position during all-atom MD simulation. (C) steered MD profiles 
of ligand unbinding showing the time required to separate FR (black trace and squares) and YM (red trace and 
squares) from the protein. 
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Figure 10-42: Figure taken from Takeshita et al.244 16S rRNA gene sequences of selected Burkholderia 
species/strains and Pandoraea pulmonicola LMG 18106T as outgroup were aligned by using MAFFT v7.273 (L-
INS-i)245. Gap-including and ambiguous sites in the alignments were then removed, resulting in the final alignment 
data with 1,317 nucleotide sites. Phylogenetic relationships were reconstructed with RAxML v8.2.3246 using the 
GTR+Γ model of nucleotide protein substitution and maximum likelihood method. The bootstrap support values 
of 1,000 replicates were calculated and values higher than 50% are depicted at the nodes. The main Burkholderia 
clades, BCC&P, PBE and SBE/BGC, are respectively shown in red, blue and green. The gut symbionts of stink 
bugs are shown in bold, and those of Largidae and Bllisidae are indicated by a circle and triangle, respectively. 
The isolation sources of the Burkholderia and accession numbers in the DNA database (DDBJ/EMBL/GenBank) 
are represented in parentheses and square brackets, respectively. GS: gut symbiont. 
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Table 10-7: PCR results of endosymbiotic bacteria of A. lucida equally distributed over the whole leaf. 
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Figure 10-43: Feeding experiments with C. vaccinii and several carboxylic acid substrates monitored by LCMS 
measurements. 
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Table 10-8: 1H-1H-COSY, 1H-13C-HMBC and 1H-1H-ROESY spectroscopic data for FR900359 (CDCl3, 
293K). 
Residue[c] No C/H[b] 
1H-1H-
COSY 
1H-13C-HMBC[a] 1H-1H-ROESY (selected) 
Ala 1 –   
 2 3 1, 3, 4, 5(w) H-3, H-38 
 2-NH –   
 3 2 1, 2, 4(w)  
N-Me-Dha 4 –   
 5 –   
 6a b 4, 5 H-6b 
 6b a 4, 5 H-7, H-6a 
N-Me 7 – 8, 5, 6(w) H-6b, H-9 
Pla 8 –   
 9 10a 6, 8, 10, 11, 17 H-10a/b 
 10a 10b 8, 9, 11, 12/16 H-9, H-12/16 
 10b 9 8, 9, 11, 12/16 H-9 
 11 9   
 12/16  14, 10  
 13/15  11  
 14  12/16  
N-Ac-Hle-1 17    
 18 NH-18 23, 17 H-19, H-20, H-21, H-24 (w) 
 18-NH 18 23, 18, 17 H-24, H-18, H-20, H-38 (w) 
 19 20 25, 20, 22 H-18, H-20, H-21, H-22 
 20 19, 21 22 18, 19, 22 H-19, H-21, H-22, H-24, 
 21 20 19, 20, 22 H-22 (w), H-20, H-18, H-19 
 22 20 19, 20, 21 H-20 
N-Ac 23 – 24  
 24 – 18 H-39 (w), NH-18 
N,O-Me2Thr 25 –   
 26 27 25, 27, 28, 29, 31 
H-32, H-33, H-28, H-29 (w), 
H-30 (w) 
 27 28, 26 26, 28, 30 H-29, H-30 
 28 27 27, 29 H-26, H-30 
N-Me 29 – 26, 31 H-30 (w), H-7 (w) H-43, H-27 
O-Me 30 – 27 H-27 
Hle 31 –   
 32 NH-32 26, 31, 33, 34, 37 H-34, H-36 
 32-NH 32 32, 33, 37 H-40, H-38, H-32 
 33 34 32, 36, 41 H-30, H-33, H-34, H-35 
 34 33, 35, 36 32, 33, 34, 36 H-35, H-36, H-40 
 35 34 33, 34, 36 H-34, H-36, H-26 
 36 34 33, 34, 35 H-34, H-35 
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N-Me-Ala 37 –   
 38 39 1, 37, 39, 40 H-39 
 39 38 37, 38 H-40 
N-Me 40 – 1, 38 NH-32, NH-42(w), H-34, H-39 
N-Pr-Hle-2 41 –   
 42 43 47, 41, 43 NH-42, H-43, H-45, H-39(w) 
 42-NH 42 47, 43, 42 H-44, H-48, H-40, H-42 
 43 OH-43 41, 44, 45 H-42 bis 46, H-26 
β-OH 43-OH 43, 45 43, 44, 46 H-43, NH-32, H-33 
 44 43, 46 42, 43, 45, 46 H-45, H-39, 42-NH, H-42 
 45 44 43, 46  
 46 44 43, 44, 45 H-43, H-44 
N-Pr 47 –   
 48a 49 47, 49 H-49 (w), NH-42 
 48b    
  49 48 47   
[a] Numbers refer to carbon resonances. (w): weak. [b] Numbers according to Figure 4-1. [c] Residues: Ala = 
alanine, N-Me-Dha = N-methyldehydroalanine, Pla = 3-phenyllactic acid, N-Ac-Hle = N-acetylhydroxyleucine-1, 
N,O-Me2-Thr = N,O-dimethylthreonine, Hle = hydroxyleucine, N-Me-Ala = N-methylalanine, N-Pr-Hle = N-
propionylhydroxyleucine-2. 
 
 
Figure 10-44: 1H NMR spectrum of compound 1 (FR-1, 600 MHz H2O/D2O = 9:1, v/v, at 277-318K). 
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Figure 10-45: 1H-NMR spectrum of YM and compound 1 (600 MHz H2O/D2O = 9:1, v/v, at 277K). 
 
Figure 10-46: 1H-1H COSY NMR spectrum of compound 1 (FR-1, 600 MHz H2O/D2O = 9:1, v/v, at 277K). 
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Figure 10-47: 1H-13C HSQC NMR spectrum spectrum of compound 1 (FR-1, 600 MHz H2O/D2O = 9:1, v/v). 
 
Figure 10-48: 1H-1H TOCSY NMR spectrum of compound 1 (FR-1, 600 MHz H2O/D2O = 9:1, v/v, at 277K). 
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Figure 10-49: 1H-1H NOESY NMR spectrum of compound 1 (FR-1, 600 MHz H2O/D2O = 9:1, v/v, at 277K). 
 
Figure 10-50: 1H NMR spectrum of YM-254890 (600 MHz H2O/D2O = 9:1, v/v, at 277-318K). 
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Figure 10-51: 1H-1H COSY NMR spectrum of YM-254890 (600 MHz H2O/D2O = 9:1, v/v, at 277K). 
 
Figure 10-52: 1H-13C HSQC NMR spectrum of YM-254890 (600 MHz H2O/D2O = 9:1, v/v, at 277K). 
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Figure 10-53: 1H-1H TOCSY NMR spectrum of YM-254890 (600 MHz H2O/D2O = 9:1, v/v, at 277K). 
 
Figure 10-54: 1H-1H ROESY NMR spectrum of YM-254890 (600 MHz H2O/D2O = 9:1, v/v, at 277K). 
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Figure 10-55: 1H-1H ROESY NMR spectrum of YM-254890 (600 MHz H2O/D2O = 9:1, v/v, at 277K). 
 
 
Abbreviations and Units 
 
 
 Abbreviations and Units 
 
°C   Degrees Celsius 
α   optical rotation 
[α]TD   specific optical rotation, sodium D-line (589 nm); T: temperature 
 δ   NMR chemical shift [ppm] 
ε   Extinction coefficient (UV/VIS spectroscopy) 
λ   Wavelength [nm] 
μ   micro (10-6) 
μg   microgram (10-6 gram) 
μl   microliter (10-6 liter) 
µm   Micrometer 
μM   10-6 molar, micromolar (= 10-6 mol/L) 
ν   wave number [cm-1] 
1D   One-dimensional 
2D   Two-dimensional 
A   Absorption 
AAA  Amino acid analysis 
A-domain  Adenylation-domain 
Ab   Antibody 
Ac   Acetyl 
ACN  Acetonitrile 
ACP   Acyl carrier protein  
approx.  Approximately 
c   Concentration 
C18   C-18 modified silica gel 
Abbreviations and Units 
 
 
C -domain  Condensation-domain 
CT-domain  Condensation-like domain 
calcd  Calculated 
CDCl3  chloroform-d 
CD3CN  acetonitrile-d3 
CD3OD  methanol-d4 
CH2Cl2  dichloromethane (DCM) 
CH3CN  acetonitrile 
cm   10-2 meter 
CoA   Coenzyme A 
conc.  concentration 
COSY  Correlation spectroscopy 
d   Doublet (in connection with NMR data) 
Da   Dalton 
DAD  Diode array detector 
DCM  Dichlormethane 
DEPT  Distortionless enhancement by polarization transfer 
DH   Dehydratase 
DMAP  4-Dimethylaminopyridine 
E-domain  Epimerization-domain 
EC50 half maximal effective concentration (drug concentration causing 50% of 
maximal effect) 
EDC   N-ethyl-N’-(3-dimethylaminopropyl)carbodiimide 
e.g.   Latin “exempli gratia”; for example 
et al.   Latin “et alii”; and others 
ESI   electron spray ionization 
Abbreviations and Units 
 
 
EtOH  ethanol 
Fmoc  9-Fluorenymethyloxycarbonyl 
FR   FR900359 
g   Gram 
GPCRs  G protein-coupled receptors 
G protein  heterotrimeric guanine nucleotide-binding protein 
GTP   guanosine-5´-triphosphate 
Gαi   adenylate cyclase inhibitory G protein subunit 
Gαq   phospholipase C activating G protein subunit 
Gαs   adenylate cyclase stimulating G protein subunit 
h   Hour 
HCl   Hydrochloric acid 
HMBC  Heteronuclear multiple-bond correlation 
HPLC  High-performance liquid chromatography 
HSQC  Heteronuclear single quantum correlation 
Hz   Hertz 
i.e.   id est (Latin for “that is”) 
IP1   Inositol-1-phosphate 
J   Spin-spin coupling constant [Hz] 
KD   Dissociation constant 
L   Litre 
LC-ESI-MS  Liquid chromatography Electrospray-ionization mass spectrometry 
m   Multiplet (in connection with NMR data) 
M   Molar [mol/l] 
M-domain  Methylation-domain 
Mr   Molecular Mass 
Abbreviations and Units 
 
 
MALDI-ToF Matrix-assisted laser desorption/ionization - time of flight 
Me   methyl 
MeOH  Methanol 
MeOD  methanol-d4 
mg   milligram (10-3 gram) 
MHz  Megahertz 
min   Minute 
mL   milliliter (10-3 liter) 
mm   millimeter (10-3 meter) 
mM   millimolar (10-3 molar, = 10-3 mol/L) 
mult   Multiplicity 
nM   nanomolar (10-9 molar, = 10-9 mol/L) 
NMR  Nuclear magnetic resonance 
No   Number 
NRPS  Nonribosomal peptide synthetase 
obsd   Observed 
PCP   Peptidyl carrier protein 
ppm   Parts per million 
q   Quartet (in connection with NMR data) 
ref.   Reference 
RP   Raw product 
rpm   Rounds per minute 
RP   Reverse-phase RT 
rt   room temperature 
s   singlet (in connection with NMR data) 
SDS   sodium dodecyl sulfate 
Abbreviations and Units 
 
 
sec   Second 
sp.   Species 
t   Triplet (in connection with NMR data) 
T (-domain)  Thiolation-domain 
tR    Retention time 
TE   Thioesterase 
TE-domain  Thioesterase-domain 
TFA   Trifluoroacetic acid 
V   Volume 
VLC   Vacuum liquid chromatography 
wt%   percentage by mass (m/m) 
YM   YM-254890 
 
Abbreviations for amino acids 
Ala   alanine    A 
β-HyLeu  hydroxyleucine   L’’ 
N-Me-Ala  N-methylalanine   A’ 
N-Me-Dha  N-methyldehydroalanine  A’’ 
N-Ac-β-HyLeu1 N-acetylhydroxyleucine1  L’ 
N,O-Me2-Thr N,O-dimethylthreonine  T’ 
N-Pr-β-HyLeu2 N-propionylhydroxyleucine2  L’’’ 
Phe   Phenylalanine    F 
Pla   Phenyllactic acid   F’ 
Ser   Serine     S 
Thr   Threonine    T  
  
Acknowledgements 
 
 
 Acknowledgements 
I wish to express my sincere and cordial gratitude to my supervisor Prof. Dr. G. M. König for 
the expert guidance, encouragement and kind support during my PhD thesis program. In 
particular, I want to thank her to entrust me this intriguing project and let me be a part of an 
interdisciplinary team (FOR 2372). I would like to thank her that she provided constructive 
freedom on the one hand while at the same time always had an open door for dialogue and 
advice. The friendly atmosphere within in the working group made the work very motivating 
and pleasant. 
Special thanks go to Prof. Dr. E. Kostenis (Institute for Pharmaceutical Biology, University of 
Bonn, Germany) for officiating as second referee and most importantly offering me her great 
expertise, idealism, and advice in both, science what it is supposed to be, but also science, what 
it can be in reality (politics and begging for money). 
I thank: 
Especially Dirk Schmitz (Botanical Garden Bonn) for planting and providing me with Ardisia 
crenata (dried and fresh material). I thank Dr. Wolfram Lobin, Dr. Claudia Löhne and Bernhard 
Reinken for providing me leaves of A. lucida. 
Especially Prof. Dr. Leo Eberl, Marta Pinto-Carbo (Univ. of Zurich) for introducing me into 
the fascinating Leaf Nodule Symbiosis and Prof. Dr. Aurelièn Carlier (Univ. of Ghent) for 
providing the BAC library containing the frs gene cluster. 
Especially Prof. Dr. Piel, and Dr. Alexander Brachmann (ETH Zurich) for supervision and 
guidance during my research stay to perform MALDI imagin of a young A. crenata leaf. 
Prof. Dr. C. E. Müller and Markus Kuschak (Institute for Pharmaceutical Chemistry, University 
of Bonn, Germany) for Gq-affinity testing isolated and synthesized FR analogs in competitive 
binding studies against triatiated FR-Radioligand 3[H]PSB-15900. 
Prof. Dr. Diana Imhof, Dr. Daniel Tietze (also for my research stay at TU Darmstadt) and Dr. 
Toni Kühl for the collobrative work on SAR insights of FR. 
Prof. Dr. Michael Gütschow and Jim Küppers for the collaborative work and synthetic expertise 
towards superior fluorescent FR analogs. 
Acknowledgements 
 
 
Jun-Prof. Daniela Wenzel + Alexander Seidinger (Univ. of Bonn), Prof. Dr. Till Schäberle 
(Univ. of Giessen), Timo Hartmann (Museuem König Bonn), Prof. Y. Kikuchi (Univ of ), Dr. 
O. Tsubasa + Prof. Dr. P. Mergaert (CNRS Paris), for the collaborative work on the ecological 
function of FR. 
Prof. Dr. Häberlein, Dr. Thomas Sorkalla, Dr. Sebastian Franken, and Stefan Aatz for 
performing FCS studies on FR-RR-BP (compound 46). 
Dr. Marc Sylvester (Institute for Biochemistry and Molecularbiology, University of Bonn, 
Germany) for performing Tandem MS and Bernd Gehrig for MALDI-TOF MS measurements. 
Many specific tasks involved in this study were performed in cooperation with other members 
of the Institute for Pharmaceutical Biology, University of Bonn. For this work cordial thanks 
go to: 
Dr. S. Kehraus for providing professional laboratory support during all phases of this study, for 
proofreading manuscripts and for indispensable help concerning the implementation and 
interpretation of NMR experiments, for which he has my great admiration and gratitude. 
Dr. Max Crüsemann for measurement and analysis of HR-LC-MS and Tandem-MS 
measurements. He also introduced and trained us to apply LC-MS²-based GNPS molecular 
networking and guided about biosynthetic investigations. 
Nina Heycke, Suvi Annala, Tobias Benkel, Dr. Davide Malfacini for performing the IP1 
accumulation and DMR assays most important for all parts of this thesis. 
Ekaterina Egereva for recording LC-MS spectra and Marion Schneider for measurement and 
analysis of HR-LC-MS measurements. 
Dr. M. Koch and Dr. Ralf Schröder for their help in administrative questions. 
Thomas Koegler for his support in all technical matters, regarding computer, software and 
equipment. 
Drs. Till, Katharina, Frieda and Max, for mediating excellent teaching skills in the supervision 
of students. 
Special thanks go to my office colleagues and close friends, especially Jan Schroer (teaching a 
lot of Ruhrpott-vocab and always having at least a klitzekleinen, kühlen Hobel to offer), Henrik 
Acknowledgements 
 
 
Harms (teaching me lab work and “Rheinische Lebensart” en detail) and Alexander Bogdanov 
(teaching me maximal criticism towards anything and anybody as well as a vast number of 
valuable and just as much pointless advisory about science and life itself). The discussions with 
you during and after work made the laboratory work much easier.  
Further I thank Paul Barac, Emilie Goralski for the fun trip to Transylvania and lots of coffee I 
owe them, and Nils Böhringer for his great parties. I thank Ben Libor, Cora Hertzer and all the 
other nerds introducing me to weird games and the world apart from the lab. 
I would like to thank especially Henrik Harms, Max Crüsemann, Jan Schroer and Paul Barac 
for proofreading parts of this thesis. 
I would like to thank also all other members of the Institute for Pharmaceutical Biology, 
University of Bonn, as well as all SS08 members of the University of Münster, especially 
Dome, Nikita, Jochen, and Stephi, present or past for cooperation and friendship. 
I would like to express my deepest gratitude to my family, in particular my mother and 
stepfather, who have always supported me and enabled this study by their limitless love, trust 
and encouragement. The latter also applies for my siblings, father, and friends Daniel Vey, 
Marius Staggenborg, Christina Hoegen-Leist, Oliver Bestmann and last but not least Ines 
Bresler. 
  
